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Non-infectious uveitis is an autoimmune disease characterised by infiltrating leukocytes such 
as T cells due to loss of immune tolerance to retinal proteins. Experimental autoimmune 
uveitis (EAU) is an animal model of non-infectious uveitis that shares many features with 
human disease and can be induced in mice by the transfer of autoantigen specific 
lymphocytes. The purpose of this thesis was to look at leukocyte trafficking specifically CD4+ 
T cells during initiation of clinical disease and throughout active clinical disease. 
The data presented uses an adoptive transfer to induce clinical disease. This was developed 
to study antigen specific and non-antigen specific recruitment during EAU. This robust 
technique also allows investigation into the role of specific chemokine and cytokine receptors 
during EAU by using knockout mice.  
The results demonstrate that antigen specific CD4+ T cells that initiate disease or their 
progeny persist within the tissue during active clinical disease and after active clinical disease 
has subsided. At day 2 after transfer, increased recruitment of endogenous CD4+ T cells and 
retention of transferred CD4+ T cells was observed, this was further investigated using non 
antigen specific cell transfers using ovalbumin specific CD4+ T cells which showed that the 
pathogenic stimulus needed to be present locally to initiate clinical disease in recipients. 
Further to this ovalbumin specific cells are recruited to the eye if the antigen is introduced to 
the ocular tissue or if a pathogenic stimulus is present. Using the adoptive transfer technique 
further analysis using chemokine knockout mice showed that during active clinical disease 
CX3CR1 is expressed on CD4+ T cells which are selectively retained within the eye. Using 
cytokine receptor knockout mice IL-27Rα-/- cells were found to be more potent in nature to 
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Humans are constantly exposed to pathogenic and non-pathogenic microbes. Whilst the 
immune system is eliminating pathogens and toxic or allergenic proteins it must avoid 
responding in a way that produces excessive damage to tissues or which eliminate beneficial 
microbes (2). The three essential properties of the immune system are determined by 
function: recognition of self and non-self and the ability to discriminate between the two; 
activation of pathways that eliminate pathogens and the development of long lasting memory 
(3). The immune system can be divided into the non-specific innate immune response and the 
highly specific adaptive immune response (3).  
The innate immune system can be defined as hard-wired responses that are encoded by 
genes in the host’s germ line, thus allowing recognition of molecular patterns shared by many 
microbes and toxins that are not found within the mammalian host (2). Although the main 
role of the innate immune system is defence against infection, the effects of the response 
allow for surveillance of host tissue damage and protection against progression of malignancy 
due to mutation (3).  
The adaptive immune system uses antigen-specific lymphocyte responses to give successful 
immune protection (4). The adaptive immune response is composed of cells with specificity 
(through receptors) for an individual pathogen, allergen or toxin, the responding cells after 
antigen encounter will then proliferate in order to attain sufficient cell numbers for an 
effective immune response. An important feature of the adaptive immune response is the 
production of long-lived cells that are capable of persisting in a dormant state but possess the 
ability to re-express effector functions quickly after further encounters with the same antigen 
ensuring the adaptive immune system to manifest immune memory (2).  
 
1.1 Innate immune response 
The innate immune system is the first defence mechanism against pathogens and is 
comprised of cellular components and physiological and chemical barriers to protect against 
pathogen entry, replication and survival (3). This is achieved by establishing a protective 
response that has the ability to develop at a rapid pace from initiation to a full inflammatory 
response, followed by resolution to restore tissue integrity (5). The initial phase of the 
inflammatory response is focused on the destruction of pathogens that is followed by a phase 
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of dead and dying cells and cellular debris being eliminated from the site of inflammation. The 
final phase is a restoration phase in which tissue appears to be repaired and in a healthy 
condition (5). 
1.1.1 Physiological, physical, and chemical barriers of the innate immune system 
Anatomical barriers of the innate immune system are comprised of epithelial layers including 
mucous membranes and the skin which prevent the entry of pathogens into the host (3). 
Pattern recognition receptors (PPRs) allow recognition of invading organisms and are 
expressed on various immune cells, they are responsible for the recognition of non-
mammalian molecular patterns known as pathogen associated molecular patterns (PAMPs) 
(6). Activation of protective inflammatory cellular responses can be achieved by binding of 
PAMPs such as bacterial and fungal cell-wall components and viral nucleic acid (6) to PRRs on 
the surface and within the cytoplasm of the host cells (3, 7). The recognition of pathogens by 
PRRs plays a vital role in the generation of an effective innate immune response (7). The 
sensing of microbes by PRRs expressed on antigen-presenting cells, in particular dendritic cells 
leads to the activation of adaptive immune responses (6). 
1.1.2 Inflammatory mediators and cellular components of innate immunity 
Cellular components of the innate immune system include several polymorphonuclear cells 
such as; neutrophils, eosinophils, basophils, mast cells, phagocytic cells (such as: monocytes, 
macrophages), dendritic cells and natural killer (NK) cells (3).  
Neutrophils are major players during acute inflammation, they are typically the first 
leukocytes to be recruited to the site of inflammation and are capable of eliminating 
pathogens by several mechanisms (8). They are continuously generated in the bone marrow 
from myeloid precursors and during inflammation the neutrophil number within tissues 
increases. Over time these cells die and are removed by macrophages and dendritic cells. 
Neutrophils can eliminate pathogens by multiple mechanisms both intracellularly and 
extracellularly, when microorganisms are encountered phagocytosis occurs, or highly 
activated neutrophils are capable of eliminating microorganisms by releasing neutrophil 
extracellular traps (NETs) (8).  
Monocytes can be found circulating in the blood, bone marrow and spleen making up roughly 
10% of total leukocytes within humans and 2-4% in mice. They can remain in the circulation 
for up to 1-2 days. If an inflammatory response has not initiated recruitment to the tissue in 
this time the cells will die and be removed (5). The physiological role of monocyte subsets in 
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vivo are yet to be fully defined but they are suggested to play roles in inflammation and tissue 
repair due to their capacity to be activated and secrete inflammatory cytokines, immune 
defence mechanisms, antigen processing and presentation, pro-angiogenic and patrolling 
behaviour and also in maintaining homeostasis (5).  
Macrophages are professional phagocytes defined as mobile cells with the ability to engulf 
and digest pathogens, particles and dead cells (9). Resident macrophages are heterogeneous 
and versatile cells found in tissue in adult mammals, they represent up to 10-15% of total cell 
number when the tissue is non-inflamed (5). The long-term persistence of adult tissue 
macrophages relies on replenishment by bone-marrow derived monocytes (10) especially 
during inflammation (11). 
Dendritic cells are a distinctive group of specialised antigen-presenting cells that have the 
ability to influence both the innate and adaptive immune response (12, 13). Although 
dendritic cells are only present in a small population within lymphoid tissues, they are also 
considered important in terms of the initiation of antigen-specific immunity and the T cell 
mediated response, as well as the induction of immunological tolerance (13). DCs support 
immunity or tolerance by antigen-presentation to T cells and delivering immunomodulatory 
signals through cell to cell contact and cytokines (12). 
Eosinophils are a minor component of circulating leukocytes that develop and differentiate in 
the bone marrow; they can be long-lived granulocytes involved in a variety of regulatory 
functions (14). In normal conditions, eosinophils can be found within the thymus, spleen, 
blood, lung, uterus, adipose tissue, mammary gland, and lamina propria of the 
gastrointestinal tract, suggesting a physiological function in each organ. Eosinophils have the 
ability to regulate lymphocyte recruitment and function but are not known to have the 
capacity to function as an antigen-presenting cell to T cells. Immunologic regulation of 
eosinophils has been suggested to extend from innate immunity to adaptive immunity and 
can involve non-immune cells (14). 
Basophils are the least frequent granulocyte population within the mammalian body. The 
accumulation of basophils has been observed in allergic disease, organ rejection, 
autoimmunity, and cancer (15). Unlike other granulocyte populations the lifespan of mature 
basophils is quite short and estimated to be between 1-2 days, therefore the constant 
presence of basophils in periphery is thought to be down to continuing development and 
replenishment of the population (15). 
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Natural Killer (NK) cells are important immune cells with an essential role in tumour immunity, 
antibacterial immune response, anti-viral immune response and human pregnancy (6). NK 
cells are now included as a group 1 innate lymphoid cell (ILC) along with ILC1 cells (16). NK 
cells are recognised as a separate lineage of lymphocytes with effector functions that are 
considered both cytotoxic and cytokine producing. Accordant with their main function as 
innate sentinels, NK cells can be found within both lymphoid and nonlymphoid tissues. 
However, NK cells represent a small fraction of total lymphocytes in most tissues (~2% of 
murine splenocytes and between 2-18% of lymphocytes detected within human blood). 
Subsets of NK cells can be distinguished in mice and humans based on their phenotype and 
anatomical and functional features (17). 
 
1.2 Innate control of adaptive immunity 
The innate and adaptive immune systems have been described as two separate contrasting 
arms of the immune response; however, they are usually found to act together. The host’s 
initial defence being the innate immune response, and the adaptive response becoming the 
more prominent through clonal expansion of antigen-specific T and B cells after several days 
(2). Control of adaptive immunity by the innate immune system is considered to be a firmly 
established paradigm. Microbial pathogens are recognised by the innate immune system 
using pattern recognition receptors (PRRs) that have the ability to detect conserved  
pathogen-associated molecular patterns (PAMPs) which are present in bacterial and fungal 
cell-wall components and viral nucleic acids (6). PAMPs detected by PRRs induces an 
inflammatory response of innate host defences, the recognition of microbes by PRRs 
expressed on antigen-presenting cells initiates adaptive immune responses (6). 
 
1.3 Adaptive immune Response 
The innate immune system has evolved to sense and eliminate a wide range of pathogens, 
but the variety of common pathogenic molecular patterns it has the ability to recognise is 
limited. The variation present in antigenic structures combined with pathogens mutating to 
avoid host detection can be paralleled with the evolution of the adaptive immune response 
(18). Unlike the recognition receptors of the innate immune response that are all encoded in 
the germline genome in their fully functional form, the adaptive immune response depends 
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on receptors that are specific and selected by somatic recombination of a large array of gene 
segments (18). After initial pathogen encounter, cells with expression of specific immune 
receptors can persist in the host for life, thus providing immunological memory and giving the 
capacity for a highly targeted, rapid response in the event of re-exposure to the same 
pathogen (3, 18). In response to the inflammatory environment created by the innate immune 
response, cells of the adaptive immune system (including B and T cells) are stimulated to 
proliferate and differentiate into cells with various functions that are useful for immunological 
challenge (19). After the invading pathogen is removed, most of the cells recruited from the 
adaptive immune response die but leave behind an array of memory subsets against the 
pathogen within the host (19). 
Following host pathogen exposure, cells, and inflammatory mediators from the site of 
infection travel to local lymph nodes. Non-host antigens presented using MHC molecules on 
antigen-presenting cells (APCs) are recognised by B and T lymphocyte receptors present in 
the host (3). Clonal selection involves the processes of clonal deletion and the expansion of 
lymphocytes to create a population of specific cells capable of targeting the original pathogen 
(3). Although the adaptive immune response is more specific than the innate response to the 
pathogen (18).  
The principle cells of the adaptive immune response include two major lineages of 
lymphocytes that have the ability to specifically recognise and respond to antigenic 
determinants of pathogens and toxins (20). These cells develop in the primary lymphoid 
organs such as the bone marrow and thymus, then traffic to secondary lymphoid organs 
which include the lymph nodes and spleen. These organs serve to capture circulating antigens 
from lymph and blood respectively (18). The cells are named T (thymus-derived) and B (bone-
marrow derived) lymphocytes, similar to other blood cells early T and B cells are derived from 
hematopoietic stem cells (20).  
In early stages of development T and B lymphocyte progenitors reorganise various sets of 
prototypic immunoglobulins (Ig) diversity (d), joining (j) and variable (v) gene segments to 
produce antigen binding regions of their T cell receptors (TCRs) and B cell receptors (BCRs) 
(20). The antigen binding regions of the various V(D)J combinations are further diversified 
through enzymatic addition of nonencoded nucleotides in the joints made during V(D)J 
assembly. The random nature of this diversification process generates receptors that are 
capable of recognising self-antigens (20).  
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Non-host antigens found on antigen-presenting cells can be identified by B and T cell 
receptors. Clonal selection of lymphocytes gives a population of specific cells that are capable 
of targeting the original pathogen presented (3).  
 
1.4 Cells of the adaptive immune response 
1.4.1 B cell response 
The humoral response is mediated by B lymphocytes that are produced in the bone marrow. 
On activation by T cells they differentiate into plasma cells, memory cells or antigen-
presenting cells (21). Memory B cells represent the outcome of the humoral response, these 
cells express high affinity antigen-specific B cell receptors for specific antigens so that the 
second response on re-exposure is much quicker and heightened (21, 22).  
1.4.2 B cells 
B cells are classified by their anatomic localisation and ontogeny. Three main classes exist 
B1a, B1b and B2 B lymphocytes in both mice and humans, including marginal zone and 
follicular B cells (23). B1 progenitors develop into B1 lymphocytes present from the foetal 
liver and survive beyond the neonatal period as a self-renewing population. Whereas B2 
lymphocytes are produced from BM precursors that develop from transitional 2 (T2) B cells 
and continue output throughout life (23). A crucial function of B lymphocytes is antibody 
production (23). 
BCR antigen receptors are present on mature B cells. They are comprised of glycosylated 
proteins known as membrane-bound or surface immunoglobulins, specifically IgM and IgD 
classes of antibody (24). Alternatively, antibodies are released from the B cell to target 
antigens within the extracellular space to bind and neutralise them efficiently (23). Plasma 
cells secrete antibodies which consist of two similar heavy chains distinguished by the C-
terminus regions, which are sustained and do not partake in antigen binding.  These chains 
determine the type of antibody e.g. IgA, IgD and IgE, IgG and Ig(M) with two similar light 
chains (21, 23). There are four subclasses of IgG antibodies in humans IgG1, IgG2, IgG3 and 
IgG4 (23), and is the principle mediator of opsonisation, IgA is involved in mucosal immunity, 
IgD is cell bound and IgE is involved in mast cell degranulation (21). Antibodies apply effector 
functions in three ways: they activate immune cells including macrophages by binding to the 
Fc receptor to allow recognition of the constant regions of specific antibody classes, binding 
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to a specific target to neutralise it and therefore preventing it from entering a cell, or binding 
to C1q to activate the complement immune response, specifically the classic pathway (23). 
The chosen effector mechanism of the cell is determined by both the cells affinity to bind and 
activate the Fc receptor present on immune cells and the isotype of the heavy chain (23).  
Follicular B cells are activated after antigen recognition by the BCR and critical helper signals 
derived from antigen specific CD4 T cells (23). When bound to antigen, the BCR initiates two 
processes, firstly necessary gene expression programmes are triggered by signals sent from 
the BCR to the cell, and secondly, the antigen is internalised and brought into the endosomal 
compartments to be broken down in order to be presented by MHC class II complexes in 
peptide form to the B cell (23). Recognition of peptide MHC class II complexes by antigen 
specific CD4+ T cells is achieved through intimate contacts with B cells to form an interaction 
known as ‘cognate’ or ‘linked’ T-B interactions (23). 
1.4.3 T cell response 
In order to become a mature thymocyte, bone marrow derived precursor cells must go 
through a highly regulated program of intrathymic development to then leave the thymus 
and form the peripheral T cell pool (25). The early stages of thymocyte development are 
defined by a number of molecular events; expression of RAG1 and RAG2 gene products, 
expression of CD4 and CD8 coreceptor molecules, somatic rearrangement of the T cell 
receptor β locus and recombination of TCR α locus (25). For a T cell to develop from a 
haemopoietic progenitor to a mature TCRα/β+ T cell a series of commitment events take place 
including TCR V(D)J gene rearrangement, TCR β selection and positive/negative selection of 
thymocytes (26). 
T lymphocytes produced in the bone marrow migrate to the thymus and undergo selection 
(21). During development, the DNA undergoes rearrangement and the T cell receptors (TCRs) 
become specific for foreign antigens. This is  by a process of education that allows the cell to 
distinguish between self and non-self (21). The ability to recognise self from foreign or non-
self is achieved through selection by cell surface molecules known as major histocompatibility 
complex (MHC) (21). T cells are able to recognise antigen that has been processed and 
presented to them by MHC molecules on APCs. There are two types of MHC molecules: MHC 
class I and MHC class II (21). All parenchymal cells express MHC class I molecules and therefore 
have the capabilities to present internal peptide molecules. Monocytes, macrophage, B cells, 
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dendritic cells, and endothelial cells express MHC class II and can present external peptides 
that are processed by APCs (21). 
During embryonic development immature T cells interact with epithelial cell surface 
molecules such as MHC class I and II molecules when passing through the thymus. This is to 
ensure the T cells are both reactive and specific. From this, immature T cells are processed by 
functional or positive selection in the thymic cortex, then in the medulla the cells undergo 
negative selection to ensure elimination of autoreactive T cells (21). In the periphery, 
regulation of co-stimulation molecules and cytokines control if T cells remain quiescent or 
become activated; on activation, T cells become either T-helper cells, T-suppressor cells or 
cytotoxic T cells (21).  
1.4.4 T cell activation 
Each unique T cell in the periphery carries a TCR that is made up of an α chain and a β chain. 
The TCR has the potential to recognise a small number of peptide antigens in combination 
with MHC. These cells are actively surveying but are in a resting state unless they encounter 
cognate antigen. The generation of the TCR occurs by genomic DNA sequences undergoing 
recombination during the development of T cells, each TCR is unique and highly specific (19). 
Recombination to form a functional TCR gives rise to a resting T cell that emerges from the 
thymus gives. The resting T cell is capable of migrating through secondary lymphoid tissues 
which include the lymph nodes and spleen or the periphery but cannot yet produce a 
response that would protect the host from infectious challenge (19).  
In order to produce a T cell with the capabilities of mediating immune responses the naïve T 
cell must be activated, this is achieved through coordinated interactions between the APC 
and the molecules that are present on the surface of T cells (19). An APC is capable of carrying 
an antigenic peptide bound to an MHC class molecule non-covalently from an infectious 
agent. The TCR recognises a peptide antigen when bound to the correct MHC class I or class 
II molecule (19). In the T cell plasma membrane, the alpha/beta TCR connects with CD3 which 
is a complex membrane protein comprised of δ-, ε- γ-, and ζ- subunits, an intracellular signal 
is produced following ligation of the TCR by the cytosolic region of this complex (19). CD4 or 
CD8 coreceptor together with the TCR bind to class I or class II MHC class molecules; class I 
for CD8 cells and class II for CD4 cells,  this is to stabilise the interaction between the T cell 
and APC (19). After the recognition of the cognate peptide bound to a MHC molecule by the 
specific corresponding TCR, the APC and T cell begin forming an immunological synapse by 
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undergoing actin-mediated membrane reorganisation to facilitate grouping of the TCR on the 
surface of the cell (19, 27).  
However, to induce T cell activation, stimulation with cognate antigen alone is not sufficient 
and will instead produce a refractory T cell to any further stimulus. The identification of T cell 
activation needing the primary costimulatory pathway of CD28 confirmed T cell activation 
requires two signals, firstly association of CD3 with antigenic proteins followed by ligation of 
CD28 (19).  
1.4.5 T cell types 
The support that T cells provide to immune responses can be separated in to two categories; 
generation of T helper cells and generation of cytotoxic T cells, T helper function is associated 
with CD4 T cells and cytotoxic function is associated with CD8 T cells (19).  
Helper CD4+ T cell responses generate cytokines and chemokines to support the immune 
system. These interact with each other to activate neighbouring T helper cells to perform 
specific functions including the recruitment of immune cells to encounter pathogen at sites 
of inflammation (19). The main function of cytotoxic CD8+ T cells is specific elimination of host 
cells infected by a pathogen by cytotoxic methods, but they are also capable of a producing a 
diverse array of cytokines. This is done by delivering cytotoxic granules into the cytosol of the 
infected cell, this process is initiated by TCR binding to specific peptide/MHC molecules on 
the target cell (19).  
Naïve T cells express a specific TCR which allows specificity of the T cell population, however 
until the TCR is engaged and molecular signals downstream of their cytokine receptor is 
integrated they remain uncommitted to their T helper fate (19). T cells stimulated with 
antigen have the potential to differentiate into a variety of effector cell subsets depending on 
the cytokine milieu present and further modified by the nature of  pathogen (19). Helper T 
cell responses can be classified into T helper subsets such as; Th1, Th2, Th17, Th9, Tfh, Tr1 
and Tregs (19).  
1.4.6 Th1 Response 
Differentiation into Th1 cells is regulated by  signal transducer and activator of transcription-
4 (STAT-4) and T-bet (28), and cytokines including; interleukin 12 (IL-12), interleukin 18 (IL-
18), interferon-γ (IFN-γ) and interferon-α (IFN-α) (Figure 1) these all favour the development 
of Th1 cells but will inhibit development of Th2 response (28). Th1 cells produce interferon-
gamma (IFN-γ), interleukin 2 (IL-2) and tumour necrosis factor (TNF) (Figure 1). The 
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production of these cytokines initiates macrophage activation that are responsible for 
phagocyte-dependent protective responses (29).  
1.4.7 Th2 Response 
 In contrast, Th2 development is dependent on STAT-6, GATA-3 and c-maf (30), Th2 cells 
produce interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 10 (IL-10) and interleukin 13 (IL-
13) (Figure 1) that promote B cells to produce IgE and IgA isoforms of antigen-specific 
antibody which circulate to mucosal surfaces and neutralise future threats of parasitic 
encounter (19).  
1.4.8 Th17 Response 
In response to extracellular bacteria and fungi, innate immune cells produce  IL-6 and TGFβ, 
when naïve T cells receive these signals with additional and constant interleukin 21 (IL-21) 
and interleukin 23 (IL-23) they differentiate into Th17 helper cells under the control of RORγT 
(19) (Figure 1), this particular T cell subset is characterised by the expression of the cytokine 
interleukin 17 (IL-17A and IL-17F), interleukin 22 (IL-22), interleukin 21 (IL-21) and interleukin 
10 (IL-10) (Figure 1). 
1.4.9 Tregs and Tr1 cells 
Unchecked or persistent immune responses lead to immunopathology. To control this, the 
immune system produces a regulatory subset of T cells (Tregs) that provide negative feedback 
to terminate the inflammatory process (19). Tregs are produced directly from thymic 
selection (tTregs), from this FoxP3+ CD4+ T cells can be differentiated from naïve FoxP3- CD4+ 
T cells in the periphery and are known as induced Tregs (iTregs) or peripheral Tregs (pTregs) 
(19, 31). 
Tr1 cells were first described in 1997 by Roncarolo et al (32). It was demonstrated that a 
specific subset of CD4+ Tregs were of a FoxP3- phenotype that were capable of suppressing 
antigen-specific responses and preventing the development of colitis (32, 33). This CD4+ 
FoxP3+ subset appeared to exert their immunosuppressive functions through IL-10 (33). Tr1 
cells express CD49b and LAG3 along with normal levels of co-stimulatory molecules including 
CD40L, CD69,CD28, CTLA4 and HLA-DR and increased levels of glucocorticoid induced 
transcription factor (GITR), CD134 (OX40), Tumour necrosis factor receptor TNFRSF9, CD18 





1.4.10 T Follicular helper cell 
Follicular helper T cells (Tfh) are found in lymph nodes, specifically the germinal centres. 
Cognate interaction between Tfh, B cells and IL-21 induces proliferation of B cells to 
differentiate into plasma cells and induce the production of antibody (34). Tfh cells and IL-21 
are involved in immunodeficiencies, infectious and autoimmune diseases, cancer and 









1.4.12 T Cell Memory 
After the primary response is finished and the infection cleared there is a drastic contraction 
in the T cell population, leaving a population of T cells known as memory T cells that carry the 
‘memory’ of a specific pathogen that has previously invaded the host and altered functional 
abilities (19). In comparison to naïve T cells, memory T cells are more easily activated and 
Figure 1.1: T cell subsets in the adaptive immune response. Naïve T cells can differentiate 
into various CD4+ T cell subsets depending on the cytokine environment and by the signals 
the cells receive. After differentiation, the cells will produce specific cytokines to mediate the 
immune response. Figure adapted from Palmer et al. 2010. 
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have an increased proliferative potential when they come into contact with an antigenic 
stimulus or costimulatory receptors in order to cause a more rapid response to specific 
pathogens. They are maintained as a population by a homeostatic proliferation (19). Two 
main subclasses of memory CD4+ and CD8+ T cells exist: effector-memory (TEM) T cells and 
central memory (TCM) T cells. TCM cells can be defined by high expression of the adhesion 
marker CD44 and interleukin 7 (IL-7) receptor (CD127) and high levels of chemokine receptor 
C-C chemokine receptor type 7 (CCR7), combined with low levels of the adhesion marker 
CD62L, low levels of the surface marker killer cell lectin-like receptor subfamily G member 1 
(KLRG-1) (19). 
1.4.12 Antigen-presenting cells 
Stimulation of mature T cells requires the presence of a specialised antigen-presenting cell 
(APC) including macrophages and dendritic cells, however macrophages are unable to initiate 
a primary immune response which is the principle role of the dendritic cell (35). Dendritic cells 
express receptors that detect microbial molecules in their environment and then act to 
promote an adaptive immune response interfacing the innate and adaptive arms of immunity 
(35). Both macrophages and dendritic cells are strategically placed in T cell dependent areas 
within lymphoid tissue and express costimulatory molecules at high levels that are required 
for optimal signalling by T cells (36).  
In order to present antigen to T cells, APCs must first degrade native proteins into peptides 
which are then loaded on to MHC molecules; MHC class I for CD8+ T cells and MHC class II to 
present to CD4+ T cells (36). Loading of peptide for class I molecules occurs mainly within the 
endoplasmic reticulum and for class II molecules in the endosomes. When displayed on the 
cell surface, peptide-bound MHC molecules on APCs are recognised by an antigen-specific αβ 
T-cell receptor (36). Specialised APCs also express a number of costimulatory molecules 
including CD28 and CTLA4, high levels of expression of these molecules is mostly restricted to 








1.5 Cytokines and Chemokines  
1.5.1 Cytokines 
Cytokines are proteins secreted by cells to induce a specific effect on the way cells interact 
and communicate with each other (37).  
The name cytokine can be interchanged with names such as; interleukin (cytokines made by 
one leukocyte, acting on other leukocytes),  lymphokines (cytokines made by lymphocytes), 
and monokines (cytokines made by monocytes) (37). Cytokines can act in various ways 
including on cells that produce and secrete them (autocrine action) or neighbouring cell 
populations (paracrine action) or on faraway cell populations (endocrine action).  
It is not unusual for the same cytokine to be secreted by different cell types or several 
different cell types to be influenced by a single cytokine. They often act in a cascade as one 
cytokine stimulates its target cell to make additional cytokines that can act synergistically or 
antagonistically. Cytokines can be produced by many different cell populations, often by 
helper T cells but also by activated neutrophils, macrophages and non-immune cells such as 
fibroblasts and endothelial cells during cell injury, infection, invasion and inflammation (37). 
Major pro-inflammatory cytokines include interleukin 1β (IL-1β), interleukin 6 (IL-6) and 
tumour necrosis factor-α (TNF-α) and are often associated with inflammasome activation. The 
pro-inflammatory cytokine response is controlled by a series of immunoregulatory molecules 
known as anti-inflammatory cytokines.  
Specific cytokine inhibitors and soluble cytokine receptors act in harmony with cytokines in 
order to regulate the immune response. Major anti-inflammatory cytokines include 
interleukin 1 receptor antagonist, interleukin 4 (IL-4), interleukin 10 (IL-10), interleukin 11 (IL-
11) and interleukin 13 (IL-13) (37). 
In this thesis the role of IL-27 is interrogated in the mouse model of uveitis. Interleukin 27 (IL-
27) is a newly discovered cytokine that belongs to the IL-6/IL-12 cytokine family (38, 39). 
Similarly, to members of the IL-12 and IL-6 family, IL-27 is a heterodimeric cytokine. It consists 
of two subunits known as p28 and Epstein-Barr virus-induced gene 3 (EBI3) (39). EBI3 can exist 
in three forms a homodimer, p35 heterodimer and a p28 heterodimer (39). Secretion of EBI3 
is not necessary for the secretion of IL-27p28 and therefore promotion of T cell and NK cell 
activation can be achieved by the heterodimerisation of IL-27p28 to cytokine-like factor (CLF) 
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(40). However, there is little evidence of heterodimers being formed between IL-27p28 and 
IL-12p40 naturally (40).  
IL-27 plays a role in the innate and adaptive immune response. In innate immunity, IL-27 has 
been demonstrated to induce production of IL-1, TNF-α, IL-18 and IL-12 in monocytes and IL-
1 and TNF-α in mast cells (39). IL-27 was first described as a proinflammatory cytokine due to 
its ability to promote IFN-γ production by CD4, CD8 T cells and NKT cells and has been 
identified as an early initiator of Th1 differentiation but inhibits Th17 responses (39, 41, 42). 
However, further studies have highlighted the role of IL-27 as a negative regulator of IL-2 and 
can therefore restrict the development of immune responses (42). Further immunoregulatory 
functions of IL-27 include the generation of IL-10 producing Tr1 cells and the suppression of 
the pathogenic Th17 response (43). 
1.5.2 Chemokines 
A variety of cytokines are known to play a role in chemotaxis (37). Chemokines are small 
molecules that are related structurally and are capable of regulating cell trafficking of various 
cell types by interacting with a subset of seven-transmembrane, G protein coupled receptors. 
In humans roughly 40 chemokines have been identified that mainly act on eosinophils, 
lymphocytes, monocytes and neutrophils (44). Studies have shown that chemokines play 
fundamental roles in homeostasis, development, and function of the immune system. They 
have a wide range of effects on many different cell types beyond the immune system 
including endothelial cells and various cells of the central nervous system where the effects 
are angiogenic or angiostatic (44).  
Chemokines can be divided into two major subfamilies based on arrangement of the two N-
terminal cytosine residues, that is whether the first two cysteine residues have an amino acid 
between them (CXC) or are adjacent (CC). Further to this two more classes of chemokines 
have been described; lymphotactin which unlike the typical chemokine structure lacks 
cysteines one and three so can be described as C or SCϒc and fractalkine which is the only 
chemokine to act through a mucin like stalk to bind to membranes, the structure of fractalkine 
differs from stereotypical chemokines by the presence of three amino acids between the first 
two cysteines and can therefore be described as CX3C or SCϒd (44). 
Regulation of T helper responses by chemokines has been demonstrated. They are known to 
have several functions and exert chemotactic activity on cell types such as Th1, Th17 and Th2 
cells (28). The selective recruitment of Th1 cells to inflamed tissue is usually independent of 
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Th2 cells, however, some chemokines appear to be able to influence the polarisation of Th1 
or Th2 responses by direct interaction with these cells as precursors and/or favouring the 
production of Th1 or Th2 specific cytokines (28).  
Specific chemokines and their ligands play a central role in the recruitment of inflammatory 
cells, Th1 lymphocytes are attracted to the site of inflammation by CXCL9, CXCL10 and CXCL11 
which are all secreted by damaged cells (45). The Th1 lymphocytes that are recruited to the 
inflamed tissue will enhance production of IFN-γ and TNF-α from the tissue which in turn 
induces production of Th1 chemokines by different cells, causing an amplification loop (45).  
In this thesis the role of the chemokine receptor CX3CR1 in the mouse model of uveitis is 
investigated. CX3CL1 (fractalkine) is a pro-inflammatory chemokine capable of inducing 
chemotaxis of circulating monocytes and inducing the selective recruitment of Th1 
lymphocytes through interaction with the CX3CL1 receptor CX3CR1 (46). CX3CR1 has been 
further implicated in the recruitment of monocytes to sites of inflammation. Studies have 
illustrated a population of CX3CR1 positive monocytes patrolling the endothelium in its steady 
state but when signs of infection occur, this population are able to rapidly infiltrate the tissue 
(47). 
B-cell antigen encounter takes place within the lymphoid follicles present in the 
compartments of lymphoid organs that are known to be rich in B cells (48). Chemokines can 
be considered organising factors of the immune system and co-ordinate microenvironmental 
architecture of primary and secondary lymphoid organs during physiological and pathological 
conditions (49). 
 
1.6 Immune tolerance 
Immunological tolerance describes a diverse range of host processes that can prevent 
potentially harmful immune responses from developing within the host tissue (50). Therefore 
the immune system is not normally activated by self-antigens (51). Tolerance is generated at 
an ‘upper’ level and a ‘lower’ level; the upper level is known as central tolerance and the 
lower level of peripheral tolerance, a faulty central tolerance and peripheral tolerance 
initiates  an autoimmune disease (51). 
Central tolerance is involved in the differentiation of immature thymocytes in primary 
lymphoid organs including the bone marrow and thymus. The major mechanisms involved in 
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central tolerance include clonal deletion and inactivation of clonal lymphocytes (52). 
Peripheral tolerance deals with mature B and T lymphocytes that have left the primary 
lymphoid tissues which are found in the secondary lymphoid tissue including lymph nodes 
and the blood (53). When mature lymphocytes have left the primary lymphoid tissues the 
antigen that would be of concern would be detected within the tissues instead of the primary 
lymphoid tissues (52). Positive selection is the process of maturation of immature double 
positive thymocytes that express T cell receptors with an intermediate affinity or avidity for 
self-peptide complexes by differentiation into single positive thymocytes (54), It further 
shapes the T cell repertoire. Negative selection or clonal deletion is the elimination of single 
or double positive expressing thymocytes within the thymus that express high affinity T cell 
receptors that are specific for self-antigen (54). Negative selection is efficient for deleting T 
cell precursors that have high avidity TCRs for self MHC complexes present on DCs. This 
suggests that peripheral tolerance mechanisms occur after central tolerance and are 
important for the control of mature T cells that bear a TCR with a lower avidity for self MHC 
molecules that have escaped central tolerance and are present in the periphery (55). 
Mechanisms of peripheral tolerance include deletion of cells, inducing anergy or by clonal 
ignorance (56) 
To achieve tolerance there are a number of categories of adaptations that the immune system 
makes; firstly, newly differentiated T cells and B cells test their receptors for recognition of 
autoantigens. Strongly reactive T cells are censored by a deletional mechanism, these 
processes are termed ‘negative selection’ and ‘central tolerance’ (57) (Figure 1.2). A mature 
lymphocyte will move into the circulation and encounter new antigens, but the lymphocyte 
will require co-stimulation in addition to an antigen-specific response to make a positive 
response, without this response the cell will become hyporesponsive or die (57). In addition 
to this, natural T regulatory cells (nTregs) that have been selected for recognition of self-
antigens can dampen early immune response. When a positive response from the lymphocyte 











To prevent tissue destruction, induction of unresponsiveness or changes to the nature of the 
effector class involved in the response are made. New cells mediate immunoregulation by 
using cytokine release and bystander suppression to inhibit effector cell generation of a 
specific type (57).  
The organism is known to be tolerant so long as the immune system does not cause any 
damage. By this definition of tolerance, an intact immune system does not react in a 
Figure 1.2: Overview of central tolerance. Induction of autoimmune disease due to failure 
of tolerance. Central tolerance is a censor mechanism to stop autoreactive T cells from 
entering the periphery to induce autoimmune disease, failure of tolerance combined with 




destructive manner against the host, in this instance equilibrium is seen as a physiological 
state (57).  
 
1.7 Autoimmunity 
Autoimmune disease is a significant and growing clinical problem, it is chronic in nature 
leading to high healthcare costs, and is prevalent in the younger population effecting prime 
working and reproductive years (58).  
Autoimmune disease can be defined as organ-specific or non-organ specific, several diseases 
fit into these two groups, but some diseases fall into the spectrum in between. Autoimmune 
disorders range from those in which antibodies and T cells react to self-antigens localised 
within a specific tissue, to systemic conditions which can be characterised by reactivity against 
a specific antigen or antigens spread throughout several tissues within the body (59). 
However, classification of autoimmune disease is complex and continues to evolve as our 
understanding of the underlying mechanisms increases, for example by the understanding of 
inflammatory conditions. 
 Current therapies to treat autoimmune disease include cytokine antagonists such as TNF 
antagonists. Most therapeutic interventions target the terminal phase of inflammation and 
don’t address the problems causing initiation and progression of the disease (58). An immune 
response to a specific antigen involves the same components as an autoimmune response to 
an autoantigen, including APCs, B lymphocytes and T lymphocytes; messenger molecules 
including chemokines and cytokines and their corresponding receptors; and molecules 
present on the cell surface including signalling and costimulatory molecules (51).  
All autoimmune diseases are thought to have three sequential phases of initiation, 
propagation and resolution (58) (Figure 1.3). Disruption of regulatory mechanisms are 
associated with each of the phases, the resolution phase occurs when the balance of effector 
and regulatory mechanisms has occurred this is normally a partial and short term ability (58). 
Significant parts of the disease process are clinically silent, making diagnosis of early disease 
difficult (Figure 1.3). 
1.7.1 Initiation of autoimmune disease 
Most patients will start showing symptoms after abnormal immune interactions have taken 
place, therefore it is often difficult to accurately depict which factors are responsible for the 
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initiation of disease in humans (58). Strong evidence shows that autoimmune disease arises 
from a combination of genetic and environmental factors. Environmental agents can trigger 
autoimmunity, but only in people with a permissive set of immune response genes go on to  
develop an autoimmune disease (51).  
Environmental factors  
Infection is strongly connected as it has the capability to breakdown cellular or vascular 
barriers to expose antigen to the immune system, induce bystander activation of T 
lymphocytes and macrophages to provide costimulatory signals and superantigen effects of 
bacterial products and induce cell death by necrosis instead of apoptosis, all these effects are 
capable of disrupting peripheral tolerance (51). 
There is also the process of molecular (antigenic) mimicry, this involves an antigen of a 
microorganism that sufficiently resembles a self-molecule that can induce a cross-reactive  
autoreactive response (51). Other environmental initiators that can break tolerance act like 
infections to cause tissue damage (51). 
Genetic factors 
Many genome wide association studies (GWAS) have identified genetic polymorphisms that 
are associated with autoimmune disease. Most polymorphisms are in non-coding  regions of 
genes, especially enhancers, but many associations are with genes that play a role in the 
immune response (51). Of all the genes associated with autoimmune disease, the strongest 
associations are with MHC alleles, however genes that are associated with autoimmune 
disease are often not specific to a single disease but are instead associated with multiple 
autoimmune diseases (60).  
1.7.2 Propagation of autoimmune disease  
Most patients present with clinical disease during the propagation phase characterised by 
progressive inflammation and tissue damage, as positive feedback amplifies the disease (58). 
Firstly the self-antigen that initiates autoimmunity often cannot be eliminated by the host, 
and the problem is intensified by the emergence of new autoantigenic epitopes as tissue 
damage and alterations in self-proteins occur, in a process that is known as epitope spreading 
(58) (Figure 1.3). 
When newly generated antigenic epitopes activate different specificities of lymphocyte a 
recruitment of leukocytes to the site of inflammation occurs, this creates more damage to the 
tissue and gives rise to even more novel epitopes to be targeted by autoreactive lymphocytes 
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thus epitope spreading creates a vicious cycle that influences inflammation within the tissue 
(58). An inflammatory environment is created by the production of cytokines and cellular 
mediators by numerous immune cell types within an autoimmune reaction, these serve to 
amplify the reaction. However the driving force behind the autoimmune reaction could be 
due to the increase in the number of effector cells in comparison to the number of regulatory 
cells present (58). After the induction of a pathological immune reaction, there is increasing 
accumulation of effector T cells to the inflamed tissue that are driving the immune reaction, 
this is accompanied by a decrease in the number of Tregs or increased number of 
dysfunctional Tregs (58). 
1.7.3 Resolution of autoimmunity 
It is likely that the control of immune reactions involves the induction and activation of 
regulatory mechanisms that dampen the effector response to restore the effector 
cell/regulatory cell balance (58) (figure 1.3). 
Autoimmune disorders are a result of the breakdown of immunological tolerance which leads 








Figure 1.3: The sequential phases of autoimmune disease. Initiation includes the genetic 
predisposition of the individual combined with environmental triggers imitates clinical 
symptoms within patients. Propagation involves the immune response amplifying within 
the individual such as cytokine production and epitope spreading. These steps are then 
followed by regulatory mechanisms dampening the effector response to initiate resolution 
of the autoimmune disease. Figure adapted from Rosenblum et al (2015). 
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1.7.4 The role of CD4+ T cells in autoimmunity 
In organ-specific autoimmunity, CD4+ T cells are essential to the autoimmune response. 
Pathogenic antigen-activated CD4+ T cells can adopt several different phenotypes depending 
on external cues and the transcription factors that they induce (61).  
Th1 cells are predominantly involved in inducing macrophage activation to clear intracellular 
pathogens and inducing immunoglobulin class switching to complement-fixing antibodies 
through production of large quantities of IFN-γ (62). They are involved in cell-mediated and 
delayed-type hypersensitivity responses but have been implicated in the development of 
organ-specific autoimmune disease and more specifically in organ-specific T cell driven 
autoimmune diseases whereas Th2 cells reportedly exerted inhibitory effects (62).  
However, the hypothesis that Th1 cells exclusively drive autoimmune tissue damage was 
challenged when blocking IFN-γ signalling did not protect mice from the induction of 
autoimmune disease and in fact caused a more severe disease phenotype (62). 
The Th17 subset of T helper cells were discovered after the IL-17 family of cytokines was 
discovered. This was further supported by the finding of mediation of expansion of IL-17 
producing cells by IL-23. Th17 cells require specific transcription factors and cytokine 
mediation to differentiate (63). Studies have shown that Th17 cells are generated from CD4+ 
T cells by stimulation from cytokines such as interleukin-6 (IL-6), transforming growth factor-
β (TGF-β), interleukin-21 (IL-21) and interleukin-23 (IL-23) which all play an integral role in the 
induction of the autoimmune disease process (63).  
Increased IL-17 was found in human autoimmune diseases such as multiple sclerosis and 
rheumatoid arthritis and in the corresponding mouse models of disease, which has caused 
much research to be focused on defining what role Th17 cells plays in the pathogenic process 
of tissue inflammation (62). The importance of Th17 cells in the pathogenesis of organ-specific 
autoimmunity has been demonstrated in several animal studies showing Th17 cells and Th1 
cells are capable of inducing disease. These studies illustrate a role for both Th1 and Th17 
cells in autoimmune disease.  
 
1.8 Immune maintenance of the eye 
The anatomy of the eye can be described as a fibrovascular sphere that contains an aqueous 
humor, lens, vitreous body and is lined with a retina (64). The cells of the retina are highly 
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diverse containing various neuronal cell types. It is considered to be a vital component for the 
production of nerve activation from light (64, 65). The retina is protected by a blood-retina 
barrier (BRB) and similarly to the brain and spinal cord is part of the central nervous system. 
It is made up of an intricate network of specialised cells that can be described as 
interconnected and heterozygous neuronal in nature such as bipolar cells, photoreceptors 
and ganglion cells (66). These cells present within the retina play an important role in creating 
neural impulses that are relayed to the brain by converting light from the outside 
environment that are then perceived as visual information by the individual. (66). To ensure 
regular neural conduction the neural retina is given support from glial cells including 
astrocytes and Mϋller cells (66).  
Specialised members of the immune cell family of macrophages that reside within the retina 
are known as microglia, they are yolk sac derived and are found throughout the neural retina. 
The neural retina is a hemispherical sheet that curves towards the centre of the eye made up 
of neural tissue, it sits next to retinal pigment epithelium (RPE) and the retina.  Tight junctions 
are important between vascular endothelial cells at retinal vessels and within the BRB 
between the RPE  (66).  
The layer that separates the choroid from the neural retina is known as the RPE, it is a 
monolayer of pigmented cells and is of neuroectoderm origin so is included as part of the 
retina (67). 
The mammalian retina is made up of ~60 different cell types which all play a role in the 
processing of visual images (68), it is highly specialised with specific metabolic and 
physiological needs, to meet the demands of the extracellular environment and facilitate 
rapid neural conduction. The outer retina receives nourishment from the vascular choroid 
which receives its blood supply from the inner retina. The retinal blood supply is able to 
regulate the environment by excluding leukocytes (including, lymphocytes, granulocytes and 
myeloid derived cells) erythrocytes and large molecular weight proteins and therefore acts as 
a highly specialised blood barrier (66). 
 The normal retina is considered an immune privileged tissue due to the exclusion of immune 
cells, a property of a tissue to display highly attenuated responses to alloantigens (66). 
1.8.1 Immune privilege  
The term used to describe the relationship the eye has with the immune system is immune 
privilege, a term coined by Sir Peter Medawar in the 1940’s who observed that foreign tissue 
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grafts placed in the anterior chamber of the eye were not rejected (69, 70). The concept of 
immune privilege may appear simple but research into this area has illustrated that multiple 
mechanisms are required to maintain the state of immune privilege within the ocular tissue 
(69). These mechanisms include; stopping the free movement of larger molecules into and 
out of the eye by the presence of the BRB and the absence of efferent lymphatics, the 
presence of cell-bound and soluble factors of an immunosuppressive nature to create an 
inhibitory ocular environment to stop the activity of immune-competent cells and the eye 
actively regulates systemic immune responses (69).  
An unregulated innate immune response has potential to inflict significant damage to the eye, 
granulocytes and macrophages elaborate a variety of proteases and reactive oxygen species 
that can damage bystander cells (71).   
The adaptive immune response is characterised by antigen specificity and memory, 
antibodies produced by B cells and T cells are both capable of inducing inflammation and 
injury to the eye (71). Membrane bound molecules that inhibit T cell proliferation or induce 
apoptosis of infiltrating immune cells are secreted by cells of the BRB that line the interior of 
the eye. In response to viral infections FasL is expressed throughout the ocular tissue to 
remove activated T cells and neutrophils (71, 72).  
Sites considered to be of immune privilege such as the eye use membrane-bound and soluble 
molecules to reduce immune-mediated inflammation within the tissue, they also promote 
the dampening of the adaptive immune response by generating immunoregulatory processes 
(71). In the late 1970s studies performed by Streilein and colleagues introduced the paradigm 
of anterior chamber-associated immune deviation (ACAID) and described the concept of 
deflecting the adaptive immune response from effector type mechanisms that could impose 
severe injury to the tissue to sustain immune privilege (71). This was achieved by the injection 
of allogenic lymphoid cells into the anterior chamber of rat eyes and noted that alloantigens 
introduced into the eye were detected by the systemic immune apparatus and elicited an 
aberrant immune response characterised down regulation of cell-mediated alloimmunity by 
an antigen specific response and a concomitant activation of humoral antibody responses (73-
75). Since the original experiments by Streilein and Kaplan, ACAID has further been 
demonstrated with a number of antigens including viruses, haptenated cells, tumour 
antigens, histocompatibility antigens and soluble proteins (75). 
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Multiple mechanisms contribute to ocular immune privilege including the inhibition of T cell 
proliferation by factors such as TGF-β2, VIP, Mueller cells and retinal epithelial cells, inhibition 
of Delayed-Type Hypersensitivity by ACAID, TGF-β, CGRP and α-MSH, deletion of infiltrating 
inflammatory cells by FasL, inhibition of NK cells by MIF, TGF-β2 and inhibition of complement 
by membrane bound regulatory proteins and soluble complement regulatory proteins (75). 
Since these findings, the definition of ocular immune privilege has become broader to 
encompass induction of ACAID after antigenic induction and the capacity of the ocular tissue 
microenvironment to suppress immune effector responses and ocular inflammation (76).  
1.8.2 Immune Surveillance 
No organ is exempt from autoimmune disease, although immune privilege influences the 
nature and tempo of immune surveillance in the tissue (77). The main role of immune 
surveillance is to determine if the immune effector response is needed in order to address an 
invading pathogen, a cancerous cell or tissue injury (78).  
Studies of human CSF obtained from healthy individuals allow further understanding of 
normal immunosurveilance of immune privileged tissue; mainly CD4+ T cells of the effector 
memory phenotype were detected (77, 79). Although anatomical and functional barriers 
protect the tissues of the brain and eye from the circulation in health, profound changes occur 
locally within the tissue when an immune response is triggered; the modification of the 
processes of immunosurveilance when local inflammation becomes established is still yet to 
be determined (77). 
1.8.3 Immune mechanisms within the eye 
The immune response appears to be customised to the organ in which it is initiated as well as 
being specialised for the region where it functions (80). There are also differences in 
responses based on route of antigen administration for example injection into the eye is used 
to induce tolerance but subcutaneous injection can be used to produce inflammation (80). 
The eye is filled with immunosuppressive factors such as neuropeptides, somatostatin, 
cytokines and complement inhibitors. There is also low expression of MHC class II molecules 
to limit antigen-presentation within the eye, furthermore stromal cells from the iris, ciliary 
body and retina within the eye have the capacity to convert immune T cells into regulatory T 
cells (Tregs) and RPE cells that line the borders of the eye can directly inhibit primed T cells. 
Lastly, death inducing molecules such as FasL are expressed by stromal cells within the eye to 
induce apoptosis of immune cells that pass the ocular boundary (80). 
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1.8.4 Endothelium within the eye 
The cells that supply and drain the neural retina are the retinal endothelial cells, these cells 
line the microvasculature, anatomically and physiologically. The characteristics of these cells 
suit the nutritional requirements and protection of the tissues critical for vision (81). The 
endothelium allows the access of circulating cells and must ensure the oxygen supply to the 
metabolically active retina. This is necessary to maintain the vasculature and survey the retina 
for the presence of pathogens (81). The endothelium is considered a part of the blood-retina 
barrier that is involved in protection of the retina by excluding circulating molecular toxins, 
microorganism and pro-inflammatory leukocytes, thus the retinal endothelial cells are an 
important component in retinal ischemic vasculopathies and retinal inflammation such as 
posterior uveitis (81). 
1.8.5 The endothelium during inflammation 
When a tissue is injured or an infection occurs, endothelial cells are responsible for 
coordinating the recruitment of inflammatory cells. Endothelial cells produce communication 
signals, including cytokines and growth factors as well as a range of adhesion molecules and 
integrins to facilitate recruitment of inflammatory cells (82). Under stimulation with agents 
such as IL-1b and TNFα, the phenotype, morphology, and function of endothelial cells 
changes, to allow involvement in the immune response, this is known as endothelial 
activation. 
The term was coined in the 1960’s by investigators who observed that the endothelium 
became plump and leaky in DTH, with the term activated illustrating a change in function and 
morphology. The main changes of endothelial cell activation are loss of vascular integrity, 
expression of leukocyte adhesion molecules and cytokine production (83). Loss of vascular 
integrity can expose sub endothelium and permit the efflux of fluids from the intravascular 
space, upregulation of leukocyte adhesion molecules, including E-selectin, ICAM-1, and 
VCAM-1 allows leukocytes to adhere to the endothelium and move into the target tissues (83, 
84).  
Tethering and Rolling- Firstly, leukocytes adhere to the endothelium that lines the blood 
vessel walls in order to pass through to reach the inflamed tissue, the vascular leakage follows 
haemoconcentration in the early stages of the inflammatory response will slow the blood flow 
enough so leukocytes have the ability to make contact with the endothelium (85). The initial 
contact of leukocytes to the endothelium serve to tether, these interactions are mediated by 
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the selectin family which are found on both leukocytes and endothelial cells (82, 85). For cells 
to tether, interactions between adhesion molecules must form rapidly, in contrast, for cells 
to roll these interactions must break rapidly (86). Rolling adhesion is an important checkpoint 
for cells to encounter tissue-specific signals before entering a specific organ (86). 
Arrest and Adhesion- In vivo, leukocytes will tether and roll along the endothelium. Both 
these processes are reversible and many of these leukocytes will not remain tethered to the 
vessel surface, they will instead re-enter the bloodstream all while still rolling throughout the 
entire process (86). Rolling of leukocytes can be stopped by high affinity adhesion of 
leukocytes to the surface of endothelial cells, which replaces the low affinity transient 
interactions that are made due to leukocyte rolling (85, 86). Chemokines and integrins can 
promote leukocytes to form a high affinity adhesion bond with the endothelium. ICAM-1 and 
-2 and VCAM-1 are receptors expressed on the endothelial cells that activated leukocytes can 
bind to using integrins, when no inflammation is present within the tissue these receptors are 
expressed at low levels particularly in the vascular beds, however inflammatory cytokines 
increase their expression drastically (85). 
Migration on the Endothelial Surface- For a leukocyte to migrate into the tissue it must first 
adhere to the endothelium, the leukocyte may roll over several endothelial cells before 
arresting and forming a high affinity adhesion bond. To enter the tissue the leukocyte must 
then cross the border of the endothelial cell which it has adhered to (85).  
 
1.9 Intraocular inflammation 
Although inflammation of the eye is unusual, immune privilege within the eye can be 
overcome and allow the infiltration of proinflammatory immune cells including; T cells, B cells, 
macrophages/monocytes, natural killer cells, neutrophils and dendritic cells that invade the 
retina, choroid and vitreous along with anterior chambers of the eye (87).  
1.9.1 Classification of Uveitis 
Uveitis is a group of sight-threatening, intraocular inflammatory diseases (88). The term 
uveitis means inflammation of the uvea, in particular the choroid, ciliary body and iris but 
surrounding structures including the optic nerve, retina, and sclera are also effected (89). 
Uveitis encompasses a diverse group of ocular disorders classified as; anterior, intermediate, 
posterior or panuveitis based on the anatomical location within the eye (90). Classifying 
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uveitis into specific subgroups helps a clinical scientist to take a logical approach to diagnosis 
of the patient and management of disease (89). Anterior uveitis is the inflammation of the 
anterior chamber and is the most common form of uveitis, intermediate uveitis can be 
defined as the presence of inflammatory cells in the vitreous humor including; pars planitis, 
posterior cyclitis and hyalitis (90). Retinal and choroidal inflammation (choroiditis, 
chorioretinitis and hyalitis) is known as posterior uveitis, whereas panuveitis involves 
inflammation of all parts of the uvea i.e. retina, choroid, vitreous humor and the anterior 
chamber, (90). Uveitis can be classified based on anatomical involvement of the uveal tract 
but can also be classified by the etiology of inflammation (90).  
The main causes of uveitis are infection, systemic immune-mediated disease, tissue-specific 
autoimmune disease and autoinflammatory disease, other causes include; post-traumatic, 
post-surgical and drug-induced uveitis (90).  
1.9.2 Etiology of Uveitis  
Infectious causes of uveitis can normally be treated with antimicrobials, with the remaining  
cases being of autoimmune origin or immune-mediated despite having different 
presentations within patients (91). Infectious agents, specifically viruses, have been proposed 
as one of the environmental triggers of autoimmune disease including uveitis through 
mechanisms that have not yet been fully characterised (91). There are instances when 
molecular mimicry can account for the development of autoimmune disease within the eye 
however potential bystander activation is thought to be limited due to the 
immunosuppressive nature of the eye but this kind of activation should not be ruled out (91). 
1.9.3 Epidemiology of Uveitis  
Uveitis accounts for 5-20% of legal blindness in both the United States and Europe and up to 
25% of cases in the developing world (89, 92). The incidence of uveitis has been estimated to 
be between 17 to 52 cases per 100,000 per year with a prevalence of 38-714 cases per 
100,000 population (93). Uveitis mostly has an equal gender distribution but in some studies 
a slight female predominance can be observed (93).  
Uveitis can occur at any age, but the mean age incidence is between 30-40 years of age with 
60-80% of uveitis cases occurring between the ages of 20-50 years (93). The prevalence of 
anterior uveitis is reported to be 24.5-52.3%, panuveitis 11.8-52.9%, posterior uveitis 7.1-46% 




1.9.4 Clinical features of Uveitis 
Uveitis is a term that is used to describe a number of etiologies and disease phenotypes, in 
order to effectively manage the disease, correct anatomical location, assessment of disease 
activity, etiological diagnosis, identification of any potential complications and presence of 
any systemic disease associations are very important to identify (89, 97). Symptoms of acute 
forms of uveitis include ocular pain, photophobia, lacrimation and redness (98).  
Uveitis is a disease that varies in phenotype and visual prognosis, inflammation can range 
from mild to  severe (89). When a patient starts displaying symptoms, complications that 
could affect or threaten their sight may have already occurred. The severity of the symptoms 
displayed by the patient often effect the decision making in relation to determining the 
correct treatment as not all uveitic diseases require treatment. If the anterior chamber is 
involved in the disease process patients can be very symptomatic including vitritis with 
several floaters and macular edema. Patients who present with mild or intermediate uveitis 
may not require treatment as the risks associated with treatment outweigh the visual benefit 
for the patient (89). 
Treatments are not curative, but suppress inflammation and need to be administered until 
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Table 1.1: Classification of Human Uveitis. Posterior uveitic disease can be classified based on both 
etiology and clinical characteristics. If the disease is caused by an infectious or non-infectious agent 
(Etiology) or the clinical characteristics of a lesion present within the eye. Table adapted from 
Sudharsham et al (2010). 
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1.9.5 Current treatments for Uveitis  
Treating the systemic disease in patients that is associated with the presence of uveitis can 
sometimes control the uveitis, first line systemic treatments are usually based on 
corticosteroids and some patients being treated with steroids alone for posterior uveitis can 
control their symptoms (89, 99, 100). 
Conventional second-line immunosuppressive agents have been used for several years, 
cytotoxic drugs such as chlorambucil (101) and cyclophosphamide (102) have been reported 
to be useful in treatment of uveitis, but the side effects associated with this course of 
treatment creates difficulties for patients when managing uveitis long-term, especially in 
cases of chronic uveitis in a young, healthy population (89).  
These drugs although effective can take many weeks to months in order to be properly 
effective and can have severe side effects that can become intolerable so will therefore switch 
to a second-line immunosuppressant (89).  
Efficacy of biological agents such as anti-tumour necrosis factor (anti-TNF) based drugs 
including; adalimumab, etanercept and infliximab, etanercept and have been reported in 
several studies (89). Most biologics are recombinant antibodies to or antagonists of specific 
cytokines or cell-surface receptors but they also include recombinant cytokines, they were 
first used to treat ocular inflammation in the early 1990’s (103). Biologics are an attractive 
therapy to control the disease process by targeting individual molecules within the 
inflammatory process (103).  
TNF is a key inflammatory cytokine that is involved in the pathogenesis of several 
inflammatory disorders which includes non-infectious uveitis; in the EAU model studies have 
shown a substantial role in the pathogenesis of non-infectious posterior uveitis and similarly 
in ocular fluids from patients with uveitis (103). There are a number of anti-TNF agents 
available including; etanercept, infliximab and adalimumab, both adalimumab and infliximab 
are capable of binding with soluble and transmembrane forms of TNF effectively, but in 
contrast etanercept is less capable of forming stable bonds with TNF, specifically the 
transmembrane form (103). 
The experimental model of posterior uveitis (EAU) has implicated IL-1 and IL-2 in the 
pathophysiology, thus antiinterleukin therapies are also used for patient treatment (103, 
104). Therefore, a recombinant version of human IL-1 receptor antagonist (IL-1RA) (a 
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naturally occurring inhibitor of IL-1) was developed into a biologic agent to be used as 
treatment (103). 
Interferon-α (IFN-α) is a naturally occurring cytokine that is secreted by plasmacytoid 
dendritic cells during viral infections; IFN-α is proposed as the primary pathogenic cytokine in 
‘systemic’ autoimmune disease, whereas TNF-α in organ-specific autoimmune disease is seen 
as a more pathogenic cytokine. The separation between TNF-α and IFN-α is not absolute due 
to cross reactivity to regulate each other, if either become unbalanced there is the potential 
for an autoimmune reaction (103). In vitro studies have illustrated reduced IFN-α expression 
in plasmacytoid dendritic cells in comparison to healthy controls, in addition to this, TNF-α 
reduces IFN-α levels by inhibiting the number of plasmacytoid dendritic cells along with the 
function (103). Recombinant human IFNα-2a and IFNα-2b have both been successful in 
treatment of posterior uveitis (103). 
1.9.6 Breakdown of blood ocular barrier 
Ocular disease is usually treated with a topical administration of drugs in the form of a 
solution but due to the many anatomical and physiological barriers present within the eye 
these treatments have limited ocular bioavailability  (105). Due to the presence of the BRB 
other routes of drug administration such as intravenous, oral or subcutaneous are not often 
utilised because satisfactory drug concentration cannot enter the intraocular tissue (105-
107). The blood-retinal barrier (BRB) and blood-aqueous barrier comprise the blood ocular 
barrier which ensures homeostatic control of the tissue by protecting from entry of toxic 
substances.  
The blood-aqueous barrier is made up of endothelial and epithelial cells including; the 
endothelium of Schlemm’s canal, the endothelium of the iris vessels with tight junctions of 
the leaky type, the posterior iris epithelium and the non-pigmented epithelium of the ciliary 
body (105). Similarly, the BRB is also made up of endothelial and epithelial cells that form an 
ocular barrier which is the retinal pigment epithelium and an inner barrier which is the 
endothelial membrane of the retinal vessels, both have nonleaky tight junctions (105).  
Both functional barriers act to restrict movement of blood elements to the intraocular 
chambers which is what causes the drugs administered orally, subcutaneously and 
intravenously to only reach the tissue in low levels (105). In uveitis, immune mechanisms 
affect the integrity of the BRB and permit leukocyte infiltration into the eye. For this to occur, 
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changes are needed in both the leukocytes themselves and the cell that form the barrier 
(108). 
 
1.10 Disease models of uveitis 
1.10.1 Understanding disease processes 
Uveitis is a heterogeneous disease with both polygenic and environmental influences (109). 
Most forms of immune-mediated uveitis are due to an imbalance in the regulatory 
mechanisms that inhibit the immune response and inflammatory mechanisms which can 
result in chronic disease if activated outside an infection (109). Further understanding of the 
pathogenesis of the disease will influence therapies and treatments (110). Human samples 
for study to explore the pathology of this complex human disease are largely unavailable, so 
instead experimental autoimmune uveitis (EAU) has been (87) established in vivo that shares 
many pathological features with human uveitis (88). 
1.10.2 Experimental Autoimmune Uveitis 
Experimental autoimmune uveitis (EAU) is a T-cell mediated, organ specific autoimmune 
disease model that targets the neural retina and related tissues, it is often induced by 
immunisation with ocular antigens or by the adoptive transfer of uveitogenic T cells (111-
113). The model can be used to investigate a range of human uveitic diseases of an 
autoimmune or auto inflammatory etiology as it appears to share numerous immunological 
mechanisms with human uveitis. It can resemble the presentation of these diseases both 
clinically and histopathologically in a number of aspects (112) (114, 115).  
The EAU model in particular is very useful for the study of posterior uveitis as many of the 
clinical signs in humans such as vasculitis and vitritis are found in the EAU model (116). The 
model has become an invaluable tool for aiding in the development of conventional 
therapeutic strategies and novel immunotherapies. The model is also useful  for the study of 
basic mechanisms of organ-specific antigens in immunologically privileged tissue (such as the 
eye or the CNS) including tolerance and autoimmunity; thus the EAU model is a very useful 






1.10.3 Experimental Autoimmune Uveitis (EAU) Induction 
Peptides for Induction 
EAU can be induced in susceptible animals by immunisation with uveitogenic peptides in 
adjuvant or by adoptive transfer of antigen specific lymphocytes (117-119). The uveitogenic 
proteins most commonly used are retinal soluble antigen (S-Ag), retinal binding protein-3 
(RBP3, also known as Interphotoreceptor retinoid-binding protein (IRBP)), Rhodopsin, 
Recoverin and Phosducin (117).  
Retinal soluble antigen is a 48 kDa intracellular photoreceptor protein found in rod outer 
segments and is involved in the photo-transduction cascade by binding to the photo-activated 
phosphorylated rhodopsin thereby preventing the transducin-mediated activation of 
phosphodi-esterase and is often used in rat models of EAU (120, 121). 
Interphotoreceptor retinoid-binding protein (RBP3) is a large glycoliprotein that can be found 
in the inter-photoreceptor matrix (IPM) between the neural retina and retinal pigment 
epithelium, it is capable of binding retinoids and fatty acids with retinol bound in a light-
dependent manner (121, 122). Based on these characteristics, transport between retinal 
photoreceptors and pigment epithelial cells, the protein can induce EAU in rats, monkeys, 
mice and may be involved in the induction of human uveitic conditions (123, 124). 
Rhodopsin and opsin, this 40-kDa membrane protein is found in rods present in the retina, 
pathogenicity of the protein seems to be conformation dependent as rhodopsin is more 
pathogenic than opsin (121, 125).  
Recoverin is a 23-kDa calcium-binding protein, it controls phosphorylation of the visual 
receptor rhodopsin by inhibition of rhodopsin kinase in photoreceptor cells (121, 126). 
Phosducin is a 33-kDa soluble cytosolic photoreceptor protein and regulates the G-protein 
mediated signalling in the retina. From all the peptides mentioned above the most commonly 
used for EAU induction are S-Ag and RBP3 (121, 127). 
Induction in animals 
EAU can be induced by active immunisation or by adoptive transfer of uveitogenic leukocytes 
in several species of animal including mice and rats, guinea pigs, rabbits, monkeys, and horses, 
unfortunately no animal model fully represents the spectrum of human disease, but each 
model allows the study of a unique characteristic from human disease course. The rat, in 
particular is a useful model due to the detailed characterisation of the model both immune 
genetically and immunologically as well as being average in size (117). The most susceptible 
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strain in the mouse model is the B10.R111 followed by B10.A. However, the C57BL/6 mouse 
strain is a very useful model for studies into the basic mechanism of uveitis (121), and a strain 
where many genes have been targeted. 
Inbred mouse strains have identical MHC complexes, and only a few mouse strains are 
susceptible to EAU, early studies have illustrated that for a mouse strain to be susceptible to 
EAU induction it has to have both a susceptible haplotype and a permissive background (121, 
128). The haplotypes that have been identified range from highly to moderately susceptible; 
H-2r being the most susceptible such as a B10.R111 mouse, then H-2k from a B10.BR mouse 
followed by H-2b from a C57BL/6 background that is moderately susceptible to disease 
induction (121). If the uveitic response in mice involves T lymphocytes expressing specific V-
gene elements, clonal deletion of such populations might result in resistance to disease in the 
corresponding background or MHC combinations (128). For all the EAU-susceptible 
haplotypes the most ‘permissive’ background was the B10 mouse which is not known to 
delete any TCR Vβ elements, however in some genetic backgrounds, factors controlling 
cytokine and hormonal responses could also be an important element in susceptibility (128). 
Methods for Induction of EAU 
The classic EAU model in mice was reported in 1988 and further modified for efficacy of 
induction, the protein used was RBP3 as S-Ag is poorly uveitogenic in mice (121, 129). RBP3 
is emulsified in complete Freund’s adjuvant (CFA) that consists of a suspension of tuberculosis 
bacteria in a mineral oil (121). CFA plays an integral part in disease induction in both mice and 
rats, many strains also require an additional inflammatory stimulus in the form of pertussis 
toxin (121, 129). Less susceptible strains to EAU induction can be rendered non-resistant by 
treatment with pertussis toxin (PTX) at the time of immunisation (117). This is thought to 
enhance vascular permeability disrupting the blood retina barrier to allow leukocytes to 
accumulate in the target organ (130). Subcutaneous injection of the (RBP3) peptide emulsified 
in CFA with a concurrent intraperitoneal injection of pertussis toxin induces uveitis in 
susceptible mouse strains within 2-3 weeks. The role of the adjuvant is to trigger a Th1 like 
response (121). Both Th1 and Th17 cells can initiate EAU, strains that are naturally high Th1 
and Th17 responders tend to be susceptible to immunisation with uveitogenic peptides such 
as the C57BL/6 and B10.RIII mouse strains (117, 131).  
An alternate method of EAU induction is known as adoptive transfer, this technique induces 
disease by inoculating animals with lymphocytes specific for retinal antigen, these cells are 
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taken from genetically compatible donors who had been immunised for EAU and are cultured 
in vitro with the same antigen (121, 132). 
One of the advantages of using the adoptive transfer technique is that the recipients do not 
require adjuvant to induce disease and the disease resembles the clinical situation in a 
patient. It more effectively portrays a uveitic disease that arises because of circulating 
lymphocytes that have been exposed to retinal Ags (121). Specifically, knowing which cells 
within the recipient mice have been previously exposed to antigen and how the recipient’s 
endogenous immune system interacts with these cells, with the added bonus of no adjuvant 
means controlled priming of the endogenous immune response apart from the presence of 
the antigen specific cells. 
1.10.4 Other models of human uveitis 
Humanised model of experimental autoimmune uveitis in human leukocyte antigen class II 
transgenic mice 
This model uses mice that lack the murine MHC class II molecule I-A and are made transgenic 
(Tg) for the human leukocyte antigen HLA class II molecules HLA DR3, HLA DR4, HLA DQ6 or 
HLA DQ8, of these strains the HLA-DR3 mice develop the most severe disease when 
immunised with S-Ag (121, 133). Normally, several HLA class II molecules are expressed 
together, and it has been observed that transgenic mice expressing two HLA alleles are more 
susceptible than a single transgenic model; this is an indicator that different HLA molecules 
can influence each other for the development of the disease process (121, 133). Humanised 
EAU models show promise in helping identify the antigenic molecules that are responsible for 
human uveitis (121, 133). 
Experimental melanin induced uveitis 
To induce a disease that affects the uvea, melanin antigenic extracts are used. The disease 
presents as recurrent anterior uveitis (RAU) with choroiditis (121). Experimental autoimmune 
anterior uveitis (EAAU) and experimental melanin induced uveitis are induced by injecting 
crude fractions of bovine ciliary body, iris and RPE; EAAU is a well-established model of 
anterior uveitis that resembles the human disease both clinically and pathologically (121, 134, 
135). 
Endotoxin induced uveitis 
Endotoxin-induced uveitis is a useful model of anterior uveitis, it is not an autoimmune based 
model but is triggered by the intravitreal, subcutaneous, or intraperitoneal injection of 
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bacterial endotoxin lipopolysaccharides (LPS) (121, 136). Breakdown of the blood-aqueous 
barrier occurs within 2 hours after LPS injection. By histology, leukocyte infiltration is 
observed in the iris and ciliary body from 8-12 hours after injection with cell numbers reaching 
their maximum by ~24 hours (136). Most cells are polymorphonuclear leukocytes but in 
addition to this a significant increase in the mononuclear cell component of the infiltrate 
(136). Leukocytes can also appear in the anterior chamber with eosinophilic material, very 
low levels of neutrophilic infiltrate is sometimes present within the conjunctiva (136). 
Although EIU is considered to be an inflammation predominantly of the anterior uvea, 
posterior segment inflammation such as choroiditis, vitritis, vitreous haemorrhage, retinal 
vasculitis, retinal haemorrhage and inflammatory cell infiltration of the retina with focal 
destruction of photoreceptor cells (136, 137) is also seen. 
An alternate model of EAU induced with inter-photoreceptor retinoid-binding peptide 
presented by dendritic cells 
Dendritic cells are the main antigen presenting cells that have the capabilities of stimulating 
naive T-cells. A model of EAU induced by the infusion of antigen loaded DCs has been 
developed by harvesting the spleens of mice injected with Flt3L DNA and which are later 
matured in vitro with LPS and anti CD40 antibody the cells are then pulsed with RBP3 peptide 
161-180, this model differs from the classical EAU model immunologically, clinically and 
pathologically (121).  
Spontaneous uveitis models 
Human transgenic mice including the HLA-A29 Tg mouse developed by Szpak et al (138) 
spontaneously develop posterior uveitis that resembles birdshot choroidoretinopathy (121). 
Another model of spontaneous ocular inflammation is the R161H mouse that express a Tg T-
cell receptor specific for RBP3 residues 161-180 that spontaneously develop ocular 
inflammation by 6 weeks of age (121, 139). 
Autoimmune regulator (AIRE) knockout mice spontaneously develop ocular inflammation 
(140). AIRE-deficient mice fail to express many tissue antigens in the thymus, among them 
are RBP3, S-Ag and other retinal antigens, therefore over time AIRE deficient mice develop 





1.11 Immune mechanisms of EAU 
1.11.1 EAU Disease mechanisms  
Clinically, EAU is characterised by photoreceptor loss and the infiltration of lymphocytes and 
monocytes into the retinal tissue (141). The inflammatory process that occurs after disease 
induction involves the massive infiltration of lymphocytes along with mononuclear and 
polymorphonuclear cells and therefore causes a loss in vision (110). As seen in figure 1.4, it is 
useful to split EAU disease progression into 3 phases, a prodromal phase followed by a 
primary peak phase then a phase of secondary regulation (1).  Histology in early disease has 
shown extensive large numbers of cellular infiltrate including T cells, macrophages, and 
neutrophils, within the choroid, anterior uvea, retina. This type of infiltration is also often 
associated with large exudative retinal detachments (116, 142, 143).  
In mice, MHC and non-MHC gene control influences susceptibility to immunisation with RBP3. 
MHC control is suggested to be connected to the ability of the mouse strain to bind to and 
present uveitogenic epitopes whereas, it is assumed that non-MHC control is more 
complicated (117). Another important factor is the type of effector response that each strain 












Figure 1.4: EAU disease progression seen in the mouse strain B10.RIII immunised with RBP 




1.11.2 Cellular mechanisms in EAU 
Autoreactive effector CD4+ T cells have been associated with the pathogenesis of a number 
of autoimmune disorders (144). A number of animal models have been used to transfer 
autoreactive T cells to illustrate induction of autoimmune disease such as EAU and the 
multiple sclerosis model (EAE), thus the pathogenic importance of autoreactive T cells can be 
formally demonstrated (145, 146).  
EAU is a CD4 T-cell mediated disease model. It has been established in EAU models that 
immunisation with a peptide that is uveitogenic in nature triggers a peripheral immune 
response characterised by the activation and clonal expansion of pathogenic autoreactive 
CD4+ T cells (1). The activated T cell population are capable of crossing the BRB to interact 
with local APCs present within the tissue and induce a mixed population of leukocytes to 
localise within the eye and cause retinal disruption (1). 
 Autoreactive CD4+ T lymphocytes of a Th1 phenotype are critical in the pathogenesis of EAU 
alongside another CD4+ effector cell type known as Th17, which can be characterised by the 
secretion of IL-17 (147), Th17 cells have also been found to cause pathology in a number of 
other autoimmune diseases (1).  
It is difficult to determine the individual roles of Th1 and Th17 cells when they are combined 
in the establishment and maintenance of EAU, as it appears that both cell types can 
independently promote disease onset and without the use of fate mapping we cannot be sure 
of the origin of the cells causing disease (148). Long lasting changes occur within the eye after 
inflammation in the retina due to EAU these include changes in the dynamics of leukocyte 
recruitment and phenotype. The breakdown of the BRB allows antigen specific T cells to enter 
the circulation but this is not the sole trigger to cause the recruitment of lymphocytes and 










1.12 Thesis Objectives 
EAU has provided information on lymphocyte subsets entering the tissue at different times 
during the inflammatory process of the disease. In order to study the role of pathogenic CD4+ 
T cells that initiate disease, the adoptive transfer model will be utilised in naive C57BL/6 
animals not treated with adjuvant. 
 This model can be used to induce disease with uveitogenic T cell lines from an allelically 
marked donor animal into a naïve recipient, this enables the understanding of the relative 
contribution of endogenous and transferred cells in each eye by quantification by flow 
cytometry at various time points in disease progression and more generally, allows sensitive 
studies of pre-clinical disease. To track the transferred cells the mouse strains used will carry 
the allelic marker CD45.1 or CD45.2 so endogenous and transferred CD45+ cells can be 
separated.  
Within this study several genetically modified mouse models on the C57BL/6 background are 
utilised as donors and recipients within the adoptive transfer protocol. Firstly, the 
C57BL/6B6.SJL-PtprcaPepcb/BoyJ which is allelically marked Ly5.1 (also known as CD45.1).  
Using susceptible mouse strains, transgenic knock in mice have become very useful in vivo 
and in vitro research including the C57BL/6 CX3CR1 +/GFP for study of resident microglia cells 
within the eye and the brain (149).  The C57BL/6 CX3CR1 +/GFP mouse is allelically marked with 
CD45.2, within this model one of the CX3CR1 alleles has been replaced with a green 
fluorescent protein (GFP) gene. Chemokines are small proteins that are chemoattractant and 
recruit inflammatory cells to the site of inflammation (150). CX3CL1 also known as fractalkine 
exists in two forms; a membrane bound form and a soluble form (150). CX3CR1 is the specific 
receptor for CX3CL1 which makes it an attractive possibility for therapeutic intervention 
(151). The high affinity interaction of CX3CL1 with CX3CR1 mediated leukocyte arrest under 
flow conditions (152, 153).  
The third mouse model used is the RAG2-/- model allelically marked CD45.2. This model carries 
a germline mutation which results in a large portion of the RAG2 coding region being deleted. 
The homozygous mutant mice are viable but lack the ability to produce T and B lymphocytes 
(154). Therefore, this model has no endogenous adaptive lymphocyte cell compartment, so 
the only T cells present within the model will be the transferred uveitogenic T lymphocytes.  
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Another model used within this study is the TCR transgenic, C57BL/6 Ly5 OTII model allelically 
marked CD45.1. T cell receptor transgenic mouse models have had a big impact on the 
understanding of T cell biology and immunity (155). The OTII transgenic mouse have CD4+ T 
cells that express transgenic  αβ-TCRs that recognise OVA (155). This mouse strain is useful 
for transferring activated non-antigen specific leukocytes into naïve recipients.  
The final model used is the C57BL/6 IL27R- (WSX-1-/-) mouse allelically marked CD45.2. IL-27 
is a member of the IL-12 family and is produced by antigen- presenting cells, it is important in 
the regulation of CD4+ T cell differentiation and immune response (156). There are now 
studies that highlight the inhibitory effects of IL-27 on differentiation of Th17 cells and Tregs 
but will promote the differentiation of Th1 cells (156, 157). IL-27R is a heterodimer composed 
of IL-27Rα also known as T- cell cytokine receptor (TCCR) or WSX-1 and a signal transducing 
chain glycoprotein 130 (gp130) (156). This model is useful to understand further the 
complicated biology underlying IL-27 and IL-27R within autoimmune diseases. It has been 
suggested in recent studies that IL-27/IL-27R could be a useful therapeutic target to suppress 
inflammatory diseases (158). 
 
STRAIN CD45 ALLELIC MARKER 
C57BL/6 LY5 CD45.1 
C57BL/6 CX3CR1+/GFP CD45.2 
C57BL/6 CX3CR1 GFP/GFP CD45.2 
C57BL/6 OTII LY5 CD45.1 
C57BL/6 OTII LY5 CX3CR1+/GFP CD45.1 + .2 
C57BL/6 RAG2-/- CD45.2 
C57BL/6 IL-27RΑ-/- CD45.2 
 








In summary, interrelated hypotheses within this thesis relate to the tracking of antigen-
specific disease-causing immune cells at different stages of clinical disease and using the 
retinal-antigen induced model of uveitis to look for potential targets for translatable 
treatments. 
 
Allelically marked uveitogenic CD4+ T cells will initiate and drive clinical disease by 
recruitment to the ocular tissue. Do these cells concurrently stimulate an endogenous 
response causing infiltrate to be recruited to the ocular tissue throughout clinical disease 
from the endogenous compartment. 
Uveitogenic transferred cells that are recruited to the ocular tissue by an antigen-specific 
mechanism initiate clinical disease which activates the endothelium. Investigate the role of 
non-specific T cell activation.  
CX3CR1 is upregulated on CD4+ T cells in inflammatory disorders, suggesting a more long-
lived phenotype that survives in the tissue throughout disease course and could therefore 
play a role on CD4+ T cells during EAU. 
IL27Rα-/- CD4+ T cells will cause a more severe and persistent clinical disease phenotype using 


















In order to test these hypotheses, this thesis aimed to: 
 
Optimise an adoptive transfer technique to induce disease, develop a standardised method 
of imaging using optical coherence tomography to compare between eyes and experiments, 
optimise a sensitive method of quantifying cellular infiltrate by flow cytometry (chapter 3 and 
4) 
Transfer allelically marked CD4+ T cells into naïve recipients to track pathogenic cells 
throughout disease course and assess the endogenous response to the pathogenic stimulus 
(chapter 4) 
Investigate the recruitment of uveitogenic vs activated CD4+ T cells to the eye and disease 
initiation by the introduction of OVA antigen to the ocular tissue and track activated CD4+ T 
cells specific for that antigen within the recipient and the recruitment of these cells to the 
ocular tissue to induce disease (chapter 5) 
Using CX3CR1+/GFP and CX3CR1GFP/GFP mice to look at the effect of loss of CX3CR1 in recipient 
tissue on clinical disease and the effect of CX3CR1 loss on transferred cells during clinical 
disease (chapter 6).  
Analyse CX3CR1 expression on CD4+ T cells after adoptive transfer of EAU using the 
CX3CR1+/GFP mice as donors denoting CX3CR1 expression as GFP positive cells (chapter 6) 
Using the IL27Rα-/- mice, look at the effect of the loss of the receptor on transferred cells and 
the effect on disease (chapter 7).  
Characterise the effect on disease phenotype in both active immunisation and adoptive 











































Materials and Methods 
 
2.1 Reagents 
2.1.1 Immunising Peptides 
RBP-3 peptide 629-643 (EAHYARPEIAQRARA) (159) was obtained from Severn Biotech Ltd 
(Worcestershire, UK). Peptide purity was determined by HPLC. Peptide was prepared with 
distilled water and aliquoted and stored at -80°C. 
 
2.1.2 Peptides used for Intravitreal Injection 
Chicken Ovalbumin peptide (OVA) (ISQAVHAAHAEINEAGR) (159) and L144/R147 
(HSLGKLLGHPDKF) (160) was obtained from Severn Biotech Ltd (Worcestershire, UK).Peptide 
purity was determined by HPLC. Peptide was prepared with distilled water and aliquoted and 
stored at -80°C. 
 
2.1.3 Recovery Anaesthetic 
Mice were anaesthetised to perform experiments using an intraperitoneal (i.p.) injection of 
90μl/10μg of body weight of a solution containing 6mg/ml ketamine (Ketavet, Zoetis Ireland 
Ltd. Dublin, Ireland) and 2mg/ml Xylazine (Rompun, Bayer plc. Newbury UK) mixed with sterile 
water. 
 
2.1.4 Topical Eyedrops 
In order to perform clinical imaging or intravitreal injections pupils were dilated using 
tropicamide 1% and phenylephrine 2.5% (Minims, Chauvin Pharmaceuticals. UK). For corneal 
anaesthesia oxybropucaine 0.4% (Minims) was administered and Viscotears (Novartis 










2.2 Mouse Models 
Several strains of C57BL/6 mice were utilised for this work including the CX3CR1 GFP/GFP, 
CX3CR1 +/GFP, Ly5, Ly5 OTII, Ly5 OTII CX3CR1+/GFP, RAG2-/- and IL-27Rα-/-.  
 
STRAIN NAME BACKGROUND IN-HOUSE 
NAME 
SUPPLIER 
CX3CR1-GFP C57BL/6J CX3CR1+/GFP/ 
CX3CR1GFP/GFP 
A gift from 
Heping Xu 
B6.SJL-PTPRCBPEPCB/BOYJ (LY5 MICE; 
CD45.1) 
B6/SJL (Ly5) Ly5 JAX 











Table 2.1: Mouse strains and backgrounds used in this thesis 
Breeding colonies were established within the Animal Services Unit at University of Bristol, 
UK for experimentation. All mice were housed under specific pathogen-free conditions with 
continuous food and water available. Ear notches from CX3CR1GFP/GFP and CX3CR1+/GFP were 
genotyped using PCR to test the mice were of the correct genotype before experiments 
began. Blood was obtained from Ly5 OTII and Ly5 OTII CX3CR1+/GFP for phenotyping using flow 
cytometry to check the transgenic TCR before experimentation. Disease was induced in 
female mice aged between 6-8 weeks. Treatment of animals conformed to the ARVO 
statement for the use of animals in ophthalmic and vision research. 
All procedures had local ethical approval and performed in accordance with home office project 
licence (30/139) and personal licence (I073AB938) under the United Kingdom Animals (Scientific 
Procedures) Act (1986). 
 
Genetic variation has been detected in widely used C57BL/6 J CD45.2 model and the C57BL/6 
SJL CD45.1 model based on the vendor source of the mouse strains (161), however the mice 
in these studies were all obtained from the same vendor and bred within the facilities at the 























2.3 Induction of EAU 
EAU was induced in a susceptible mouse strain (C57BL/6) using active immunisation or 
adoptive transfer of uveitogenic cells. 
 
2.3.1 Active Immunisation  
Female mice were immunised subcutaneously (s.c) in both flanks with 200μl of emulsion 
containing peptide immersed in CFA (Mycobacterium Tuberculosis) was injected 
subcutaneously into C57BL/6 mice to induce EAU. 400μg/mouse RBP-3629-643 peptide in dH20 
was emulsified in Complete Freund’s Adjuvant (CFA) (1mg/mL; 1:1 vol/vol) supplemented 
with Mycobacterium tuberculosis complete H37 Ra (BD Biosciences). Bordetella pertussis 
toxin (Sigma- Aldrich) was given intraperitoneally (i.p) at 1.5μg per mouse. 
 
2.3.2 Adoptive Transfer of EAU 
Mice were immunised using the protocol described for active immunisation, 11 days after 
immunisation mice were culled by schedule 1 and spleen and various lymph nodes harvested 
in Dulbecco’s modified medium (DMEM). 
After harvest spleen and lymph nodes were mashed in DMEM using the base of a 10ml syringe 
under sterile tissue culture conditions and filtered through a 70μm filter. Cells were then 
counted and plated down in 75cm3 flasks at 1-2x106 cells per 1cm3 in complete media.  
Complete media was further supplemented with 10μg/ml RBP 629-643 peptide and 10ng/ml 
IL-23 (R&D Abingdon, UK). Cells were cultured in the incubator hydrated at 37°C and 4% CO2.  
At 24 hours, cells were removed from the incubator and supplemented further with 10ng/ml 
IL-2 (Peprotech London, UK) in a further 10ml of complete medium. Then replaced in the 
incubator in the same conditions. 
At 72 hours, flasks were removed from the incubator and washed using the medium 
containing the cells, then all media was removed from flasks. Supernatant was removed and 
the cell pellet washed in complete medium. Cells were then resuspended in 12ml of complete 
medium and split into two 15ml falcon tubes, 4ml of 1044 Histopaque (Sigma-Aldrich) was 
then layered underneath each cell suspension. The suspension was spun at 1800rpm for 20 
minutes at 21°C with 1 acceleration and 0 brake to avoid the Histopaque and cells mixing 
when spun.  
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Cells were removed using a 5ml Pasteur pipette and washed in complete medium. Cells were 
then counted using a haemocytometer and transferred at 2x106 per recipient in 100μl of PBS 
via intraperitoneal (i.p) injection. 
 
2.3.3 Adoptive Transfer using MACS separated CD4+ T cells and other leukocytes 
 Leukocytes were stimulated as previously described for adoptive transfer. After isolation 
using Histopaque, leukocytes were then separated using MACS. Whole leukocyte populations 
were run through MACS columns (Miltenyi Biotec. Ltd. Surrey, UK) in MACS wash buffer (PBS 
supplemented with 10% BSA) selecting for a CD4 negative population.  
After the column was run the CD4+ and CD4- population were both counted and transferred 
into naïve recipients at 2x106 cells per mouse in 100μl of PBS. 
 
2.3.4 Adoptive Transfer using MACS sorted cells followed by fluorescence sorting 
Leukocytes were stimulated as previously described and separated using MACS columns. The 
CD4+ and CD4- population were then counted and stained using the protocol for flow 
cytometry staining (Described in 2.6). Specifically staining for CD4+ and CD8+ T cells, the 
leukocytes from the CD4+ and CD4- populations were then run through the BD InfluxTM (BD 
Cytometry Systems. Oxford, UK) to sort for CD4+ T cells in the CD4+ MACS population and 
CD8+ T cells in the CD4- MACS population. CD4+ or CD8+ populations were then transferred 
into naïve recipients at ~50,000 cells per recipient. 
 
2.3.5 Adoptive Transfer using OTII TCR transgenic cells 
Splenocytes from OTII TCR transgenic mice were cultured in the presence of 1μg/ml of the 
OVA peptide. 
After the 72-hour cell culture, cells were prepared for transfer, in some experiments 
recipients were anaesthetised in order to perform an intravitreal injection of 2μl of OVA 
peptide at 1μg/ml. After the mice have recovered from the anaesthesia leukocytes isolated 

























2.4 Clinical Imaging  
To monitor clinical disease course after disease induction two techniques were used: Topical 
Endoscopic Fundal Imaging (TEFI) and Optical Coherence Tomography (OCT). 
2.4.1 Topical Endoscopic Fundal Imaging (TEFI) 
Using a method previously developed in the lab (162), adapted from Paques et al,(163) an 
endoscope with a 5cm long telescope of 3mm outer diameter (1218AA; Karl Storz. Tuttlingen, 
Germany) was connected to a Nikon D80 digital camera with a 10-million-pixel charge-
coupled device image sensor and Nikkor AF 85/F1.8 D (Nikon. Tokyo, Japan.), with an 
additional +4.00 dioptre magnifying lens. This system was used through pupils dilated by 
topical tropicamide 1% and phenylephrine 2.5% and topical oxybropucaine 0.4% and 
Viscotears were used for corneal anaesthesia. 
Images were obtained by direct contact of the cornea to the endoscope. Images were then 
processed using Adobe Photoshop (Adobe Corporation. Mountain View, CA). Using an 
adapted clinical grading system fundal images were scored according to inflammatory 
changes to the optic disc and retinal vessels along with any retinal lesions and structural 
damage that has occurred. Scores were calculated using the clinical scoring criteria presented 
in Table 2.1.  
 
2.4.2 Optical Coherence Tomography (OCT) 
Mice were anaesthetised using recovery anaesthetic by intraperitoneal injection and pupils 
were dilated using tropicamide 1% and phenylephrine 2.5% to prepare for imaging.  
Optical coherence tomography (OCT) scans and brightfield and fluorescence images were 
obtained using the Micron IV retinal imaging microscope (Phoenix Research Laboratories. 
Pleasanton, CA). Prior to beginning imaging the eyes the Micron IV CCD and OCT were fully 
calibrated according to the manufacturer’s protocol. The gain was set to +4 dB and the frames 
per second (FPS) set to 15 for brightfield imaging and +15dB for green fluorescence imaging. 
For green fluorescence protein imaging a filter within the Micron IV system was utilised. 
Settings for acquisition of the OCT scans were defined according to the manufacturers 
protocol, and scans were taken 30 times in rapid succession with the final image being an 
average from these images. Full-length B-scans were taken vertically and horizontally through 
the optic disc centred and one circle around the optic disc. A 3D cube scan is also taken 
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consisting of 512 images centred around the optic disc. All images were stored in TIFF file 
format, where cube images can be rendered into 3D cube videos using image processing 
techniques. 
 
2.5 Analysis of EAU 
2.5.1 Clinical Scoring of Disease  
A scoring system obtained from (Table 2.2) previously published within the group (164) was 
used to accurately score the clinical disease in recipients using the TEFI fundal images 
acquired in chapter 3 and the OCT fundus images. The single OCT line scans acquired with 
corresponding fundus imaging were scored independently by individuals experienced with 
scoring and masked to the origin of the data (Table 2.2). 
Fundal images were scored for changes due to an inflammatory response effecting the optic 
disc, retinal vessels, retinal lesions, and causing structural damage. All scores were added 




































Table 2.2: Clinical scoring overview for TEFI and OCT Fundal images. Table taken from Kerr et al 2008 
(114). 
 
2.5.2 Sample preparation for analysis 
Retinal Preparation for Flow Cytometry 
Retinal and vitreous infiltrating cells were isolated by dissection of retina and vitreous from 
enucleated eyes. The suspensions including the retina were then mechanically disrupted and 
passed through a 40-μm cell strainer to obtain a single cell suspension for staining for analysis 
by flow cytometry. 
Retinal Preparation for Flatmounting and Lightsheet imaging 
Enucleated eyes were pierced using a needle and left in fresh CytofixTM (BD Biosciences. 
Franklin Lakes, NJ) for 2 hours at room temperature (RT). The anterior chamber was then 
removed, and the eyes were placed back into the Cytofix solution overnight at RT. Retinal 
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whole mounts were then prepared by peeling the retina from the choroid under a dissecting 
microscope ready for immunofluorescence staining. 
Preparation of whole eyes for immunohistochemistry 
Mice were sacrificed at pre-defined time points and eyes were enucleated and snap-frozen, 
oriented in optimal cutting temperature (OCT) compound (R. Lamb Ltd. East Sussex, UK). After 
they were prepared and stored at -80°C, serial 12-μm sections were prepared for antibody 
staining. 
Preparation of whole organ samples for Flow Cytometry 
To further analyse transferred cells during disease more tissues were obtained from each 
recipient. These tissues include spleen, lymph node, kidney, liver, and blood.  
Spleen, kidney, and liver were prepared by mechanical dissociation of the tissue which is then 
filtered through a 70μm strainer before lysing red blood cells present within the suspension 
using ammonium-chloride-potassium buffer (ACK buffer). Cells were then resuspended in 
FACS buffer for staining. Blood samples were treated with the ACK buffer to lyse red blood 





















2.6 Flow Cytometric Analysis 
2.6.1 Cell surface staining of Flow Cytometry samples 
Single cell suspensions were incubated with purified rat anti-mouse CD16/32 Fc block (Clone 
2.4G2, BD Biosciences. Oxford UK) for 10 minutes at RT before incubation with fluorochrome-
conjugated monoclonal antibodies (mAbs) against a panel of cell surface markers including: 
CD45.2, CD4, CD8 and CD11b with a biotin mAbs CD45.1 antibody. Cells were stained with the 
live dead marker 7AAD and the secondary streptavidin for 15 minutes before suspending in 
200μl of FACS wash buffer to run samples. 
Cell suspensions were acquired using a 4-laser BDTM Fortessa X-20 flow cytometer (BD 
Cytometry systems. Oxford UK). Gating strategy is presented in figure 2.3 and analysis was 
performed using FlowJo software (Treestar. San Carlos, California). FMOs were used when 
necessary to help set gates for analysis and for confirmation of specificity of antibody staining. 
 
2.6.2 Cell counting 
Cell numbers were calculated by reference to a known cell-standard similarly to a previously 
published method from the group (114). Splenocyte suspensions of known concentration 
were acquired using a fixed and stable flow rate for 90 seconds per sample. Based on the 
number acquired using the known dilutions a standard curve was generated and from this the 
unknown total cell number from tissue samples can be interpolated if acquired at the same 
flow rate and time. 
 
2.6.3 Intracellular cytokine staining 
Single cell suspensions were incubated in complete medium supplemented with 25ng/ml 
PMA and 1μg/ml ionomycin (Sigma-Aldrich. Poole, UK) and 1μg/ml Golgi stop (BD Biosciences. 
UK) for 4 hours at 37°C in 5% CO2.  
Cells were resuspended in a fixable live dead 405 (ThermoFisher. UK) for 30 minutes at 4°C. 
The cells were then washed and stained using the previously described extracellular staining 
protocol. Stained cells were fixed using Cytofix for 15 minutes at RT and kept in the fridge for 
up to 7 days to run on the cytometer. 
When the samples were to be run on the flow cytometer, the fixed cells were washed using 
1x Perm wash for 15 minutes at 4°C and then stained using intracellular antibodies such as  
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IL-17, IFN-γ and FoxP3 for 30-45 minutes at 4°C. To run on the flow cytometer as previously 
described cells were resuspended in FACS buffer. 
 
Figure 2.3: Flow cytometry gating analysing transferred and endogenous CD4+ populations. 
Allelically marked cells were transferred into naïve recipients, eyes were enucleated at pre-defined 
time points and a single cell suspension isolated using the retinal and vitreous cells and infiltrating 
leukocytes. Lymphocytes, single cells, and live cells were gated in to give the populations of interest. 
Live cells were then separated to give the CD4+ T cell population. Through the CD4+ gate the 

















Figure 2.4: Further leukocyte gating for flow cytometry to identify different populations within the 
retinal infiltrate. Along with identification of endogenous and transferred populations specifically in 
the CD4+ T cell compartment within the retinal and vitreal infiltrate, analysis of a variety of other 
leukocytes present within the eye during clinical disease was also obtained. Lymphocytes, single cells, 
and live cells were gated in to give the populations of interest. Then from this population CD11b+ 
leukocytes can be isolated and further analysed using Ly6G and Ly6C markers. The CD4- and CD11b- 








2.7 Immunofluorescence techniques 
2.7.1 Immunofluorescence whole eye sections staining 
After sections were prepared (as previously described in section 2.5), sections were fixed in 
4% PFA for 10 minutes at RT, washed and incubated in blocking buffer (5% bovine serum 
albumin/ normal goat serum) for 3 hours at RT. Sections were then stained with rat-anti 
mouse conjugated monoclonal CD3e (Alexa Fluor 647), CD4 (FITC) or CD8a (Alexa Fluor 594) 
antibodies (BioLegend. San Diego, California) overnight at 4°C.  
Sections were then washed in PBS and stained with DAPI for 3 minutes before washing again 
and mounting using Vectashield to image on the EVOS fluorescence microscope 
(ThermoFisher. Waltham MA USA). 
 
2.7.2 Ce3D media preparation 
Ce3D media was prepared to clear and fix samples for both confocal microscopy and light 
sheet microscopy and to run the samples on the light sheet microscope. Firstly a ~29% N-
methylacetamide solution was made by mixing 13.6ml N-methylacetamide (Sigma. Poole, UK) 
with 34ml PBS. N-methylacetamide is solid at room temperature so was warmed in a water 
bath for half an hour before use. To the N-methylacetamide 50g of Histodenz powder was 
added in small quantities while solution was being stirred and kept warm. The solution was 
then left overnight. The following day 0.1% v/v Triton X-100 and 0.5% v/v 1-thioglycerol were 
added and left to mix for 4 hours. The refractive index was then checked to be around 1.47. 
The media is based on protocol used in a study by Li et al (165). 
 
2.7.3 Whole mount preparation and staining for Confocal Microscopy 
After isolation, the whole retinal mounts were washed in 1x Perm Wash (BD Biosciences. 
Franklin Lakes, NJ) tissues were then incubated in Ce3D block (1% BSA + 1% NGS in 1x Perm 
Wash) for 5 hours at 4°C. 
The Ce3D block was then replaced with the primary antibody stain composed of Ce3D block 
containing the CD3e, CD4 and CD8a antibodies previously described for section 
immunofluorescence staining and kept at 4°C for two days. The whole mounts were then 
washed using 1x Perm Wash four times over a 2-hour period. The whole mounts were then 
incubated in DAPI for 24 hours before mounting to image.  
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Retinas were spread on clean glass slides as flat as possible cutting into the tissue if necessary 
(vitreous side up), under coverslips with Ce3D media. 
 
2.7.4 Preparation of retinal tissue for Lightsheet imaging 
Whole retinas were washed in 1x Perm Wash and incubated in Ce3D block as previously 
described. The Ce3D block (1% BSA + 1% NGS in 1x Perm Wash) was then replaced with 
primary antibodies in Ce3D block including the previously described CD3e, CD4 and Cd8a 
antibodies with an additional primary unconjugated antibody for Isolectin B4 (IB4) (Sigma 
Aldrich) and kept at 4°C for two days. The whole mounts were washed using 1x Perm Wash 
four times over a 2-hour period and incubated in secondary antibody Alexa Fluor 405 
(Molecular probes, ThermoFisher. Waltham MA USA) in Ce3D block for 3 hours at 4°C.  
Retinas were washed in 1x Perm Wash before clearing using Ce3D media over the tip of a PCR 
microtube to maintain the shape. The tube with the tissue was placed into a 500μl Eppendorf 
tube filled with 200μl of the Ce3D media to keep the tissue hydrated before imaging. 
 
2.7.5 Confocal Microscopy 
Whole mounts described using the protocol in 2.7.2 were examined using confocal scanning 
laser imaging system fitted with krypton-argon lasers and a motorised XYZ stage to allow 
multiple site imaging (Leica TCS-SP2-AOBS, Leica Microsystems. Wetzlar, Germany). For 3D 
image preparation of tissues, the upper and lower limit of the tissues were determined before 
sequential z-scans at 1.5μm increments were taken through the whole thickness of the tissue 
using a 63x 1.4 aperture oil immersion lens. 
 
2.7.6 Lightsheet Microscopy 
Whole retinas obtained using the protocol in 2.7.3 were examined using Lightsheet 
fluorescence microscopy (Zeiss Z.1 Lightsheet 7. Germany). It is a multi-laser, turnkey system 
that can be used to image whole retinas suspended in Ce3D media within the tank in the 
system. Lightsheet images are collected using two high resolution sCMOS cameras using a 
range of filter modules and objectives including 20x and 40x. Automated imaging can be 
achieved to provide 3D and 4D rendering. When images were acquired the Zeiss Zen, software 
was used (Zeiss, Germany) but for further secondary analysis for 3D and 4D rendering the 
Arivis vision4D (Arivis. Munich, Germany) software was used. 
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2.8 In vitro assays 
2.8.1 Complete medium 
Complete medium used for in vitro assays such as the adoptive transfer cell culture consisted 
of Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% heat inactivated 
fetal calf serum (TCS Cellworks. UK), 100U/ml penicillin-streptomycin, and 2mmol/L L-
glutamine (Invitrogen. Paisley, UK).  
 
2.8.2 Antigen specificity assay 
Spleens and lymph nodes were collected from RBP3 629-643 immunised donors 11 days after 
immunisation and mechanically disrupted through a 70μm filter and red blood cells lysed. 
Cells were seeded into 96-well round bottom plates at 1x105 cells/well and stimulated with 
different concentrations (100μg/ml, 10μg/ml, 1μg/ml and 0.1μg/ml) of OVA RBP3 1-20 or RBP 
629-643. 
After 72 hours, supernatant was removed and stored at -20°C until used for LegendPlex 
analysis. 
 
2.8.3 Legendplex assay 
Cytokine production in adoptive transfer cell culture supernatants and the antigen specificity 
assay were measured using a LegendplexTM kit (BioLegend. San Diego, CA). Briefly, the 
Legendplex is a bead-based immunoassay that uses the same principle as a sandwich-based 
immunoassay. Bead populations are distinguished from one another based on APC 
fluorescence and size with each bead set being conjugated to a specific antibody to serve as 
a specific capture bead for that analyte being present within the sample. After washing a 
biotinylated detection antibody is added to the sample to bind to the specific analyte bound 
to the capture beads, Streptavidin-phycoerythrin (SA-PE) was added to bind to the 
biotinylated detection antibody to provide a fluorescent signal with intensities that 
represents the proportion of analyte within the sample.  
The PE signal can then be picked up by a flow cytometer (BD FACS Canto II (BD Biosciences)) 
and concentrations of each analyte quantified using a known standard curve using the 




2.9 Statistical analysis 
Animal numbers are assessed such that the experiments are powered to a probability of 80% 
that a statistically significant result is observed. Statistical analysis was performed using 
GraphPad Prism software.  
Where studies comprised of two experimental groups, for data that was not normally 
distributed a Mann- Whitney U- test was used to determine statistical significance. 
To identify statistical significance between multiple groups a one-way ANOVA with Dunnett’s 
multiple comparison test was used. 
For OCT disease scoring, Area under the curve (AUC) was calculated and then tested using a 
Mann Whitney U- test to compare the calculated AUC numbers. 
A p<0.05 was considered statistically significant. Graphs are presented as mean+ standard 
error of the mean (SEM) unless indicated otherwise. 
 
2.10 Figure adaptation 
Some figures from this thesis were adapted from previously published work using clipart 


















Table 2.3 Flow Cytometry Antibodies 
Name Isotype Format Dilution Supplier Catalogue 
number 
CD45.1 Mouse IgG2a Unconjugated 1/200 Becton 
Dickinson 
553774 
CD45.2 Mouse IgG2a BV605 1/200 BioLegend 109841 
CD45 Rat IgG2b AF700 1/200 BioLegend 103128 





BV786 1/200 BioLegend 100355 




CD4 Rat IgG2b BV421 1/200 BioLegend 100437 
CD8 Rat IgG2b PE-CY7 1/500 BioLegend 126616 
CD11b Rat IgG2b APC-CY7 1/500 Becton 
Dickinson 
557657 
LY6G Rat IgG2a PE 1/200 BioLegend 127608 
LY6C Rat IgG2c AF700 1/200 BioLegend 128024 
CD19 Rat IgG2a BV510 1/200 BioLegend 115545 
IFN-γ Rat IgG1 APC 1/200 Becton 
Dickinson 
557735 
FoxP3 RatIgG2b PE 1/200 Becton 
Dickinson 
560408 
IL-17 Rat IgG1 BV605 1/200 Becton 
Dickinson 
564169 





V450 1/500 Becton 
Dickinson 
560797 
Each dilution factor is used for samples of no more than 5x106 cells 
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2.4 Immunofluorescence Antibodies 
Name Isotype Format Dilution Supplier Catalogue 
number 
CD3 Rat IgG2b AF647 1/200 BioLegend 100209 
CD4 Rat IgG2a FITC 1/200 BioLegend 100532 
CD8a Rat IgG2a AF594 1/200 BioLegend 100758 
CD19 Rat IgG2a AF594 1/200 BioLegend 115552 
IB4 


























































Animal models of uveitis have proven very useful for the study of the underlying mechanisms 
of intraocular inflammation and as a pre-clinical model for treatments of human uveitis (159). 
Retinal antigens can be used as targets to induce EAU, they are typically derived from retinal 
photoreceptor cells that can function in the visual cycle and are highly evolutionary conserved 
(166).  
In the C57BL/6 model, mice are immunised with adjuvants (CFA and pertussis toxin) combined 
with interphotoreceptor retinoid binding protein (RBP3) derived peptides, specifically in this 
thesis using the 629-643 peptide sequence to induce EAU (159, 167).  
Alternatively, EAU can be induced using the adoptive transfer technique by transfer of primed 
uveitogenic cells (159, 167, 168). RBP-3 is a key protein in establishing ocular tolerance, the 
transfer of uveitogenic T cells from RBP-3 knockout animals illustrates the importance of RBP-
3 in the shaping of the T cell repertoire (159).  
 
3.1.1 Adoptive Transfer Technique 
Several animal models have successfully used the adoptive transfer of autoreactive T cells to 
induce autoimmune disease (146).  
To induce autoimmune disease by using the adoptive transfer model, T cells isolated from 
spleen and lymph nodes of immunised animals, are stimulated in vitro with cognate antigen 
to produce an activated phenotype. Upon transfer these T cells have the capacity to 
proliferate, produce cytokines, interact with APCs and induce cytotoxicity (169). The 
transferred T cells use all these mechanisms to induce and control disease (169).  
One of the advantages of the adoptive transfer technique is that T cells encounter the antigen 
for the first time before transfer into naïve recipients, thus the kinetics of responses of specific 
T cells to the self-antigen can be monitored from earliest encounter i.e. from point of transfer 
(170). Specifically in this study the main advantage of the adoptive transfer technique is the 
ability to track disease causing pathogenic cells throughout disease and compare it with the 






3.1.2 Adoptive Transfer of EAU 
Passive transfer was first demonstrated in EAU in 1971 by Aronson and McMaster using 
guinea pigs as the experimental model (171). The transfer technique was originally developed 
using guinea pigs with chronic uveitis as donors, cells were transferred intravenously (i.v) or 
intraperitoneally (i.p) with all recipients developing clinical disease by day 4 post transfer, 
determined by histology and uveal photography (172). This method used high numbers of 
donor cells to effectively induce disease in naïve recipients (173). When the adoptive transfer 
of lymphocytes was performed in rats, donors immunised with S-antigen were unable to 
induce EAU when injected at x108 or x109 per recipient, so the protocol was adapted to use 
an in vitro cell culture step to enhance the immunological capacities of lymphocytes, thus 
causing them to become highly uveitogenic by preincubating with the specific antigen 
required to induce disease. When subsets of T cells are purified to perform adoptive transfer, 
CD4+ T cells and T cell lines could induce EAU with an in vitro cell culture whereas CD8+ T cells 
alone were not capable of inducing the disease (173) 
Current protocols for adoptive transfer in mice uses lymphocytes from animals immunised 
with uveitogenic antigen as donors, cells are isolated from spleen and lymph nodes and to 
transfer disease after cells are activated in vitro before transfer (174). The EAU model that is 
induced by RBP3 is a useful system to study migration and the fate of autoreactive T cells that 
mediate chronic EAU.(172). The addition of IL-23 has recently been used in both EAE (175) 
and EAU (176) adoptive transfer protocols to drive a highly pathogenic CD4+ T cell population 
that are highly essential for the induction of inflammation or autoimmune disease of the CNS 
(175). To yield the highest number of pathogenic CD4+ T cells I decided to further supplement 
the cultures with IL-2 to encourage cell expansion. 
In this thesis, a more robust adoptive transfer technique was optimised for use in the C57BL/6 
mouse model using the 629-643 RBP3 peptide to induce disease, which has not yet been used 
for disease induction by adoptive transfer.  
Further to this, optimisation of the in vitro cell culture step such as the addition of IL-23 and 
IL-2 provides a pathogenic, expanded transfer population capable of inducing disease in lower 
numbers than found within the literature. The use of allelic markers in this study more easily 




3.1.3 Distinguishing Transferred from Endogenous Cells 
A major goal in study of the adaptive immune system and its responses is to understand the 
development and progression of antigen-specific T cells from naïve precursors to activated 
effector cells and long-lived memory cells (177, 178). In order to achieve this investigators 
need to track distinct populations of T cells with specificity to a single antigen (such as RBP3) 
throughout the course of an immune response (178). Discrimination of donor T cells from the 
endogenous T cells is dependent on donor T cells expressing a marker that is unique but 
doesn’t provide a target that would cause the recipient mouse to reject the transferred cells 
(178).  
A number of allelic variations of surface receptors have been bred into transgenic mice, the 
most common are CD45.1/2 and CD90.1/2 (177). T cells expressing the CD45.1 allele can be 
adoptively transferred into C57BL/6 mice which express the CD45.2 allele (177-179). Using 
antibodies specific to the different allelic forms of these markers can then be used to identify 
the donor and recipient populations (177). The flexibility of using the allelic markers CD45.1 
and CD45.2 can be used to investigate both transferred and endogenous cells. This therefore 
allows for monitoring of antigen-specific transfer cells throughout disease course not only in 
the eye but in other organs within the recipient and how the recipient’s own immune 
response interacts with the transferred cell population. 
 
3.1.4 Analysis of Clinical Disease in vivo 
Analysis of clinical disease in vivo is a very useful tool to understand clinical disease course in 
recipients. Retinal imaging has been revolutionised by the development of optical coherence 
tomography (OCT) in both mouse and humans (180). Quantification of changes within the 
retinal layers has relied upon histology but histology is labour intensive and does not allow 
for the same mouse to be monitored for disease over time (180).             
OCT recognises structures in the retina based on the scatter of reflected light and reaches 
axial resolutions down to 4μm, advancing the prospect of observing histological detail in vivo 
throughout disease (181). One of the most important benefits of using OCT for clinical scoring 
of EAU similar to the detail of histology would permit the same staging of disease over time 




To develop a scoring system for analysing disease, a standardised method would allow 
comparison of images not just through disease in one eye but comparison of eyes across 
experiments and between experiments.  
 
This aim of this chapter is to on develop a robust adoptive transfer technique that allows in 




























3.2 Materials and Methods 
 
3.2.1 Adoptive Transfer Technique 
Pathogenic polyclonal antigen specific cells were produced by immunising different donor 
strains with RBP3 peptide, these donor cells were then transferred using i.p injection into 
C57BL/6 recipients at variable cell concentrations to determine the optimum number of cells 
needed to induce a disease. 
C57BL/6 Ly5 (CD45.1) were immunised and cells transferred into RAG2 deficient mice as a 
leukocyte population or sorted cells. 
 
3.2.2 Flow Cytometry Analysis 
Flow cytometry was used to identify subsets of cells within the transferred cell population 
and retinal infiltrate using extracellular and intracellular staining. 
Within transferred recipients’ allelic markers CD45.1 and CD45.2 were used to identify 
endogenous and transferred populations of cells within the retina. 
 
3.2.3 MACS Sorting and Fluorescent Associated Cell Sorting 
CD4- MACS sorting was used to isolate a CD4+ population from a total leukocyte cell 
population from WT C57BL/6 mice, the CD4+ and CD4- population were then transferred into 
RAG2-/- mice. A purer population was required after MACS sorting so additional FACS was 
used to obtain a purer population of CD4+ and CD8+ T cells for transfer into RAG2-/- recipients. 
 
3.2.4 Legendplex 
Legendplex analysis is a bead-based immunoassay that utilises the same principles of 
sandwich immunoassays, where a soluble analyte is captured between two antibodies 
(Biolegend,2019). 
Legendplex analysis was used on supernatant from splenocyte cultures taken from 
immunised donors stimulated with different peptides to identify and quantify cytokines 
expressed by cells present within the culture supernatant. 
Supernatant from cultures of transferred cells were also analysed using LegendPlex and 
compared across recipient genotype.  
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3.2.5 Clinical Imaging 
TEFI was used to study onset of disease and disease severity without anaesthetising the 
animal, this was then followed by OCT scans and fundus images standardised across recipients 































3.3.1 Optimisation of cell culture for use in adoptive transfer protocol to 
induce EAU 
Useful information about immunopathogenic mechanisms of autoimmune disease have been 
obtained from studies of the adoptive transfer of serum or lymphoid cells from immunised 
donors (132).  More reproducible attempts to induce EAU have been made by transferring 
lymphoid cells (132, 171, 182). The efficacy of the transfer of disease by lymphoid cells was 
increased greatly by preculturing the cells with the organ-specific antigen such as RBP3, a 
number of studies demonstrated this in models of EAE using the pMOG peptide but this effect 
has also been shown in the EAU transfer model (132). 
Cells were transferred as total leukocyte populations, to determine optimal cell density, the 
concentration of cells was then compared with the cell yield (Figure 3.1a) for transfer, that 
concurrently can provide the greatest percentage of CD45+ CD3+ (Figure 3.1b) and  CD4+ cell 
numbers (Figure 3.1c) to allow more transfers to be performed. The density most suited in 
terms of yield from cells plated down and highest percentage of CD4+ T cells yielded from the 
culture is at 1x106 cells plated down per 1cm3 (figure 3.1a and figure 3.1c).  
To further increase the efficacy of the cell culture conditions, the T cell growth factor IL-2 to 
maximise cell viability and the cytokine IL-23 was used to select a pathogenic cell population 
of IL-17 and IFN-γ producing phenotype. Therefore, experiments investigating the time point 
of cytokine addition of IL-23 and IL-2 to cultures can affect percentage yield of CD45+ CD3+ 
(Figure 3.1d) and CD4+ and CD8+ (Figure 3.1e). Yield also changed with the concentration of 
the cytokine IL-23 (Figure 3.2a) and origin of the IL-2 (mouse or human) (Figure 3.2b).  Further 
analysis considered the percentage of CD4+, CD8+ and CD11b+ cells present within the 
cultures using different IL-23 concentrations and species origin of IL-2 (Figure 3.2e and 3.2f). 
The highest percentage yield of CD4+ T cells was addition of IL-23 at 0 hours followed by IL-2 
at 24 hours (figure 3.1e). Study of the species origin of the IL-2 highlighted a greater total cell 
yield per flask and a greater disease incidence when using murine IL-2 when compared to 
human IL-2. The addition of 10ng/ml IL-23 gave a high enough cell yield that cells could be 
used at and a good disease incidence and severity when transferred into recipients, whereas 
the 20ng/ml gave a doubled cell yield compared to the 10ng/ml of IL-23 but a similar disease 
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incidence suggesting no added effect on pathogenicity was caused by doubling IL-23 
concentration in the cell cultures. 
After analysis of cell culture and analysis of disease in recipients comparing cell cultures 
(Figure 3.2c and 3.2d) it was identified which conditions will give the most robust disease 
across recipients. This analysis is useful as reliable disease incidence and severity allows the 






















































Figure 3.1: Optimisation of culture conditions analysis for in vitro step of adoptive transfer 
protocol. (A)  Cell yield from culture based on cell density plated down at 1x106, 2x106 and 4x106 
(Mean + SEM) (B) Percentage of CD45+ CD3+ cells obtained from cell cultures at densities 1x106, 2x106 
and 4x106  (Mean + SEM) (C) Percentage of CD4+ and CD8+ cells obtained from cell cultures at densities 
1x106, 2x106 and 4x106  (Mean + SEM) (D) Percentage of CD45+ CD3+ cells obtained from cell cultures 
with different time points for addition of IL-23 and IL-2 (Mean + SEM) (E) Percentage of CD4+ and 
CD8+ cells obtained from cultures with different time points for addition of IL-23 and IL-2 (Mean + 
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Figure 3.2: Effects of cytokines added to the in vitro step of adoptive transfer protocol 
(A) Quantification of cells recovered from cultures with varying concentrations of IL-23 (10ng/ml and 
20ng/ml) (Mean + SEM) (B) Quantification of cells from cultures with murine or human IL-2 species 
origin (10ng/ml) (Mean + SEM) (C) Representative OCT time course of clinical disease in recipients that 
received cell transfers from cultures primed with varying concentrations of IL-23 (10ng/ml or 20ng/ml) 
2x106 transferred per recipient. OCT image acquired through optic disc (green line on fundal image) 
(D) Representative OCT time course of clinical disease in recipients that received cell transfers from 
cultures primed with murine or human IL-2 at 10ng/ml 2x106 transferred per recipient. OCT image 
acquired through optic disc (green line on fundal image) (E-H) Corresponding cell culture analysis of 
cells transferred into naïve recipients from cultures used to optimise cytokine addition, percentage of 
CD4+ T cells, CD8+ T cells, CD11b+ cells and other leukocytes from the transferred population. 
















3.3.2 Analysis of clinical disease using OCT  
OCT is very useful in monitoring clinical disease progression in recipients and matching 
disease severity across recipients. 
In order to compare disease across recipients in one experiment and compare recipients 
across experiments, a standardised way of acquiring OCT needed to be developed.  
Firstly, day 0 OCT was acquired before inducing disease to check if recipients are normal 
before cell transfer. At this stage the retinal layers are clearly visible and easily distinguished 
(Figure 3.3). The corresponding fundal imaging shows by the green scanning line where the 
OCT is taken and a clear fundus before disease induction (Figure 3.3). In the OCT image (Figure 
3.3) the vitreous has no infiltrate and the optic disc is not swollen. 
OCT was taken from each mouse at exactly the same points in each experiment for each eye 
which include a 0° horizontal line through the optic disc, a 90° vertical line through the optic 
disc, a circle around the optic disc and a volume scan around the optic disc (Figure 3.4b, Figure 
3.5a).  
In comparsion to the day 0 OCT (Figure 3.3), a diseased OCT (Figure 3.4a) shows lots of retinal 
infiltrate and a swollen optic disc along with a fundal image containing vitreal haze (Figure 
3.4b). The line scans allow acquisition of a 2D image through the optic disc but in order to 
obtain more information for quantification of disease a 3D cube around the optic disc allows 
a more complete assessment of the inifltrate within diseased retinas.  
A 3D volume scan was taken around the optic disc of the recipients at each time point to 
quantify disease course between different disease groups and at different time points, each 


























Figure 3.3: Baseline OCT images for standardisation throughout and across experiments. 
Baseline normal OCT taken at day 0 (A), corresponding fundus imaging taken with OCT image, the 
green line denotes where the OCT is taken from (B). Full description of retinal layers observed within 







































Figure 3.4: Diseased OCT of adoptive transfer recipients illustrating full OCT acquisition 
method. Retinal infiltrate is observed within the vitreous corresponding with a thickening retina and 
swollen optic disc with corresponding fundus image showing a vitreous haze and sheathing of immune 
infiltrate along vessels (A-B). Along with a 0° line scan a 90°-line scan and a circle around the optic disc 



















































Figure 3.5: 3D volume OCT acquisition and video. To acquire a 3D volume the optic disc is once 
again used as a reference point to acquire around a fundus image was also taken to illustrate cube 
placement on each eye (A). The cube is the acquired by the OCT made up of 512 individual slices which 




















3.3.3 Preliminary analysis of clinical disease produced by using the optimised 
adoptive transfer model  
Optimisation of the cell culture step in the adoptive transfer protocol produced disease with 
an incidence and severity that allowed preliminary analysis of the disease induced in naïve 
recipients. In previous studies, induction of disease using adoptive transfer in C57BL/6 mice 
needed a cell transfer of ~50-100x106 total leukocytes to cause disease that developed at day 
7 by fundal imaging and histopathology (117, 183).  
Using the conditions optimised from figure 1 and 2, preliminary analysis of disease induced 
by adoptive transfer could be done using techniques such as TEFI, OCT, Flow Cytometry and 
Immunohistochemistry (Figures 3.6-3.8).  
Cells were transferred as total leukocyte populations into naïve C57BL/6 mice at different cell 
numbers intraperitoneally, resuspended in PBS ranging from 5x104 – 4x106 cells per recipient 
(figure 3.6a-i). The cell number that gave a high disease incidence and a moderate clinical 
disease phenotype was 2x106 per recipient (figure 3.6b and figure 3.6j and 3.6k).  
Flow cytometric analysis of recipients at peak disease (day 7 and day 14) using allelic markers 
illustrated the ability to track cells in the endogenous and transferred cells using the markers 
(Figure 3.8a).  
The percentages of CD4+ and CD8+ T cells that are endogenous and transferred at each of the 
time points during clinical disease (Figure 3.8b-3.8e) can be calculated using the gating 
strategy in figure 3.8a. 
Further analysis of sections of whole eyes can be achieved using immunohistochemistry 
staining for CD3, CD4 and CD8 to analyse where in the tissue the cells reside (Figure 3.7a and 
3.7b) 
All methods combined can allow for in vivo analysis of clinical disease by imaging followed by 
quantitative analysis of endogenous and transferred cells at specific time points as well as 
frozen sections taken from OCT embedded whole eyes or whole mounts to analyse location 












Figure 3.6: Analysis of disease severity and incidence using TEFI and OCT after adoptive cell 
transfer of primed uveitogenic cells into naïve recipients. (A-C) Representative TEFI time course 
from day 3 to day 7 after transfer of uveitogenic cells into naïve recipients, cells are transferred as 
total leukocytes at 4x106, 2x106 or 1x106 per recipient. (D-F) Representative TEFI time course from day 
5 to day 11 after transfer of uveitogenic cells into naïve recipients, cells are transferred at 1x106, 
250,000 or 50,000 per recipient. (G-I) Corresponding OCT time course of clinical disease illustrating 
clinical features of disease using OCT imaging alongside fundal imaging.  (J) Percentage of disease 
incidence in recipients that received 4x106, 2x106 or 1x106 transferred uveitogenic cells calculated 
using TEFI imaging throughout clinical disease. (K) Percentage of disease incidence in recipients that 
received 1x106, 250,000 or 50,000 transferred uveitogenic cells. 










Figure 3.7: Immunohistochemistry allows detection of CD3+ CD4+ and CD3+ CD8+ T cells 
within sections of whole tissue. (A) Co-staining of CD3+ CD8+ T cells within sections of eyes from 
recipients of adoptive transfer of uveitogenic cells at day 7 (Magenta-CD3, Red-CD8) (B) Co-staining 
of CD3+ CD4+ T cells within sections of eyes from recipients of adoptive transfer of uveitogenic cells 








Figure 3.8: Preliminary analysis of disease induced using adoptive transfer using flow 
cytometry. (A) Exemplar gating strategy used for flow cytometry analysis, firstly gate for CD4+ and 
CD8+ cells then gate using allelic markers CD45.1+ and CD45.2+ to detect endogenous and transferred 
CD4+ and CD8+ T cells. (B-C) Percentage of total CD4+ and CD8+ T cells that express CD45.1 
(Endogenous) or CD45.2+ (Transferred) at day 7. (D-E) Percentage of total CD4+ and CD8+ T cells that 







3.3.4 Characterisation of transferred cells using extracellular and intracellular 
staining  
When cells were transferred into naïve recipients using the optimised cell culture conditions 
disease was induced with as few as 50,000 cells but the most robust cell number for disease 
incidence and severity was 2x106 cells transferred per recipient. 
A more detailed analysis of transferred cells (Figure 3.9) and supernatant from the cell 
cultures (Figure 3.10) allowed further study of the phenotype of disease-causing cells that 
were being injected into the recipients.  
As EAU is mediated by CD4+ T cells specific for retinal antigens that secrete cytokines and 
chemokines within the eye during disease (184), analysing the concentration of cytokines that 
are secreted within the supernatant of the cultures before transfer (Figure 3.9) specifically 
that are involved in polarising the culture especially CD4+ T cells to a Th1 and Th17 phenotype 
such as IFN-γ and IL-17 are valuable for understanding what cells are being transferred in the 
total leukocyte population. 
Flow cytometric analysis of cells from different donor mice using extracellular staining to look 
for markers such as CD4, CD8 and CD11b alongside intracellular cytokine staining to analyse 
CD4 T cell phenotype for cytokines such as IFN-γ, IL17 and FoxP3 was used to investigate 

























Figure 3.9: Extracellular and intracellular analysis of adoptive transfer cell cultures from 
different donor mice. (A-D) Extracellular staining of cultures obtained spleen and lymph nodes from 
different donor mice at day 11 after immunisation and 72 hours in vitro culture. (A) Donor cells 
obtained from a CX3CR1 heterozygous knockout (B) Donor cells obtained from a CX3CR1 knockout (C) 
Donor cells obtained from OTII TCR transgenic mouse (D) Donor cells obtained from Ly5 (WT). (E-H) 
Intracellular staining of cultures obtained from spleen and lymph nodes from different donor mice at 
day 11 after immunisation and 72 hours in culture, cells were re-stimulated with PMA and Ionomycin 
for 4 hours at 37°C before extracellular staining was performed then cells were fixed and intracellular 
staining performed for FACS analysis. Populations shown include, CD4+, CD4+ IL-17+, CD4+ IFN-γ+ and 
CD4+ FoxP3+. (E) Donor cells obtained from CX3CR1 heterozygous knockout (F) Donor cells obtained 
from CX3CR1 knockout (G) Donor cells obtained from OTII TCR transgenic mouse (H) Donor cells 
obtained from Ly5 (WT).  



























Figure 3.10: Legend Plex analysis of culture supernatant from donor cells. (A-M) Supernatant 
acquired from cell cultures from different donors: Ly5 (WT), CX3CR1 heterozygous knockout, CX3CR1 
knockout which were pathogenic on transfer and OTII (TCR transgenic) cells which are activated used 
for adoptive transfer to induce EAU and analysed using 13-plex Legend Plex assay. (A) Concentration 
of IL-23 in supernatant of donor cell cultures (pg/ml) (B) Concentration of IL-1α in supernatant of 
donor cell cultures (pg/ml) (C) Concentration of IFN-γ in supernatant of donor cell cultures (pg/ml) (D) 
Concentration of TNF-α in the supernatant of donor cell cultures (pg/ml) (E) Concentration of MCP-1 
in supernatant of donor cell cultures (pg/ml) (F) Concentration of IL-12p70 in supernatant of donor 
cell cultures (pg/ml) (G) Concentration of IL-1β in supernatant of donor cell cultures (pg/ml) (H) 
Concentration of IL-10 in supernatant of donor cell cultures (pg/ml) (I) Concentration of IL-6 in 
supernatant of donor cell cultures (pg/ml) (J) Concentration of IL-27 in donor cell cultures (pg/ml) (K) 
Concentration of IL-17A in donor cell cultures (pg/ml) (L) Concentration of IFN-β in donor cell cultures 
(pg/ml) (M) Concentration of GM-CSF in donor cell cultures (pg/ml). 














3.3.5 Analysis of cross reactivity between peptides causing upregulation of 
cytokines in splenocytes in vitro after immunisation  
The diversification of the immune response that is induced by a tissue to a new T cell and/or 
antibody specificities during an autoimmune disease is known as epitope spreading (185). 
Epitope spreading can be defined as the development of immune responses to endogenous 
epitopes after the release of antigens during an autoimmune response. Evidence has been 
found to support a major role of epitope spreading in the pathogenesis of chronic EAE (186). 
Multiple factors are involved in the induction of epitope spreading including enhanced display 
of previously cryptic determinants under the local inflammatory and cytokine environment. 
These follow tissue damage alongside differences in the size of the epitope specific T cell 
subsets (185). Evidence from studies in autoimmune disease shows that disease progression 
may be due to an activation of autoreactive lymphocytes, regardless of the event that 
initiated them (186, 187). These autoreactive lymphocytes are specific to epitopes that are 
distinct from and non-cross-reactive with disease inducing epitopes that result in chronic 
tissue damage (186, 187). The broadening of the immune response can target epitopes either 
within the same antigen known as intramolecular spreading or another antigen known as 
intermolecular spreading (185).  
Mice were immunised with RBP3 peptide and spleens isolated at day 11, all cultures were 
stimulated in culture with IL-23 (10ng/ml) at 0 hours and IL-2 (10ng/ml) at 24 hours. At this 
stage it may be considered too early to observe epitope spreading as the immunised mice 
have not reached peak clinical disease. The cultures were split at 0 hours and one of 3 
peptides were added OVA, RBP3 629-643 or RBP3 1-20 at varied concentrations of 0.1μg/ml, 
1μg/ml, 10μg/ml or 100μg/ml. This data shows no evidence of epitope spreading at the time 
of adoptive transfer but further experimentation into the transferred and endogenous CD4+ 
populations present in the eyes of recipients during peak disease could be used to further 
look into epitope spreading when using the adoptive transfer technique. 
Overall, stimulation in vitro with RBP3 629-643 gives an increase in secretion of IFN-γ and IL-
17 compared to OVA and RBP3 1-20. There is also a correlation between increase of 
concentration of peptide causing increase in secretion of IFN-γ and IL-17 suggesting an 
increase of Th1 and Th17 CD4+ T cells within the culture (Figure 3.11a and 3.11b). The same 

















Figure 3.11: Analysis of antigen specificity in splenocytes obtained from C57BL/6 mice 11 
days after immunisation with RBP3 (629-643) peptide using 13-plex Legend Plex analysis. 
(A-M) Supernatant obtained from 72 hour splenocyte culture from mice immunised with RBP3 (629-
643) at day 11, supplemented with 10ng/ml IL-23 and 10ng/ml IL-2 and either RBP3 (629-643) (blue) 
RBP 1-20 (purple) or OVA (red) peptide. (A) Concentration of IFN-γ in splenocyte cultures 
supplemented with each peptide (pg/ml) (B) Concentration of IL-17A in splenocyte cultures 
supplemented with each peptide (pg/ml) (C) Concentration of IL-12p70 in splenocyte cultures with 
each peptide (pg/ml) (D) Concentration of TNF-α in splenocyte cultures with each peptide (pg/ml) (E) 
Concentration of GM-CSF in splenocyte cultures with each peptide (pg/ml) (F) Concentration of IL-1β 
in splenocyte cultures with each peptide (pg/ml) (G) Concentration of MCP-1 in splenocytes in cultures 
with each peptide (pg/ml) (H) Concentration of IL-1α in splenocyte cultures with each peptide (pg/ml) 
(I) Concentration of IL-10 in splenocyte cultures with each peptide (pg/ml) (J) Concentration of IL-6 in 
splenocyte cultures with each peptide (pg/ml) (K) Concentration of IL-23 in splenocyte cultures with 
each peptide (pg/ml) (L) Concentration of IL-27 in splenocyte cultures with each peptide (pg/ml) (M) 
Concentration of IFN-β in splenocyte cultures with each peptide (pg/ml). 












3.3.6 Transfer of pathogenic cells into immunocompromised mice causes 
severe clinical disease 
When uveitogenic T cells are transferred into wildtype mice, the recipients develop clinical 
disease that peaks at day 7-10 (Figure 3.6). Analysis of retinal infiltrate by flow cytometry 
illustrates a recruitment of both endogenous and transferred CD4+ T cells in similar numbers 
to the eye during peak clinical disease (Figure 3.8). But in the CD8+ compartment a large 
number of endogenous cells are recruited but transferred cells do not appear to survive or 
proliferate and recruit to the eye during active clinical disease (Figure 3.8). 
To understand if the transferred cells alone are sufficient to cause clinical disease without 
recruiment of endogenous T cells, a pathogenic transfer into immunocomprimised mice was 
undertaken. 
RAG2-/- mice lack mature T and B cells so will not have an endogenous repsonse to the transfer 
of pathogenic T cells. 
When  a whole leukocyte population of pathogenic wildtype cells are transferred into       
RAG2-/- mice, clinical disease is induced by day 7 similar to the previous transfers (Figure 3.6) 
but by day 14 a more severe disease is observed in the RAG2-/- recipients in comparison to 
the wildtype recipients. When retinal infiltrate was analysed by flow cytometry, an increase 
of CD4+ T cells is observed between day 7 and day 14. In the CD8+ T cell compartment an 
expansion and recruitment of transferred cells is observed at day 7 and day 14 within the 
retinal infiltrate, showing that CD8+ T cells survive within recipients that are 
immunocompromised and may play a part in the disease process, but this is not the case 
within wildtype recipients (Figure 3.12).  
Due to the expansion of CD8+ T cells within RAG2-/- recipients, to assess if CD4+ T cells alone 
were sufficient to induce disease, a pure population of CD4+ T cells were transferred to these 
mice. A CD4 negative MACS isolation was used to isolate CD4+ T cells, when the population 
was analysed by flow cytometry a small population of other leukocytes such as CD8+ cells was 
detected within the transferred cell population (Figure 3.13) the CD4+ population was >65% 
compared to previous cultures with no MACS isolation where the percentage of CD4+ cells 
was ~35% (Figure 3.6). After transfer, clinical disease incidence and severity was analysed 
using in vivo imaging. By day 7 both the CD4+ and CD4- transfers developed clinical disease 
(Figure 3.13h), at day 22 eyes were analysed by flow cytometry to quantify leukocyte 
populations within the retina (Figure 3.13i-k).  
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Due to the RAG2-/- recipients developing clinical disease after MACS isolation of a CD4- 
leukocyte population (Figure 3.13), a purer CD4- CD8+ cell population was prepared using a 
CD4- MACS seperation that was then sorted using fluorescent associated cell sorting to isolate 
a CD8+ population for adoptive transfer. Recipients were monitored using clinical imaging to 
day 28, the CD4+ transferred population caused clinical disease to occur by day 7 after 
transfer with disease continuing through to day 28. Whereas, the CD8+ transfer did not induce 
clinical disease observed by clinical imaging fom day 7 through to day 28 (Figure 3.14a-h) 
when retinal infiltrate was analysed by flow cytometry at day 28 a small CD4+ population 
could be detected in the CD8+ transfer suggesting an expansion of the small CD4+ population 
that after MACS isolation and FACS sorting still was present in the CD4- CD8+ population 
transferred into RAG2-/- recipients (Figure 3.14i-k). 
Finally to  study, leukocyte trafficking of CD4+ T cells within the eyes of recipients in RAG2-/- 
mice intravitreal injections of MACS isolated CD4+ T cells were injected into the left eye of 
recipients. The recipients were then monitored using the micron IV with fluorescent filters to 
track transferred CAG GFP expressing cells from the left eye to the right eye over time (Figure 
3.15a-i). Clinical disease was not observed through clinical imaging to day 28 (Figure 3.15a-i), 
at day 28 analysis of retinal infiltrate illustrated a small population of CD4+ T cells was present 
in both eyes along with blood, spleen and lymph node (Figure 3.15j-n) but an increased 
number of CD4+ T cells were found in the eye that received the CD4+ population transfer in 
























AVERAGE CELL NUMBER 
  
 
Day 7 Day 14 
CD4 11000 25033 
CD8 172 835 
CD11B 57720 56339 
 
 
Figure 3.12: Analysis of transfer of 2x10
6
 Ly5 uveitogenic cells as a whole population of 
leukocytes isolated using Ficoll density centrifugation into RAG2
-/-
 mice at day 7 and day 14. 
(A) OCT and fundus imaging of RAG2
-/-
 recipients at day 7 after transfer of uveitogenic cells (B) Fundus 
imaging of RAG2
-/-
 recipients at day 14 after transfer of uveitogenic cells (C-E) Analysis of eyes taken 
from RAG2
-/-
 recipients at day 7 and day 14 after transfer using flow cytometry to identify immune cell 
infiltrate using extracellular markers and absolute numbers to quantify infiltrate. (C) Total number of 
CD4+ T cells present within the eyes of recipients at day 7 and day 14 after transfer using extracellular 
staining and absolute numbers protocol (D) Total number of CD8+ T cells present within the eyes of 
recipients at day 7 and day 14 after transfer using extracellular staining and absolute numbers protocol 





































AVERAGE CELL NUMBER 
  
 
CD4+ MACS CD4- MACS 
CD4 13864 5926 
CD8 155 1329 
CD11B 13036 13001 
 
Figure 3.13: Adoptive transfer of MACS isolated leukocytes using a CD4 negative MACS 
isolation into RAG2
-/-
 recipients at 2x10
6
 CD4+ or 2x10
6
 CD4- cells per mouse. (A-D) Analysis 
of cells transferred into RAG2
-/-
mice (A) Extracellular analysis of CD4+ cells isolated by CD4 negative 
MACS isolation for cell transfer (B) Extracellular analysis of CD4- cells isolated by CD4 negative MACS 
isolation for cell transfer (C) Intracellular analysis of CD4+ T cells isolated for transfer by CD4 negative 
MACS isolation (D) Intracellular analysis of CD4+ population present within the CD4- population 
obtained using CD4 negative MACS isolation. (E-H) OCT and fundus imaging following clinical disease 
in both CD4+ and CD4- groups of recipients (E) Fundus imaging of CD4+ transfer at day 7 after cell 
transfer at 2x10
6
 cells transferred per mouse, no OCT is shown due to severity of cellular infiltrate (F) 
OCT and fundus imaging of CD4+ transfer at day 22 after transfer (G) OCT and fundus imaging of CD4- 
transfer at day 7 after cell transfer at 2x10
6
 cells transferred per mouse (H) OCT and fundus imaging 
of CD4- transfer at day 22 after transfer (I-K) Flow Cytometry analysis of eyes from RAG2
-/-
 recipients 
at day 22 after transfer of CD4+ or CD4- populations. (I) CD4+ populations present within the eyes of 
the groups of CD4+ and CD4- transfer recipients at day 22 (J) CD8+ populations present within the 
eyes of the groups of the groups of CD4+ and CD4- transfer recipients at day 22 (K) CD11b+ populations 














AVERAGE CELL NUMBER 
  
 
CD4+ Sort CD8+ Sort 
CD4 70566 111 
CD8 1157 66 
CD11B 28374 1762 
 
Figure 3.14: OCT and flow cytometry analysis of transfers of MACS isolated CD4+ and CD4- 
leukocytes. Populations are stained using flow cytometry antibodies and sorted using a fluorescence 
cell sorter to obtain a purer population of CD4+ and a purer population of CD8+ T cells which are then 
transferred at 500,000 cells per mouse into RAG2
-/-
 recipients. (A-H) OCT and fundus imaging of CD4+ 
and CD8+ transfer following disease course from day 7 to day 28. (A) Representative clinical imaging 
at day 7 by fundus and OCT of recipients that received a CD4+ T cell transfer (B) Representative clinical 
imaging at day 15 by fundus and OCT imaging of recipients that received a CD4+ T cell transfer (C) 
Representative clinical imaging at day 22 fundus and OCT of recipients that received a CD4+ T cell 
transfer (D) Representative clinical imaging at day 28 by fundus and OCT of recipients that received a 
CD4+ T cell transfer (E) Representative clinical imaging at day 7 by fundus and OCT of recipients that 
received a CD8+ T cell transfer (F) Representative clinical imaging at day 15 by fundus and OCT of 
recipients that received a CD8+ T cell transfer (G) Representative clinical imaging at day 22 by fundus 
and OCT of recipients that received a CD8+ T cell transfer (H) Representative clinical imaging by fundus 
and OCT of recipients that received a CD8+ T cell transfer. (I-K) Analysis by flow cytometry of eyes from 
CD4+ and CD8+ transfer recipients at day 28 using extracellular staining and absolute numbers to 














AVERAGE CELL NUMBER 
     
 
Blood Lymph Node Spleen Invit eye (LE) RE 
CD4 1223 2289 14194 151 132 
CD8 26 74 887 117 166 
 
 
Figure 3.15: OCT and flow cytometry analysis of RAG2-/- recipients of CD4+ and CD8+ MACS 
then FACS sorted populations. CD4+ or CD8+ cell populations were isolated from cell cultures of 
CAG GFP tagged donor cells firstly using a CD4- MACS isolation, then after antibody stains for CD4 or 
CD8 cells are sorted using fluorescent associated cell sorting for pure populations of CD4+ or CD8+ T 
cells. Recipients then received an intravitreal injection of 50,000 CD4+ or CD8+ T cells into the left eye. 
RAG2-/- recipients were monitored using the micron IV camera with fluorescent filters to track GFP 
tagged cells in the left and right eyes (A-I). 
At day 28, retinal infiltrate was analysed in all recipient eyes and CD4+ and CD8+ numbers quantified 
(J-K). To analyse leukocyte migration from the eye to the blood (L) and lymphoid organs such as 






























This chapter outlines a robust adoptive transfer technique using total leukocyte populations 
to induce EAU along with preliminary analysis of recipients at peak disease after transfer and 
of the cell populations transferred. It also illustrates the use of allelic markers to track 
transferred and endogenous cells throughout disease using allelic markers. 
Before proceeding with full analysis of clinical disease course after adoptive transfer, I 
characterised a transfer technique using a novel RBP3 peptide to induce disease for analysis. 
This involved inducing a phenotype that could be easily monitored using clinical imaging, the 
protocol was adopted from the method developed by the Caspi group (176). The first step of 
the protocol is immunisation with RBP3 peptide which has already been optimised within our 
group (188) followed by a 72 hour cell culture which was optimised in terms of addition of 
antigen and cytokines. The addition of the immunising antigen to the cell culture is used to 
re-stimulate the CD4+ T cells in vitro, the cells may also be propagated in vitro using the 
addition of IL-2 (189). The addition of IL-23 has been demonstrated to play a pivotal role in 
establishment and maintenance of organ-specific inflammatory autoimmune disease (175). It 
has also been shown in vitro that IL-23 promotes a T cell population characterised by 
production of IL-17A, IL-17F, TNF and IL-6, when these cells are used for adoptive transfer into 
naïve recipient mice IL-23 dependent T cell subsets invade the target organ and can promote 
the development of organ-specific autoimmune inflammation (175). So, the optimisation of 
the addition of IL-23 and IL-2 to the transfer cell cultures to give the most effective leukocyte 
population for cell transfer was a necessary step in the adoptive transfer protocol. Each 
culture was then analysed for percentage of cell populations specifically CD4+ T cells, 
cytokines expressed by CD4+ T cells and cytokines within the culture supernatant. Future 
chapters will discuss the sole surviving population of the total leukocyte cell transfers to be 
CD4+ T cells. 
Secondly, the number of cells needed to induce disease was optimised to allow full analysis 
of disease in vivo and in vitro, using cell titration experiments the optimum cell number to 
use to induce consistent disease across all recipients was 2x106 of which ~20% are CD4+, 
which is significantly lower than the paper by the Caspi group originally published which was 
50x106-100x106 total cells which has been reduced to 5x106 total cells but still uses 
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significantly more cells than this optimised adoptive transfer technique to induce clinical 
disease  (117, 176). 
After the cell number for transfer was optimised, the identification of transferred cells within 
recipients during clinical disease could be validated. Congenic mouse strains with allelic 
variants of CD45, including CD45.1 and CD45.2 can be differentiated using flow cytometry and 
are used routinely in experiments to track populations of immune cells (190). Allelic markers 
can be used to track where transferred cell populations have been recruited not only to the 
target tissue but also to lymphoid and non-lymphoid tissue and blood. Disease is defined by 
increased number of cells infiltrating the eye, thickening of the retina, swelling of the optic 
disc by OCT imaging and large numbers of leukocytes present in flow cytometric and 
histological analysis.  
During clinical disease, a large percentage of the CD4+ T cells present within the eye are from 
the transferred population based on allelic markers, thus suggesting that the antigen specific 
transferred cells are driving the disease process and being recruited to the eye. Although the 
transferred cells make up a large compartment of the CD4+ T cells present within the eye, 
endogenous CD4+ T cells from the recipient are also recruited during clinical disease and 
contribute to the disease progression as the percentage of endogenous cells are present in 
the eye increase at day 14 compared to day 7.  
Due to this recruitment of endogenous CD4+ T cells, the question stood of whether 
transferred cells alone are enough to drive clinical disease with no recruitment of 
lymphocytes from the endogenous compartment of the recipients. Therefore, experiments 
were carried out using RAG2-/- mice that lacked mature T and B cells so the only CD4+ T cells 
present within the recipient were the transferred cells. By day 7, clinical disease can be 
observed by increased cell infiltrate and increased presence of hyperintense regions in the 
retina as measured by OCT which persists through to day 14 with no resolution, this illustrates 
that transferred pathogenic cells are able to drive disease without recruitment of endogenous 
T cells. 
In summary, this chapter describes the optimisation of an adoptive transfer technique and 
preliminary analysis to study the recruitment of pathogenic T cells to the target tissue and 
induction of clinical disease. At the time of transfer there is a mixed Th1 and Th17 CD4+ 
phenotype present in the cell cultures based on cytokines present in the supernatant and 
intracellular cytokine staining. The main difference in CD4+ phenotype is observed within the 
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supernatant of the transferred cell cultures where an increase in IFN-γ is observed in the 
C57BL/6 Ly5 cultures in comparison to the OTII, CX3CR1 heterozygous and the CX3CR1 
knockout suggesting an increased Th1 phenotype is present in these cultures. The FoxP3 
staining illustrates a limited number of Tregs is present when cells are transferred. Further to 
this there is no evidence of epitope spreading to the RBP3 1-20 peptide when transfer donors 
are culled for cell culture which can be seen later and has been published previously by the 
group (159).  This approach utilising allelic markers allows tracking of transferred cells 
throughout clinical disease and to study the role of antigen-specific transferred cells in clinical 







































Chapter 4. Recruitment of transferred 


















Autoimmune diseases are a result of a breakdown in immunological tolerance against self-
molecules creating an adaptive immune response against a self-antigen (59, 61). Three major 
mechanisms are offered to explain the development and progression of autoimmunity: 
molecular mimicry, bystander activation and dysfunctional Tregs (191). The majority of 
autoimmune diseases develop through complex mechanisms due to a number of factors 
including genetic, molecular, cellular and environmental elements (192). This results in 
alterations at many checkpoints that combine to cause a breakdown in immune tolerance, 
and manifests as harmful inflammatory responses in peripheral tissues amplified by an innate 
immune response and self-antigen specific T and B cells (192). Research suggests that T cells 
play the central role in organ specific autoimmune disease both in initiation of disease and 
persistence (193). It is believed that the immune privilege can leave the eye susceptible to an 
attack by primed lymphocytes of an autoimmune nature from elsewhere within the body by 
a random or chance encounter with a self-antigen or a mimic antigen (194). 
 
4.1.1 Immune tolerance 
Central tolerance is sometimes inefficient therefore another mechanism known as peripheral 
tolerance to regulate potentially harmful autoreactive T and B cells that have been released 
into the periphery (192). Tissue specific autoimmune disease is the main consequence of the 
activation of a population of self-reactive T cells that cause destruction of single or multiple 
target tissues (170). Identifying the target antigens that are recognised by autoreactive T cells 
in autoimmune disease would allow further studies of the mechanisms involved in tolerance 
and autoimmunity. These are currently considered a challenge and therefore allow further 
study of specific lymphocyte responses to these autoantigens (170). 
Autoreactive T lymphocytes can act as both regulatory and effector cells, playing a key role in 
autoimmune diseases (146). Autoreactive memory T cells mediate autoimmune diseases of 
the CNS including multiple sclerosis where the cells recognise the myelin sheath and uveitis 
where the cells recognise the retinal tissues, in contrast to memory T cells which are known 
to be associated with a protective immunity (172). T lymphocytes can be divided into two 
major subsets based on their function, CD4+ T helper cells and CD8+ cytotoxic T cells (173). 
Peripheral blood responses against autoantigens in CD4+ and CD8+ T cells has been 
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demonstrated, using technologies such as ELISPOT and MHC-tetramer to demonstrate in vitro 
CD4+ T cell reactivities against self-antigens (195). The coexistence of both autoreactive and 
protective T cells is supported by multi-organ autoimmunity when naïve CD4+ T cells are 
transferred into immune deficient mouse strains (196). 
CD4+ T cells are involved in the adaptive immune response and play the key role in 
development of autoimmunity (61), they can be subdivided into subsets based on a network 
of transcriptional regulators and unique cytokine profiles (197). As highlighted in chapter 1, 
most organ-specific autoimmune diseases including multiple sclerosis and uveitis are 
mediated by autoreactive CD4+ T cells and can be characterised by unpredictable, explosive 
inflammatory responses which become less active with clinical features of disease subsiding 
spontaneously without treatment, but then return with repetitive attacks. It is known that 
between attacks reduced inflammation can be detected in the target tissue (172). 
Understanding the mechanisms by which autoimmunity evolves and its links to tolerance is a 
great challenge (170). 
Transgenic mouse models have become valuable tools to understand mechanisms involved 
in the pathogenesis of autoimmune disease as they provide both defined, tissue specific 
cognate antigens along with well characterised T cell receptors that recognises these 
antigens, two major approaches utilise transgenic mouse models, one of which is the adoptive 
transfer of T cells into naïve recipients (170). 
 
4.1.2 Tolerance to retinal antigens 
Central tolerance to retinal antigens is similar to the central tolerance of other tissue specific 
antigens (194). Retinal antigens such as RBP3 have been detected in the thymus to produce 
central tolerance and are under the control of the AIRE transcription factor (53, 194). 
Different mouse strains express different amounts of RBP3 in the thymus, the amount of RBP3 
expressed is linked to the susceptibility of the mouse strain to EAU induction which is inversely 
correlated (167, 194).  
As mentioned previously, within the thymus negative selection occurs to eliminate all 
autoreactive T cells, unfortunately this process is not 100% effective that is where the 
peripheral tolerance aids by controlling the autoreactive thymic migrants that have escaped 
thymic negative selection  (194). Resident retinal antigens within the healthy eye are isolated 
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behind the blood-retina barrier and are not readily available to circulating lymphocytes, 
whereas during ocular inflammation when the blood ocular barrier is compromised can lead 
to exposure of retinal antigens to circulating lymphocytes in the periphery (194).  
 
4.1.3 Bystander CD4+ T cell activation  
Antigen specific CD4+ T cell clonal expansion plays an important role in both organ-specific 
and systemic autoimmune disease  (198). Studies of T cell responses to several antigens 
illustrate that all variable components of the αβ TCR contribute to the binding of conventional 
peptide antigens with products of the MHC. Further work coined the term super antigen for 
a second group of antigens that stimulates T cells at very high frequencies, the group 
encompasses self-antigens (199). T cell clones that accumulate within the eye during clinical 
disease are qualitatively different depending on what stage of disease they are recruited, for 
example, T cells that have accumulated within the eye at early disease will be different from 
those that are found within the eye during the advanced phase of disease. Therefore, the T 
cells that are found within the eye at each disease phase are involved in disease pathogenesis 
in different ways (198).  
The first description of bystander activation was by Tough et al in 1996, it was used to attempt 
to understand in the context of cytokine secretion the large clonal CD8+ T cell expansion after 
viral infection (191). Non-antigen specific lymphocytes are activated in a heterologous 
manner to mediate the signals that indirectly favour an inflammatory milieu including 
chemokines, cytokines, extracellular vesicles, ligands of co-signalling receptors, PAMPs and 
microbial particles (191, 200).  
Classical T cell activation is mediated mainly through engagement of TCR and costimulatory 
signalling pathways which promote signalling cascades that induce cytokine production, 
proliferation, differentiation and/or apoptosis (191).  
4.1.4 Bystander T cell accumulation in autoimmune disease 
The development of autoimmunity is potentially due to the mechanism of bystander effects, 
this mechanism is different from the mechanisms of molecular mimicry and microbial agents 
(191, 201, 202). The notion of bystander activation can be described as the disturbance of 
self-tolerance due to an encounter with a pathogen, this causes the activation of resting 
autoreactive T cells that are then recruited to the tissue to cause inflammation, these cells 
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are antigen specific, however not all cells recruited to the tissue will be antigen specific some 
are known to be recruited non-specifically (202). The immunological pathways associated 
with bystander effects are not antigen-specific whether they be by effects of activation or 
suppression. The recruitment of non-specific cells can be induced by the initiation of cell 
death to cause the release of cellular antigens, perturbing of the cytokine balance or by 
increasing the antigen abundance or visibility (202). 
4.1.5 Bystander activation and recruitment after adoptive transfer  
A study conducted by Arata et al (202) using the adoptive transfer model of experimental 
autoimmune thyroiditis illustrated using GFP+ transferred T cells to study the fate of these 
cells during the development of thyroiditis (202). Immunohistochemistry staining of the 
thyroid tissue of recipient mice showed the development of thyroiditis after adoptive transfer 
of Tg-primed GFP+ cells, this was demonstrated by intrathyroidal accumulation of GFP+ T cells 
(202). GFP+ cells are also observed in the periphery of recipients such as blood, bone marrow 
and spleen but these cells are not present early within disease (202). However, a rapid 
disappearance of GFP+ T cells was observed, this may have been due to a secondary immune 
response potentially to the transgene product (202). The presence of activated GFP+ 
transferred T cells within the thyroid was observed along with the presence of infiltration 
from the host, which can be assumed to be initiated by the recruitment of transferred T cells. 
This study suggests that in this model of adoptive transfer the activated GFP+ cells may have 
initiated bystander activation of the host’s immune response by TCR-mediated activation 
such as; increasing the effect and attraction of host APCs and by causing cell death to induce 
cellular antigens to be released, or by non TCR mediated activation such as; disruption of the 
cytokine balance within the host (202). Using depletion of CD8+ cells the disease severity 
decreased, showing a necessity for the endogenous compartment to drive disease course 
(202).  
The adoptive transfer technique is a useful tool for EAU disease induction. Using allelically 
marked cells (as shown in chapter 3) allows tracking of uveitogenic primed CD4+ T cells after 
transfer including during the pre-clinical phase of disease, peak clinical disease and as disease 
resolves.  Cell counts are normalised to eyes from naïve animals. 
The aims of this chapter are to quantify total retinal cellular infiltrate after adoptive transfer 
of leukocytes before clinical disease, during and post disease. Further to this, analyse 
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endogenous and transferred cells within each leukocyte population at each time point during 
EAU. Transferred cells were also quantified within the periphery of each recipient to 
determine tissue specific recruitment to the ocular tissue and any non-specific recruitment in 




























4.2 Materials and Methods 
 
4.2.1 Adoptive transfer technique 
EAU was induced in C57BL/6 CX3CR1+/GFP (CD45.2) using RBP3 peptide 629-643, after a 72-
hour cell culture these donor cells were then transferred using i.p injection into C57BL/6 ly5 
(CD45.1) recipients at 2x106 total leukocytes per recipient. 
 
4.2.2 Flow cytometry analysis 
Flow cytometry was used to identify and quantify subsets of cells within the transferred cell 
population and retinal infiltrate using extracellular staining. 
Within transferred recipients’ allelic markers CD45.1 and CD45.2 were used to identify 
endogenous and transferred populations of cells within the retina. 
 
4.2.3 Clinical imaging 
OCT scans and fundus images standardised across recipients during transfer optimisation to 


















4.3.1 Flow cytometric analysis of naïve eyes 
An important aspect of Immune surveillance is local recruitment and retention of immune 
cells within healthy tissue (203). Peripheral tissue immune surveillance compartments are 
composed of cells from both the innate and adaptive immune system, the diversity of their 
composition reflects the specialised need for immune surveillance tailored to distinct 
locations within the body (203).  
Therefore, healthy mice will have a population of CD4+ T cells present within the eye without 
any disease induction due to maintenance of the tissue by immune surveillance. Studies have 
suggested that T cells present in a healthy or steady-state in peripheral tissues do not simply 
mirror the image of circulating T cells (203).  
Pre-clinical changes in CD4+ T cell number can be an early sign of disease initiation, therefore 
quantification of the  CD4+ T cell population present within the eye before disease induction 
is a useful measure of the small to moderate increase in CD4+ T cells within the eye before 
disease is observed by clinical imaging. Baseline numbers also set a threshold for 
distinguishing, after active disease has resolved, if the number of leukocytes present within 
the retina and vitreous remain persistently elevated. 
Total CD4+ T cells, CD8+ T cells, CD11b+. LY6G+ and LY6C+ cells (figure 4.1) were quantified 
as described in the methods in naïve C57BL/6 mice to give a baseline to compare with pre- 




















  LOWEST VALUE HIGHEST VALUE MEAN 
CD4 3 68 22 
CD8 0 58 18 
CD11B 184 2251 791 
LY6G+ 0 42 24 
LY6C+ 20 99 46 
 
Figure 4.1: Quantified leukocyte infiltrate present in the retina and vitreous in naïve mice 
before manipulation or disease induction. Retinas were dissected and vitreous flushed to prepare 
for quantification of leukocytes. Using a standard curve of known cell number CD4+, CD8+, CD11b+, 
LY6G+ and LY6C+ cell numbers were calculated. Data expressed as Mean +SEM. Table shows range 
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4.3.2 Disease course within the adoptive transfer model of EAU 
After transfer of uveitogenic leukocytes clinical disease was monitored using optical 
coherence tomography and compared with studies from the literature where disease was 
produced by active immunisation. Clinical disease follows a sequential  pattern of prodrome, 
primary peak, then secondary regulation (1).  The RBP-3 subunit 3 (629-643 peptide 
sequence) induces clinical disease in ~90% of C57BL/6 mice immunised (188). Peak disease is 
observed between days 21-27 where there is the largest number of CD45+ cells present within 
the retina and vitreal infiltrate, at day 40-45 CD45+ cell number has decreased but remains 
increased in comparison to naïve animals and is accompanied by an increase in the 
percentage of CD8+ T cells at this time point (188). 
To understand disease course more fully in the adoptive transfer model recipients were 
monitored by OCT to assess severity and disease kinetics. Figure 4.2a shows a naïve eye in a 
Ly5 recipient. The fundus is clear, and the optic disc and vessels show no signs of inflammation 
within the fundal image. In the OCT image the retinal layers are well demarcated, no swelling 
is present around the optic disc and no retinal infiltrate is detectable.  
At day 2, the fundal image remains clear of any signs of clinical disease. In the OCT image the 
retinal layers are visible and there is no obvious swelling of the optic disc. However, early 
signs of retinal infiltrate appear around the optic disc within the vitreous (figure 4.2b).  
By day 6, obvious signs of clinical disease manifestation are present within the fundal and OCT 
imaging (figure 4.2c). In the fundal image a vitreal haze is present and swelling around the 
optic disc is observed. The OCT image further confirms the onset of clinical disease, thickening 
of the retina and swelling of the optic disc and obvious cellular infiltrate within the vitreous is 
present (figure 4.2c). 
At day 13, clinical disease is still active in the eyes of the transfer recipients but is less severe 
than at day 6. The reduction in disease severity suggests that peak disease occurs between 
day 6- 12. In the fundal image, the inflammation is reduced around the optic disc and the 
vitreal haze has reduced. The OCT image shows a reduction in thickness of the retina and 
swelling of the optic disc and the infiltrate within the vitreous has reduced (figure 4.2d). 
By day 21, disease is active but has mostly resolved with minimal cell infiltrate observed, 
although the eye looks similar to day 0 in retinal thickness and optic disc thickness (figure 4.2a 
and 4.3a). The layers of the retina are visible, and the optic disc has returned to a normal 
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state. Vitreal infiltrate has further reduced, although some cells appear to persist within the 
vitreous (figure 4.3a).  
Disease continues to resolve from an active phase dominated by infiltration to a persistent 
phase characterised by retinal thinning and degenerative lesions from day 21 to day 67. 
Retinal infiltrate is not present within the OCT image at day 35 and clear retinal layers are 
present (figure 4.3b). This is reflected also in the fundal image, with no vitreal haze or swelling 
around the optic disc or sheathing of the vessels. At day 51 and 67, the OCT remains clear of 
vitreal infiltrate, but a thinning of the retina is observed. In the fundal image loss of definition 
of vessels is observed and haziness with distinct colour changes are present (figure 4.3c and 
4.3d). 
This full-time course of disease and corresponding disease scores (figure 4.4) illustrates a 
primary peak of disease at day 6-12 followed by a resolution of active clinical disease from 















Figure 4.2: OCT clinical imaging throughout peak disease, day 0-13 after adoptive transfer 
of uveitogenic leukocytes. Baseline imaging was taken at day 0 before manipulation of Ly5 
(wildtype) recipients (A). 2 days after transfer of uveitogenic leukocytes recipients were imaged at a 
pre-clinical disease timepoint (B). At day 6, peak disease occurs, and recipients had maximal infiltrate 
and retinal and optic disc swelling when imaged using OCT (C). By day 13, disease is still active but has 
reduced in severity. Reduced vitreal infiltrate is present and swelling of the retina and optic disc has 
begun resolving (D). (Images taken from different eyes throughout the time course due to quality and 
























Figure 4.3: OCT clinical imaging throughout post-peak clinical disease, days 21-67 after 
adoptive transfer of uveitogenic leukocytes. After peak clinical disease, recipients are still 
monitored for signs of a relapse of active disease. (A) Day 21 after disease induction recipients no 
longer have active disease, the retina has reduced to a thickness similar to day 0 and the vitreal 
infiltrate has reduced but is still visible by OCT. At day 35 after transfer, there are no longer signs of 
active clinical disease (B). At days 51 and 67 post transfer, signs of active clinical disease have gone 
but the retina remains scarred from disease progression (C+D). (Images taken from different eyes 




































Figure 4.4: Average clinical scores of recipients over full disease course. OCT imaging was used 
to acquire corresponding fundal images throughout disease course. The images were then scored 
blind using the criteria described in chapter 2 and the average score taken from each eye at each time 














4.3.3 Flow cytometric analysis of CD4+ T cell populations present within the 
eyes of recipients  
Recipients were monitored using clinical imaging to establish the disease course, and at 
different points retina and vitreous were isolated from recipient’s eyes for flow cytometric 
analysis to quantify leukocyte infiltrate at several time points throughout the disease.  
In the first part of the analysis, the aim is to quantify endogenous and transferred CD4+ T cell 
number at each time point through pre-clinical disease to active disease and through post 
active clinical disease, to assess total cell number and the ratio of endogenous and transferred 
CD4+ T cells present within the retina and vitreous of the eyes of the recipients. 
Day 0 is the baseline CD4+ T cell number quantified previously and shown in figure 4.1. This 
population allows comparison with pre-clinical disease. At day 2, transferred CD4+ T cells can 
be detected within the eye (figure 4.5) and there is increased recruitment of endogenous 
CD4+ T cells in comparison to the day 0 baseline CD4 cell number. 
By day 7, when peak disease is detected by clinical imaging (figure 4.2c), eyes were taken for 
analysis by flow cytometry. Quantified cell number illustrate an increase from an average of 
97 at day 2 to an average of 3967 at day 7 in the endogenous CD4+ compartment and an 
increase from an average of 62 at day 2 to an average of 822 at day 7 in the transferred CD4+ 
compartment present within the isolated retina and vitreous (figure 4.5). The ratio of 
endogenous to transferred CD4+ cells is close to 1:1 in some recipients (figure 4.5). 
At day 14, active disease is still present within the eyes of the recipients when using clinical 
imaging to assess disease progression (figure 4.2d). At this time point, the mean transferred 
CD4+ T cell number has increased in some recipients in comparison to day 7 (822-817) , 
whereas the endogenous CD4+ T cell number remains constant and has decreased in some 
recipients (3967-1384) (figure 4.5).  
Active disease is still observed at day 21, although it has mostly resolved, cellular infiltrate is 
still present within the vitreous when the eyes are clinically imaged (figure 4.3a). When 
vitreous and retina from recipient animals was analysed by flow cytometry a decrease in both 
the endogenous (1384-128) and transferred (817-115) CD4+ T cell populations was observed. 




By day 35, active disease has resolved by clinical imaging and no cellular infiltrate is detected 
within the vitreous of the recipients (figure 4.3c). The transferred CD4+ T cell population has 
persisted in the eyes of the recipients as a smaller portion of the CD4+ T cell population 
present in the eye. Endogenous CD4+ T cells are still increased in comparison to the 
population of CD4+ T cells present at baseline day 0 (figure 4.5).  
Clinical disease continues to exhibit features of secondary regulation by OCT at day 51 (figure 
4.3c) and day 67 (figure 4.3d). The retina has thinned, but there is no obvious infiltrate 
observed. When recipients’ eyes were analysed by flow cytometry at day 67 (figure 4.5), 
transferred cells are still present within the retinas of the recipients. Also, in comparison to 
baseline at day 0, the endogenous CD4+ T cell number remains increased in the recipient’s 
eyes at day 67 and have not returned to baseline that is observed in a 6-8-week old C57BL/6 
mouse. 
The data was log transformed to achieve a normal distribution and statistical analysis 
performed using one-way ANOVA (Fig 4.5). Multiple comparisons were made between 
endogenous and transferred populations throughout the time course using a Dunnett’s test. 
When the test is performed across time points throughout disease course all endogenous 
CD4+ populations are statistically significantly increased (P<0.01**-P<0.0001****). 
Comparisons between the day 2 transferred population and the transferred population 
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CD4 Lowest Value Highest Value Mean 
D0 3 68 22 
D2 15 241 97 
D7 105 13320 3967 
D14 74 4034 1384 
D21 34 891 128 
D35 55 166 95 
D67 12 132 68 
 
TRANSFER 
   
CD4 Lowest Value Highest Value Mean 
D0 n/a n/a n/a 
D2 5 154 62 
D7 24 3165 822 
D14 69 6727 817 
D21 6 287 115 
D35 6 40 19 













Figure 4.5: Total endogenous and transferred CD4+ T cells present within the retina and 
vitreous at each clinical imaging time point. Quantified CD4+ T cell infiltrate in recipients’ eyes 
throughout clinical disease in both the endogenous and transferred compartment. Baseline day 0 
CD4+ T cell number allows detection of subtle pre-active clinical disease and post-active clinical 
disease. At day 2, (pre-active clinical disease) endogenous and transferred CD4+ cell number was 
quantified to compare to the day 0 baseline. Day 7 and Day 14 illustrate endogenous and transferred 
CD4+ T cell recruitment during peak disease. Day 21, active clinical disease has begun to resolve but 
infiltrate is still observed by OCT. Active clinical disease has resolved at time points day 35 to day 67, 
endogenous and transferred CD4+ T cells are quantified in this post active clinical disease stage to 
detect differences to the baseline day 0 data. Data expressed as mean + SEM. All endogenous 
populations are statistically significantly different to the normal baseline. Statistical analysis 
performed: One-Way ANOVA multiple comparisons of against naïve for the endogenous cell 
compartment and Mann-Whitney non-parametric test between each endogenous and transferred 
population *p<0.05, ***p<0.001. 









4.3.4 Flow cytometric analysis of leukocyte populations present within the 
eyes of recipients during clinical disease 
EAU is a CD4+ T cell mediated disease model, but throughout disease course other leukocytes 
are recruited to the eye and are involved in the disease process. 
As seen in figure 4.1, baseline leukocyte number was quantified from naïve unmanipulated 
eyes to establish the sensitivity of the analysis to small changes in cell number and therefore 
pre-clinical disease and post-clinical disease changes in leukocyte number. 
At day 2, unlike endogenous CD4+ T cell number, there was no increase in other endogenous 
leukocyte numbers quantified by flow cytometry, including CD11b+ cell number, Ly6G+ cell 
number, Ly6C+ cell number and Ly6C- cell number (figure 4.6a-e).  
Transferred cells from each leukocyte compartment are detected within the ocular tissue by 
day 2, similarly to the transferred CD4+ T cells (figure 4.6a-e). 
As previously described in figure 4.2, 4.3 and 4.4, peak clinical disease occurs at day 7 after 
transfer of uveitogenic leukocytes. As seen in figure 4.5, a large increase in recruitment of 
CD4+ T cells occurs. Similarly, to this, the endogenous compartment of other leukocytes also 
reaches peak at day 7. In contrast to the CD4+ T cell data presented in figure 4.5, transferred 
cell recruitment to the eye during peak disease does not increase from day 2 in the CD11b+ 
cell compartment, Ly6G+ and Ly6C- compartments (figure 4.6b 4.6c and 4.6e). An increase in 
transferred cell number is observed in the CD8+ T cell compartment and the Ly6C+ 
compartment (figure 4.6a, 4.6b, 4.6d). Although a small increase was observed in transferred 
cell number in some leukocyte compartments, overall transfer cell number remains low in all 
leukocytes in comparison to CD4+ T cells. The transferred leukocytes are also not found in 
other lymphoid organs such as spleen and lymph node, and non-lymphoid organs such as 
kidney and liver along with blood suggesting the transferred leukocytes that are not CD4+ do 
not survive long term in the recipients after adoptive transfer. 
At day 14, transferred cell numbers within all leukocyte compartments remain constant from 
day 7. Within most leukocyte compartments bar CD11b+ (figure 4.6b), the endogenous cell 
number similarly remains constant from day 7 to day 14. This is due to a continuation of active 
disease from day 7 to day 14. 
At day 21, a minimal number of transferred leukocytes are still present within the eye in 
similar numbers at day 2 through to day 14. Whereas in the endogenous compartment 
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leukocyte number decreases (figure 4.6) due to resolution of active disease, a similar effect 
that is observed in the CD4+ T cell number (figure 4.5). Minimal transferred leukocytes persist 


































































































































































    
TRANSFER 












D0 0 58 18 
 
D0 n/a n/a n/a 
D2 0 176 81 
 
D2 0 205 50 
D7 29 5094 1554 
 
D7 0 222 23 
D14 2 6129 1027 
 
D14 0 30 8 
D21 3 488 183 
 
D21 0 26 11 
         
ENDOGENOUS 
    
TRANSFER 












D0 184 2251 791 
 
D0 n/a n/a n/a 
D2 286 2750 1239 
 
D2 0 134 34 
D7 1766 73685 27429 
 
D7 0 192 21 
D14 76 24042 7412 
 
D14 2 313 132 
D21 340 8552 2083 
 
D21 3 185 68 
         
ENDOGENOUS 
    
TRANSFER 












D0 0 42 24 
 
D0 n/a n/a n/a 
D2 4 228 43 
 
D2 0 14 2 
D7 9 353 116 
 
D7 0 16 6 
D14 0 290 61 
 
D14 0 14 3 
D21 2 27 9 
 
D21 0 10 5 
         




    
TRANSFER 












D0 20 99 46 
 
D0 n/a n/a n/a 
D2 4 33 16 
 
D2 8 50 24 
D7 18 952 217 
 
D7 8 32 22 
D14 14 113 55 
 
D14 0 56 14 
D21 13 209 44 
 
D21 20 80 40 
         
ENDOGENOUS 
    
TRANSFER 












D0 1936 2762 2279 
 
D0 n/a n/a n/a 
D2 550 1583 989 
 
D2 0 0 0 
D7 779 2758 1561 
 
D7 0 0 0 
D14 1919 5455 2930 
 
D14 0 0 0 
D21 354 2876 1330 
 
D21 0 0 0 
         
ENDOGENOUS 
    
TRANSFER 












D7 701 2395 1278 
 
D7 0 15 4 
D14 4 600 273 
 
D14 0 0 0 
D21 155 652 407 
 















Figure 4.6: Total endogenous and transferred leukocytes present within the retina and 
vitreous at each clinical imaging time point. Quantified leukocyte numbers present within the 
retina and vitreous at each clinical imaging time point during clinical disease. In the endogenous and 
transferred compartment. Full time course of CD8+ T cell number present within the eye during 
disease (A).  Full time course of CD11b+ cell number present within the eye during disease (B). Full 
time course of Ly6G+ (neutrophil) cell number present within the eye during disease (C). Full time 
course of Ly6C+ (inflammatory monocytes) cell number present within the eye during disease (D). Full 
time course of Ly6C- cell number present within the eye during disease (E). Full time course of CD19+; 
B cell number present within the eye during disease (F). Data expressed as mean + SEM. One-Way 
ANOVA multiple comparisons of against naïve for the endogenous cell compartment and against day 
2 for transferred cells *p<0.1, **p<0.01, ***p<0.001, p<0.0001. Stats not performed for day 35 as only 
one experiment, data shown to represent time course. 













4.3.5 Adoptive transfer of CX3CR1 heterozygous cells into RAG2-/- recipients 
causes recruitment of antigen-specific CD4+ T cells to ocular tissue by day 2 
As illustrated previously (figure 4.5), the recruitment of uveitogenic transferred CD4+ T cells 
to the ocular tissue is detectable by day 2 after transfer this is associated with an increased 
number of endogenous CD4+ T cells that accumulate in the eye at this time point. To analyse 
if the endogenous T cell compartment is needed for the retention of transferred cells to occur, 
this compartment was eliminated from the experiment by using RAG2-/- mice as recipients of 
uveitogenic cell transfer.  
Cells were transferred into Ly5 recipients or RAG2-/- recipients. When the two groups are 
compared (figure 4.7) recruitment of transferred CD4+ and CD8+ T cells to the eye two days 
after adoptive transfer is comparable.  
Recruitment of transferred CD4+ T cells is observed in both groups at day 2 after adoptive 
transfer is shown in figure 4.7a. There is no significant difference between recruitment of 
transferred cells within the two recipient groups. The same affect is also present within the 

















































  LOWEST VALUE HIGHEST VALUE MEAN 
CD4 HET-RAG 14 128 67 
CD4 HET-LY5 5 154 62 
CD8 HET-RAG 10 70 43 












Figure 4.7: Total endogenous and transferred leukocytes present within the retina and 
vitreous at each clinical imaging time point. Leukocytes were transferred into Ly5 (wildtype) mice 
and RAG2-/-mice.  Two days after adoptive transfer vitreous and retinas were assessed by flow 
cytometry. CD4+ (A) and CD8+ (B) transferred cell populations present within the eye were quantified 
and comparisons across the two groups made. Data expressed as mean + SEM. 



















4.3.6 Selective recruitment of CD4+ T cells to the ocular tissue during active 
clinical disease  
Recruitment of transferred CD4+ T cells to the ocular tissue during active clinical disease was 
illustrated in figure 4.5. To determine if this is a selective recruitment to the ocular tissue, 
other organs were analysed and endogenous and transferred CD4+ T cells quantified. 
Within the eye (figure 4.8), transferred cells are detected by day 2 after adoptive transfer 
(highlighted in figure 4.5), by day 7 this population has increased due to peak disease. The 
transferred population then persists through active clinical disease to day 14 and continues 
to persist through to day 21 when active disease has resolved. The transferred cells further 
persist through to day 67 where disease can be considered to be quiescent. 
In contrast within recipient’s blood (figure 4.8), transferred CD4+ T cells are detected at day 
2 but by day 7 (peak disease) the frequency of transferred CD4+ T cells detected within the 
blood has decreased. This effect is further seen at day 14 and day 21 with transferred cells 
making up a smaller frequency of the total CD4+ populations. 
In a sample taken from a whole liver at each time point (figure 4.8), transferred CD4+ T cells 
are detected at day 2, the ratio of transferred and endogenous CD4+ T cells remains 
consistent throughout disease course but in contrast to the blood the frequency of CD4+ 
transferred cells present within the liver at day 7 increases in comparison to day 2 this 
increase in the frequency of transferred CD4+ T cells coincides with peak clinical disease in 
the eye. At day 14 and day 21, the frequency of transferred cells continues to decrease as 































































































Figure 4.8: Frequency of transferred CD4+ T cells in the periphery of recipients during EAU. 
To determine if the recruitment of transferred CD4+ T cells to the eye to cause clinical disease is a 
selective recruitment, transferred populations within non-lymphoid tissues such as blood and liver 
were quantified. (A) Recruitment of endogenous and transferred CD4+ T cells present within the eye 
during clinical disease. (B) Recruitment of endogenous and transferred CD4+ T cells present within the 
blood during clinical disease. (C)) Recruitment of endogenous and transferred CD4+ T cells present 










This chapter uses the adoptive transfer technique developed in chapter 3 to induce EAU and 
interrogate disease course.  
In order to understand disease, eyes were monitored using an optimised OCT clinical imaging 
technique following disease progression from day 2 to day 67. At different time points 
vitreous and retinas were isolated and analysed to quantify leukocyte infiltrate, specifically 
endogenous and transferred CD4+ T cells. 
To establish pre-clinical changes of leukocyte number, leukocytes present within the eyes of 
naïve non-manipulated mice were quantified to give a baseline. 2 days after adoptive transfer 
recipients’ eyes were imaged, where no clinical changes can be identified by OCT. When the 
retina and vitreous is isolated and leukocytes quantified using flow cytometry transferred 
cells are detected within the tissue (figure 4.4 and 4.5). Disease scoring was obtained by 
analysing fundal images at each time point. The mean score is obtained from the set of criteria 
described in chapter 2 (Table 2.2), hence why increased scores are observed at peak disease 
due to the high levels of infiltrate and at late disease where minimal infiltrate is present but 
structural damage is greatest. Peak active clinical disease is observed at day 7 to 10 within the 
recipients and persists in an active phenotype through to day 14. Resolution of the active 
stage of disease occurs from day 21 and disease remains in a quiescent state from this time 
point. Although minimal retinal infiltrate is observed, due to the severity of the active disease 
stage the eye remains scarred and the structure damaged. 
This chapter presents the kinetics of disease in comparison to naïve control eyes, however in 
future chapters mice that have received a PBS intraperitoneal injection are used as the 
baseline control for comparison. 
In the CD4+ T cell compartment at day 2, a small population of transferred CD4+ T cells were 
detected, along with an increase within the endogenous CD4+ T cell compartment. This 
observation suggests an increased recruitment of endogenous CD4+ T cells after adoptive 
transfer of uveitogenic antigen specific leukocytes. Whether they are sticking in the eye due 
to non-specific tissue activation or whether an antigen-specific response is required is 
addressed within the next chapter. To understand if the recruitment of transferred cells to 
the eye at day 2 required an endogenous T cell response within the recipient, uveitogenic 
leukocytes were transferred into RAG2-/- mice that have no endogenous T or B cells. Retinas 
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and vitreous were isolated from recipients from the RAG2-/- group. CD4+ transferred T cells 
were quantified to analyse differences in transferred cell recruitment (figure 4.6). No 
difference in transferred CD4+ T cells was observed between the two groups at day 2 after 
adoptive transfer, demonstrating that endogenous lymphocytes are not required for the 
recruitment of transferred cells to be recruited and retained in the eye at this time point. We 
conclude that the transferred cells are sufficient to cause disease.  
In wild type recipients, throughout active clinical disease course (day 7-21), recruitment of 
both endogenous and transferred CD4+ T cells increases within the retinal and vitreous 
infiltrate in comparison to day 2 infiltrate (figure 4.4). As seen at the day 2 time point 
transferred CD4+ T cells are recruited to the eye accompanied by increased endogenous CD4+ 
T cells, this is followed by further increased recruitment of both endogenous and transferred 
CD4+ T cells to obtain a peak in clinical disease at day 7 (figure 4.4). The ratio of endogenous 
and transferred CD4+ T cells at this time point is at roughly 1:1, but in some recipients a 
slightly larger endogenous population is observed.  
At day 14, the endogenous and transferred populations have persisted to continue active 
disease. The ratio of endogenous to transfer CD4+ T cells remains at 1:1 in most recipients. 
This highlights the persistence of a large, transferred population within the tissue during 
active clinical disease. However, the larger population in some recipients continues to be the 
endogenous population due to activation within the inflammatory environment of the ocular 
tissue. When T cells encounter antigen within the eye  they have to capabilities to become 
anergic or undergo apoptosis, secrete TGF-β and release soluble regulatory factors including 
the TCR α chain (204). Antigen taken up by cells originating from the eye, escape the tissue 
and are recruited to the spleen to activate a population of antigen-specific B and T cells (204). 
Anergic cells can be differentiated from naive and activated cells by CTLA4 and PD-1 staining 
(205). 
By day 21, active disease has begun to resolve, and overall infiltrate has reduced when the 
eyes are imaged using OCT (figure 4.3). This is mirrored in the CD4+ T cell number an overall 
reduction in total CD4+ T cells is observed by flow cytometry.  
Overall, following the induction of clinical disease, the ratio of transferred to endogenous cells 
remains ~1:1 through the duration of the experiment. Therefore, the disease process sustains 
the original pathogenic cells and their progeny indefinitely. Also, using clinical scoring alone 
disease does not appear to resolve, this is due to increased tissue damage after the high levels 
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of retinal infiltrate present throughout active clinical disease. When correlating flow 
cytometry data with OCT clinical scoring it is obvious the differences in disease activity and 
tissue damage, however with the imaging data alone this is not easily distinguishable. 
At day 35 through to day 67, active clinical disease has resolved but transferred CD4+ T cells 
persist within the eye. The persistence of the original uveitogenic transferred CD4+ T cells 
within the eye throughout clinical disease suggest these cells are long lived and although may 
not be driving active disease they are persisting within the eye after active disease has 
resolved. The persistent increase in endogenous CD4+ T cells within the eye after active 
clinical disease suggests that changes in the tissue due to disease course have resulted in the 
increased retention of endogenous CD4+ T cells patrolling the tissue. In studies previously 
undertaken within the group a change in the nature of immune surveillance of the retina was 
observed following inflammation suggesting it is more likely a relapse of autoimmune disease 
is triggered by intercurrent activation of the immune system (114).  
In comparison, CD8+, CD11b+ and CD19+ cells, which are components of the cell line, do not 
survive in the long term after adoptive transfer in the recipients and minimal cell numbers 
are detected within the eye. However, in the CD8+ transfer population an increase in the 
transferred population was observed at peak disease (day 7) but decreases in numbers and 
does not persist within the tissue throughout disease.  The endogenous compartment does 
contribute cells from these lineages during active clinical disease where the changes in their 
cell numbers parallel those of the CD4+ infiltrate. 
To further interrogate the behaviour of the transferred CD4+ population within the recipients, 
lymphoid and non-lymphoid organs were also analysed by flow cytometry through clinical 
disease to calculate the frequency of transferred CD4+ T cells within lymphoid and non-
lymphoid tissue. In the blood, transferred CD4+ T cells are detected in the largest frequency 
at day 2 and as clinical disease develops the frequency is reduced (4.8). In the liver although 
a small increase in transferred CD4+ cells is observed at day 7 this could be due to the cells 
proliferating within the tissue. The frequency of transferred cells reduces from this timepoint 
(figure 4.8). BrdU staining could be used to understand if the cells are proliferating within the 
tissue between day 2 and day 7 or if the cells are being recruited from the periphery between 
these time points. The reduction in frequency of transferred CD4+ T cells in non-lymphoid 
tissue through clinical disease is in contrast to the eye where the transferred CD4+ population 
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increases through active clinical disease and persists through post-clinical disease suggesting 
a selective recruitment of the RBP3 specific transferred CD4+ T cells. 
In conclusion, adoptive transfer of antigen specific pathogenic cells induces EAU in naïve 
recipients. Transferred CD4+ cells are detectable within the eye at day 2 after transfer 
concurrently with an increase of endogenous CD4+ T cells. The recruitment of transferred 
CD4+ T cells by day 2 to the eye is not reliant on the presence of endogenous CD4+ T cell 
recruitment. Endogenous and transferred CD4+ T cell recruitment increases by day 7 when 
peak disease is observed by OCT and quantification of leukocyte infiltrate. At this time point, 
endogenous and transferred CD4+ T cells are at a ratio of ~1:1 in some recipients but with a 
slightly larger endogenous population present within the eyes of other recipients. Active 
clinical disease persists to day 14 and endogenous and transfer populations persist within the 
eye. By day 21, active disease has resolved so total CD4+ T cell number reduces. Elevated 
endogenous CD4+ T cell population persists within the eye. By this time point transferred 
CD4+ T cells are now the larger population within the eye and have persisted throughout 
active clinical disease. By day 35 through to day 67 clinical disease has resolved but elevated 
endogenous CD4+ T cells in comparison to the naïve baseline remain present within the eye. 
Transferred CD4+ T cells persist in the eye through to day 67 in a small population even with 
no active disease present. Suggesting that the tissue never returns to its original state and 
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The structure of the vasculature and lymphatic system are lined with endothelium, which is a 
single layer in thickness, this semipermeable layer lies between the vessel walls and the 
circulation. The endothelium acts as a barrier between vessels present in the blood and lymph 
and the tissues that surround them (206). The endothelium is essential in a number of 
physiological processes. It is considered a highly dynamic organ spread throughout the body 
to perform highly specialised functions. In total, in humans there are roughly 1-6x1013 
endothelial cells that make up the endothelium with a total surface area of more than 1000 
square metres (206). The heterogeneity of endothelial cells enables them to adapt their 
functions in different vascular sites (206). 
 
5.1.1 Functions of the endothelium 
The endothelium was once thought to have no specific functions other than the wrapping of 
the vasculature allowing selective permeability to water and electrolytes (207). But now it is 
understood that endothelial cells are paramount to vascular biology. The main functions of 
the endothelium are thrombosis and thrombolysis, coagulant mechanisms, regulation of 
vascular tone and growth, cell proliferation and angiogenesis and platelet and leukocyte 
interaction (207). 
 
5.1.2 The resting endothelium and how it becomes activated in inflammation 
The main site of leukocyte trafficking from the blood into non-inflamed tissues are the 
vascular endothelial cells, these cells are also responsible for maintaining the fluidity of blood 
and regulation of blood flow, and are capable of controlling the permeability of vessel walls 
(208). Interactions between leukocytes and endothelial cells influence immune surveillance 
and mediate wound repair and acute and chronic inflammation. Leukocytes accumulate 
within the tissue due to excessive adhesive interactions between the endothelium and 
patrolling leukocytes (209). Weibel-Palade bodies are secretory vesicles used by resting 
endothelial cells to accumulate leukocyte interactive proteins including P-selectin and 
chemokines to stop any interactions with patrolling leukocytes. Transcription of adhesion 
molecules is also suppressed by resting endothelial cells including vascular cell-adhesion 
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molecules (VCAM1), intracellular adhesion molecule (ICAM1) and E-selectin (208-211). 
Vascular endothelial cells will then change their phenotypes depending on the phase of the 
inflammatory process (208).  
During non-infectious posterior uveitis, activated T cells recruited to the eye contributing to 
the inflammatory response produce cytokines and chemokines that are capable of activating 
retinal vessels (212). Activation of the retinal vessels induces a change in the phenotype of 
the endothelial cells present within the eye, upregulation of adhesion molecules including P-
selectin, ICAM-1 and VCAM-1 concurrently with a downregulation of tight junction protein 
(212). This response leads to recruitment of a wide range of leukocytes that are directly 
responsible for damage to the tissue, this causes the BRB to become increasingly permeable 
to allow more immune infiltrate into the eye to create an amplification loop of the pathogenic 
process (212). 
In studies of EAU in the B10 RII mouse, Heping et al described the sequence of events after 
EAU induction to be the focal adhesion of leukocytes on postcapillary venules in discrete sites 
followed by upregulation of adhesion molecules that induces breakdown of the blood retina 
barrier (213). 
Activation of endothelial cells consists of two stages, endothelial cell activation type I and 
endothelial cell activation type II. Endothelial cell activation type I is rapidly occurring and 
stimulates endothelial cells without the need for gene upregulation or de novo protein 
synthesis, however endothelial cell activation type II takes time to have an effect on 
endothelial cells by gene transcription or protein synthesis as the stimulating agent needs 
time to take effect (83). The effects of endothelial cell activation type I are the expression of 
P selectin, the release of von Willebrand factor and the retraction of endothelial cells. the 
genes that are involved are those for adhesion molecules, cytokines and tissue factor (83). In 
order to migrate through the endothelium into the circulation, leukocytes first must adhere 
to the endothelium at preferential sites with specialised functions to undergo 
transendothelial migration within blood vessels. In non-lymphoid tissues these specialised 
sites are found at post capillary sites and in lymphoid tissue at high endothelial venules. 
Leukocytes moving through the blood will make contact with the wall of the vessel to interact 
with the endothelium, the cells will then slow and begin to roll along the endothelium and 




5.1.3 The endothelium as an antigen-presenting cell 
It has been demonstrated both in vitro and in vivo that T cells can recognise antigen on the 
surface of endothelial cells (214). In vitro, it has been demonstrated that IFN-γ induces 
expression of MHC class II molecules on endothelial cells which results in T-cell activation and 
proliferation after interaction (214). In vivo, circulating T cells have also been observed to 
recognise antigens on the surface of endothelial cells which trigger endothelial cell activation 
causing a release of mediators (214, 215).  
In rat models studying the endothelium presenting antigen within the eye during EAU, antigen 
was detected within the retinal vessels when early signs of retinal infiltrate was observed 
(216).  Further to this, studies have also shown gamma interferon expression within the eye 
induce vascular endothelium to express class II antigens at comparable levels to a 
macrophage (217). 
 
5.1.4 Antigen specific T cell recruitment during disease 
When using the adoptive transfer model that is discussed in chapter 4, T cells are stimulated 
in vitro with the cognate antigen to give an activated phenotype. Thus, when the cells are 
transferred into the recipient and enters the ocular tissue the T cell has the capacity to 
proliferate, produce cytokines, interact with APCs and induce cytotoxicity to promote 
inflammation (169).  
From data collected and presented in chapter 4, an increased recruitment of endogenous 
CD4+ T cells is observed at day 2 after transfer. From this observation the hypothesis that the 
endothelium is becoming activated by the transferred pathogenic CD4+ T cells, causing 
endogenous cells to tether to the endothelium to initiate clinical disease was considered. The 
aim of this chapter is to understand if the activation of the endothelium depends on an 
antigen specific response initiated by the pathogenic transferred T cells or a non-antigen 








5.2 Materials and Methods 
 
5.2.1 Activation of OTII TCR Transgenic splenocytes 
Splenocytes were isolated from OTII CD45.1 TCR transgenic mice or OTII CX3CR1+/GFP CD45.1.2 
mice and activated in cell culture with 1μg/ml OVA peptide antigen, 10ng/ml IL-23 and 
10ng/ml IL-2 (added at 24 hours). Leukocytes were isolated after 72 hours of culture using 
Ficoll centrifugation and transferred by intraperitoneal injection at 2x106 total leukocytes per 
recipient. 
 
5.2.2 Generation of uveitogenic leukocytes for adoptive transfer 
C57BL/6 CX3CR1+/GFP CD45.2 mice were immunised with RBP3 peptide 629-643, spleen and 
lymph nodes were isolated at day 11 and cultured for 72 hours supplemented with RBP3, 10 
no/ml IL-23 and 10ng/ml IL-2 (added at 24 hours). Leukocytes were then isolated using Ficoll 
centrifugation and transferred into naïve CD45.1 Ly5 WT recipients by intraperitoneal 
injection at 2x106 cells per mouse.  
 
5.2.3 Clinical imaging 
OCT was used to acquire clinical imaging for a disease time course from day 0 to day 25 using 
the standardised method developed and described in data chapter 3.   
 
5.2.4 Flow cytometry 
At predefined time points after adoptive transfer, retinas were analysed by flow cytometry to 
quantify total cell number for each leukocyte population. Allelic markers were used as seen 
previously to identify transferred and endogenous populations including CD45.1, CD45.2 and 
CD45.1.2.  
 
5.2.5 Statistical Analysis 
Cell numbers were calculated from the standard curve (n) and were log transformed (ln(n+1) 
and expressed as Mean + SEM. Statistical analysis such as a Mann Whitney test (for 2 sample 





5.3.1 Intraperitoneal injection of PBS causes an increase in endogenous cells 
present within the eye 
In order to establish the sensitivity of the analysis to small changes between total CD4+ and 
CD8+ T cells in naïve unmanipulated recipients and changes in cell number before clinical 
disease is observed, cell numbers in the eye were quantified using standard methods 
previously used in the group (data first shown in chapter 4) (114).  
The optimised adoptive transfer technique uses an intraperitoneal injection to transfer the 
cells into the recipients. To account for the trauma from any injection, a baseline analysis of 
the effect this might have on cell numbers is useful when studying small differences in CD4+ 
and CD8+ cell numbers between naïve animals, animals receiving PBS only and those receiving 
PBS plus an aliquot of cells. 
Naïve mice received an intraperitoneal injection of 200μl of PBS alone but with no cell 
transfer. At day 2 after injection retinas were analysed to quantify CD4+ cell numbers and 
CD8+ cell numbers. 
A statistically significant increase in CD4+ T cell number within the eye is observed at day 2 
after intraperitoneal injection of PBS (Figure 5.1) compared with naïve cell numbers, this 
shows that injection trauma effects the number of CD4+ T cells that adhere in the eye. 
In contrast, the procedure does not appear to influence the CD8+ T cell number due to the 
larger dynamic range in the naïve CD8+ dataset therefore no change in cell number can be 



























Figure 5.1: Intraperitoneal injection of PBS causes a statistically significant increase in CD4+ 
T cells sticking in the eye. Mice were age-match naïve or were given a 200μl intraperitoneal 
injection of tissue culture grade PBS. At day 2, eyes were dissected and total CD4+ and CD8+ numbers 
quantified. Data are expressed as Mean +SEM. Statistical analysis performed: unpaired non-





5.3.2 Activated and non-activated OTII cells do not activate the endothelium 
and remain in the eye after adoptive transfer 
To investigate whether the recruitment of endogenous cells at day 2 after pathogenic 
adoptive transfer requires an antigen specific response to activate the endothelium or is 
solely due to a non-specific accumulation of activated transferred cells induced by the 
intraperitoneal injection, OVA specific activated cells were transferred into naïve recipients 
and leukocytes quantified to determine changes in endogenous and transferred leukocyte 
cell number retained within the eye after transfer. 
Antigen presentation by the endothelium leads to recruitment of specific T cells. Interactions 
between circulating T cells and the endothelium could influence the development of a local 
immune response. Due to the continuous interaction of circulating T cells with endothelial 
cells full competency of the endothelium as an APC could create problems in the regulation 
of autoimmune reactivity (218). The possibility that antigen presentation by the endothelium 
can directly influence the extent of lymphocyte recruitment at the site of inflammation has 
been demonstrated in EAE (218). 
TCR transgenic OTII cells were activated in vitro with OVA antigen and then transferred into 
naïve recipients (figure 5.2) because as seen in figure 5.1, i.p injection increases ocular CD4+ 
cell numbers, analysis were carried out using i.p injections as a baseline.  
At day 2 after transfer of 2x106 activated or non-activated OTII cells, there is no significant 
increase in endogenous CD4+ T cell recruitment to the eye in comparison to a PBS 
intraperitoneal injection (data originally shown in figure 5.1) whereas at day 7 the CD4+ T cell 
number had dropped to similar numbers to a naïve unmanipulated mouse (Figure 5.2a). 
Although the number of endogenous CD4+ T cells increases at day 2 after transfer the number 
of transferred cells remaining within the eye is low and not activation state dependent, this 
continues to day 7 when the endogenous cell number decreases  to the level seen in samples 
from naïve animals (Figure 5.2b) activated and non-activated OTII cells do not reach statistical 
significance. 
Whereas in the CD8+ T cell compartment there is no significant increase in the endogenous 




 At day 2 after transfer of 5x106 activated cells an increased number of CD4+ transferred cells 
can be seen in the eyes of recipients in comparison to the transfer of 2x106 cells (Figure 5.2b 
and 5.3b). The number of activated transferred cells that stick in the eye is statistically 



































Figure 5.2: Adoptive transfer of activated or non-activated 2x106 TCR transgenic cells into 
naïve recipients. Naïve recipients received an intraperitoneal injection of activated or non-activated 
OTII cells at 2x106 cells per mouse. Retinas were dissected and analysed using flow cytometry at day 
2 or day 7 to quantify the endogenous and transferred CD4+ and CD8+ T cell populations present 
within the eye. (A+C) Endogenous CD4+ or CD8+ T cell number present within the eye in naïve 
recipients, recipients that received a PBS intraperitoneal injection (data originally shown in figure 5.1), 
recipients that received a 2x106 activated cell transfer analysed at day 2, recipients that received a 
2x106 non-activated cell transfer analysed at day 2 or recipients that received a 2x106 activated cell 
transfer analysed at day 7. (B+D) Corresponding analysis of transferred CD4+ or CD8+ OTII TCR 
transgenic cells present within the eyes of recipients after activated or non-activated transfer at day 
2 or day 7. Data are expressed Mean +SEM. Statistical analysis performed: One-Way ANOVA multiple 
























Figure 5.3: Adoptive transfer of activated or non-activated 5x106 TCR transgenic cells into 
naïve recipients. Naïve recipients received a transfer of 5x106 activated or non-activated OTII cells. 
Retinas were dissected and endogenous and transferred CD4+ and CD8+ T cells were quantified at day 
2. (A+B) Endogenous and transferred CD4+ T cells present within the eye. (C+D) Endogenous and 
transferred CD8+ T cells present within the eye. Data are expressed as Mean +SEM. Statistical analysis 
performed: One-Way ANOVA multiple comparisons against PBS (A+C). Statistical analysis performed: 





















5.3.3 Intravitreal injection of OVA with OTII cell transfer causes large amounts 
of retinal infiltrate  
As seen in figure 5.2, transfer of activated or non-activated OTII TCR transgenic cells does not 
initiate clinical ocular disease or recruitment of transferred and endogenous cells. Suggesting 
that the recruitment of endogenous cells by day 2 after pathogenic transfer is due to an 
antigen-specific response.  
To further investigate if the introduction of antigen would lead to the recruitment of OTII cells 
to the eye, OVA antigen was injected intravitreally into one eye. Activated OTII cells were then 
transferred by intraperitoneal injection.  
At day 2, there is no difference by clinical imaging of retinal infiltrate within the OVA injected 
and PBS injected eyes (Figure 5.4a and 5.4b). Flow cytometry demonstrated that transferred 
CD4+ T cells can be detected in both eyes in similar numbers as the activated cell transfer 
alone (Figure 5.2b) (Figure 5.6b). However, when the eye receives the OVA intravitreal 
injection (figure 5.6b) active disease develops after day 2, whereas when OVA specific cells 
are transferred with no intravitreal injection, at day 7 no active disease is present and minimal 
transferred cells are present in the eye. 
The increase in endogenous CD4+ cell number in both eyes is within the range seen in CD4+ 
cell numbers after PBS intraperitoneal injection (Figure 5.6a). A similar response can also be 
seen in the CD8+ and CD11b+ compartments (Figure 5.7a-d and Figure 5.8a-d). In contrast 
within the Ly6G+ and Ly6C+ cell compartment the greatest number of cells is observed at day 
2 due to the injection trauma (Figure 5.9a-d and Figure 5.10a-d). Transferred Ly6C+ cell 
number is the highest number of transferred cells recruited to the eye by that time point 
(Figure 5.10b and 5.10d). 
Whereas, at day 4 by OCT obvious retinal infiltrate was observed around the optic disc in both 
eyes of the recipients (Figure 5.4c and 5.4d) corresponding flow cytometry analysis illustrated 
a recruitment of transferred CD4+ cells to the left eye that received OVA and some non-
specific sticking of the transferred CD4+ T cells in the right eye that received the control 
injection (Figure 5.7b and 5.7d). Whereas, in the endogenous compartment the CD4+ cell 
number in both eyes remains the same as day 2 (Figure 5.6a and 5.6c). In the CD8+ and 
CD11b+ cell compartment endogenous recruitment is within the same limits as day 2, and 
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transferred cells are recruited in low cell number which corresponds with the CD4+ 
compartment (Figure 5.7a-d and 5.8a-d).  
At day 8, OCT shows peak clinical disease characterised by severe retinal infiltrate within the 
vitreous, thickening of the retina and swelling of the optic disc by OCT and vitreal haze and 
perivascular sheathing within the fundus (Figure 5.4e) in the left eye which received the OVA 
antigen in comparison to the right eye which received PBS which continues to look normal 
(figure 5.4f). 
At day 15, clinical disease continued although retinal infiltrate is visibly reduced within the 
vitreous and the retina and optic disc have thinned (Figure 5.6g) suggesting that at this time 
point the disease is past peak. In contrast the right eye still shows no clinical signs of disease 
by OCT and remains normal (Figure 5.4h). When retinal infiltrate is analysed by flow 
cytometry recruitment of endogenous to transferred CD4+ T cells is occurring at a ~1:1 ratio 
in large cell numbers (in the left eye that received the OVA antigen Figure 5.6a-b). Whereas, 
in the right eye endogenous recruitment remains constant from day 4 (Figure 5.6c), in the 
transferred compartment some CD4+ T cells stick non-specifically in the eye but this is not 
statistically significantly higher than day 2 before induction of clinical disease (Figure 5.6d). 
Recruitment of CD8+ T cells to the left eye are significantly higher than seen at day 2 in the 
left eye illustrating a recruitment of endogenous CD8+ T cells to the eye with clinical disease 
(Figure 5.7a) whereas in the right eye where no clinical disease is seen by OCT there is no 
increased recruitment of CD8+ cells (Figure 5.7c). In the transferred compartment cells are 
not recruited to either eye irrespective of clinical disease status, this effect is similarly seen in 
the recruitment of CD11b+ cells (Figure 5.8a-d). In contrast, the increase seen in the Ly6G+ 
cell number at day 2 persists in the inflamed eye (left eye) but does not increase (Figure 5.9a) 
in the non-inflamed eye (right eye) the Ly6G+ cell number decreases significantly by day 15 
(Figure 5.9c). Ly6G+ transferred cells are not recruited to the eye during clinical disease 
(Figure 5.9b and 5.9d). Both endogenous and transferred Ly6C+ cell number decreases by day 
15 (Figure 5.10a-d). 
Clinical disease persists through to day 25 in the left eye after transfer but shows signs of 
resolving by OCT such as reduced cellular infiltrate within the vitreous, and the retinal 
thickness and optic disc have returned to pre disease thickness, in the fundal image the 
vitreous haze has resolved and the perivascular sheathing is no longer visible (Figure 5.4i and 
5.4j). In the left eye, total CD4+ cell number reduces between day 15 and day 25, subsequently 
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the transferred and endogenous populations have also decreased (Figure 5.6a 5.6b). 
Endogenous CD8+ T cell number persists in both eyes, but increased cell numbers were seen 
in the left eye of the recipients in comparison to the right eyes (Figure 5.7a-d). In the CD11b+, 
Ly6G+ and Ly6C+ compartment transferred cells are not recruited to the eye, but endogenous 
cells persist throughout disease, in the left eye that received the OVA peptide there is a more 
severe clinical disease thus cell numbers are increased across all leukocyte populations in 






















Figure 5.4: OCT imaging after intravitreal injection of OVA or PBS to day 25. Time course from 
day 2 after intravitreal OVA injection with concurrent intraperitoneal transfer of activated OTII cells at 
2x106 cells per mouse. Left eye received an intravitreal injection of OVA antigen, Right eye received 
an intravitreal injection of PBS. (A-J) Representative OCT images with concurrent fundal imaging from 
day 2 and day 25. Clinical disease is characterised by retinal infiltrate within the vitreous, swelling of 
the optic disc and thickening of the retina on the OCT image and vascular sheathing and vitreal haze 







































Figure 5.5: Average OCT disease scores throughout clinical disease course. Fundal images 
acquired concurrently with OCT images at each time point were scored blind using the criteria 
detailled In chapter 2. Average score was calculated for each eye, data expressed as mean + SEM. Left 

















Figure 5.6: Flow cytometric quantification of CD4+ retinal infiltrate. Retinas were dissected 
and prepared for flow cytometry at pre-defined time points. Total CD4+ cell numbers were quantified 
and then endogenous and transferred cell populations calculated. (A) Total endogenous CD4+ T cells 
present within the left eye of recipients at each time point (B) Total transferred CD4+ T cells present 
within the left eye of recipients at each time point (C) Total endogenous CD4+ T cells present within 
the right eye of recipients at each time point (D) Total transfer CD4+ T cells present within the right 
eye of recipients at each time point. Data are expressed as Mean +SEM. Statistical analysis performed: 
One-Way ANOVA multiple comparisons against PBS (previously shown in figure 5.2) (A+C), 







Figure 5.7: Flow cytometric quantification of CD8+ retinal infiltrate. Retinas were dissected 
and prepared for flow cytometry at pre-defined time points. Total CD8+ cell numbers were quantified 
and then endogenous and transferred cell populations calculated. (A) Total endogenous CD8+ T cells 
present within the left eye of recipients at each time point (B) Total transferred CD8+ T cells present 
within the left eye of recipients at each time point (C) Total endogenous CD8+ T cells present within 
the right eye of recipients at each time point (D) Total transfer CD8+ T cells present within the right 
eye of recipients at each time point. Data are expressed as Mean +SEM. Statistical analysis performed: 
One-Way ANOVA multiple comparisons against PBS (previously shown in figure 5.2) (A+C), 







Figure 5.8: Flow cytometric quantification of CD11b+ retinal infiltrate. Retinas were dissected 
and prepared for flow cytometry at pre-defined time points. Total CD11b+ cell numbers were 
quantified and then endogenous and transferred cell populations calculated. (A) Total endogenous 
CD11b+ cells present within the left eye of recipients at each time point (B) Total transferred CD11b+ 
cells present within the left eye of recipients at each time point (C) Total endogenous CD11b+ cells 
present within the right eye of recipients at each time point (D) Total transfer CD11b+ cells present 
within the right eye of recipients at each time point. Data are expressed as Mean +SEM. Statistical 






Figure 5.9: Flow cytometric quantification of Ly6G+ retinal infiltrate. Retinas were dissected 
and prepared for flow cytometry at pre-defined time points. Total Ly6G+ cell numbers were quantified 
and then endogenous and transferred cell populations calculated. (A) Total endogenous Ly6G+ cells 
present within the left eye of recipients at each time point (B) Total transferred Ly6G+ cells present 
within the left eye of recipients at each time point (C) Total endogenous Ly6G+ cells present within 
the right eye of recipients at each time point (D) Total transfer Ly6G+ cells present within the right eye 
of recipients at each time point. Data are expressed as Mean +SEM. Statistical analysis performed: 







Figure 5.10: Flow cytometric quantification of Ly6C+ retinal infiltrate. Retinas were dissected 
and prepared for flow cytometry at pre-defined time points. Total Ly6C+ cell numbers were quantified 
and then endogenous and transferred cell populations calculated. (A) Total endogenous Ly6C+ cells 
present within the left eye of recipients at each time point (B) Total transferred Ly6C+ cells present 
within the left eye of recipients at each time point (C) Total endogenous Ly6C+ cells present within 
the right eye of recipients at each time point (D) Total transfer Ly6C+ cells present within the right eye 
of recipients at each time point. Data are expressed as Mean +SEM. Statistical analysis performed: 










5.3.4 Selective recruitment of transferred cells to the retinal tissue throughout 
clinical disease 
The recruitment of transferred activated CD4+ T cells to the eye is due to an antigen-specific 
response. As OVA is not present within the ocular tissue naturally, an intravitreal injection of 
the OVA peptide allows local presentation of that antigen to the OTII TCR carried by the 
transferred activated OTII T cells.  
When OVA antigen is present within the ocular tissue (similarly to the uveitogenic cell transfer 
where the antigen the leukocytes have been primed to recognise is present within the ocular 
tissue) a large number of cells are recruited to the tissue of both a transferred and 
endogenous phenotype which is not observed when the antigen is not present.  
At day 15, clinical disease is observed (Figure 5.5g and 5.5h) and the ratio of endogenous to 
transferred CD4+ T cells within the eye is ~1:1 (Figure 5.6a and 5.6b). At this time point within 
lymphoid and non-lymphoid tissues and blood transferred cells were also seen in comparable 
populations to the eye (Figure 5.11b).  
The transferred cell population persists within the lymphoid and non-lymphoid tissue through 
to day 25 (figure 5.11d) but transferred cell number within the left eyes (that received the 
OVA peptide) of recipients has begun to decrease as clinical disease by OCT is resolving 

























Figure 5.11: Recruitment of OVA specific cells to lymphoid and non-lymphoid tissue. After 
intravitreal injection of OVA transferred CD4+ T cells were tracked in eyes, blood, lymphoid 
tissue (spleen and lymph node) and non-lymphoid tissue (liver and kidney). A) endogenous 
CD4+ T cells present within each tissue at day 15 B) transferred CD4+ T cells present within 
each tissue at day 15. C) endogenous CD4+ T cells present within the tissues at day 25 D) 
transferred CD4+ T cells present within the tissues at day 25.  
Data expressed as ln (1+ cell number) with error bars illustrating minimum and maximum 
cell number within data set. 
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5.3.5 Non-specific recruitment of non-antigen specific activated cells during 
clinical disease 
Cellular infiltrate is a distinctive feature of infection, in many types of inflammation the role 
T cells have to play has been well documented but the specific impact of the accumulation of 
other effector cells and migration of T cells to the tissue due to antigen recognition is still 
needing to be investigated (219). In a study carried out by Ghani et al 2009, a model driven 
by an inflammatory effector phase using TCR transgenic T cells found that, (i) increased 
recruitment of effector T cells and other leukocytes was due to antigen specific T cells playing 
a critical role as ‘pioneer cells’ to prepare the tissue, (II) infiltration of T cells is not reliant 
upon antigen specificity (219). It was further demonstrated that a minimal number of antigen-
specific cells recruited to the tissue are capable of inducing a large number of cells to migrate 
to the antigen-loaded site (219). Accumulation of T cells is independent of T cell reactivity to 
antigen during the early stages of inflammation despite it being a process driven by antigen 
later on in disease course, after initial arrival both transgenic and wild-type T effector cells 
show levels of increased recruitment to the site of antigen challenge and further activation of 
antigen-specific pioneer cells (219). This study further suggests that bystander activation of 
non-specific effector/memory T cells is a general feature of inflammation (219). 
As illustrated in previous chapters, adoptive transfer of uveitogenic cells induces EAU (figure 
4.5). By day 2, antigen-specific transferred cells can be detected in the eye, by day 7 as peak 
disease is reached a selective accumulation of antigen-specific transferred cells are present 
within the eye (figure 4.5). This continues through to day 14. In contrast, adoptive transfer of 
non-antigen specific activated cells causes limited CD4+ T cells stick in the ocular tissue (Figure 
5.3a and 5.3b), if the antigen is then added to the tissue using an intravitreal injection a 
recruitment of transferred CD4+ T cells occurs and clinical disease ensues (Figure 5.6a and 
5.6b) including recruitment of endogenous cells in large numbers to the eye containing the 
antigen (Figure 5.6c).  
Further to these observations the adoptive transfer of antigen-specific leukocytes and non-
antigen specific OT-II activated leukocytes at a 1:1 ratio was performed. Clinical disease 
course followed the same pattern as the previous antigen-specific transfers (figure 4.4 and 
4.5). Clinical imaging was used to monitor recipients (Figure 5.12) from day 0 to day 14, eyes 
were then analysed by flow cytometry at ay 2, day 7/8 and day 14 to analyse cellular infiltrate 
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and using allelic markers detect the endogenous CD4+, CD8+ and CD11b+ cells (Figure 5.13a, 
5.14a and 5.15a), transferred antigen-specific CD4+, CD8+ and CD11b+ cells (Figure 5.13b, 
5.14b and 5.15b) and transferred activated OTII CD4+, CD8+ and CD11b+ cells that are non-











































Figure 5.12: OCT imaging of recipients from day 0 (baseline) to day 14 after transfer. (A) 
Baseline fundal and OCT imaging of recipients before manipulation. (B) Fundus and OCT at day 5 after 
adoptive transfer; increased levels of cellular infiltrate is observed within the vitreous, thickening of 
the retina and swelling of the optic disc in the OCT image, within the fundal image a vitreal haze has 
formed due to cellular infiltrate and whitening around the optic disc. (C) Fundus and OCT imaging at 
day 14 after adoptive transfer; traits observed are still observed but disease is past peak and clinical 
















































Figure 5.13: Flow cytometry quantification of allelically marked CD4+ T cells. Allelic markers 
allow detection and quantification of different populations of CD4+ T cells. (A) Total endogenous CD4+ 
T cells quantified using flow cytometry at different time points throughout clinical disease. (B) Total 
transferred antigen specific CD4+ T cells quantified using flow cytometry at each time point 
throughout clinical disease. (C) Total transferred OTII non-antigen specific activated CD4+ T cells 
quantified using flow cytometry at different time points throughout clinical disease.  
Data are expressed as Mean +SEM. Statistical analysis performed: One-Way ANOVA multiple 

















































Figure 5.14: Flow cytometry quantification of allelically marked CD8+ T cells. Allelic markers 
allow detection and quantification of different populations of CD8+ T cells. (A) Total endogenous CD8+ 
T cells quantified using flow cytometry at different time points throughout clinical disease. (B) Total 
transferred antigen specific CD8+ T cells quantified using flow cytometry at each time point 
throughout clinical disease. (C) Total transferred OTII non-antigen specific activated CD8+ T cells 
quantified using flow cytometry at different time points throughout clinical disease.  
Data are expressed as Mean +SEM. Statistical analysis performed: One-Way ANOVA multiple 















































Figure 5.15: Flow cytometry quantification of allelically marked CD11b+ cells. Allelic markers 
allow detection and quantification of different populations of CD4+ T cells. (A) Total endogenous 
CD11b+ cells quantified using flow cytometry at different time points throughout clinical disease. (B) 
Total transferred antigen specific CD11b+ cells quantified using flow cytometry at each time point 
throughout clinical disease. (C) Total transferred non-antigen specific activated CD11b+ cells 
quantified using flow cytometry at different time points throughout clinical disease.  
Data are expressed as Mean +SEM. Statistical analysis performed: One-Way ANOVA multiple 

































The work presented in this chapter demonstrates that both non-antigen specific and antigen 
specific stimuli induce recruitment of CD4+ T cells to the ocular tissue, although to very 
different levels.  
Intraperitoneal injection of PBS initiated a change in the numbers of endogenous CD4+ T cells 
to the eyes of recipients, compared with age matched naïve mice at day 2 after injection 
(Figure 5.2). This procedure provides a baseline for recipients after cell transfer. This increase 
in CD4+ T cells within the ocular tissue could be due to endotoxin release from the injection 
site activating endothelial cells within the eye encouraging retention of CD4+ T cells.  
In the endotoxin induced uveitis model, LPS is injected directly into the ocular tissue to initiate 
a cascade of signalling reactions, increased expression of inflammatory markers results in the 
breakdown of the blood-ocular barrier and the infiltration of leukocytes into ocular tissue 
causing clinical disease (220).  
Toll like receptor 4 (TLR4) recognises the bacterial component LPS and is ubiquitously 
expressed in the vasculature (221). The small release of endotoxin from the injection site 
induces a lesser effect and recruitment of cells in comparison to EIU induction by intravitreal 
injection of LPS. Endothelial cells can be involved in the coordination of the recruitment of 
inflammatory cells to the tissue after injury or infection to produce and release cytokines and 
growth factors to communicate with immune cells entering the tissue. The activation of 
endothelial cells through TLRs can be direct through interaction with ligand molecules or may 
require a prior inflammatory stimulus such as IFN-γ, LPS or TNF-α (221). It has been observed 
in various models of inflammation that LPS leads to cell arrest in the tissue. On the other hand, 
TLR4 activation has been demonstrated to enhance survival and proliferation of CD4+ T cells 
(222). 
To assess if the recruitment of endogenous cells observed at day 2 in the pathogenic transfer 
is due to more than a non-antigen specific response stimulating endothelial activation, 
adoptive transfer of antigen specific activated cells was contrasted with non-antigen specific 
activated OTII cells and non-antigen specific non activated OTII cells that were transferred 
into naïve recipients. Analysed by flow cytometry at day 2 and day 7 (Figure 5.3 and 5.4) the 
increase in endogenous CD4+ T cells in the non-antigen specific OTII cell transfer is 
indistinguishable from the PBS intraperitoneal injection alone at day 2 and declines by day 7. 
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In the transferred CD4+ T cell compartment, very small numbers of cells are recovered from 
the eye, showing that without an antigen specific response in the eye, T cell activation alone 
leads to very low levels of cell retention at day 2.  
As the OVA-specific T cells are not recruited to the eye of recipients when no local stimulus is 
present, two experiments were carried out. Firstly, a transfer of OVA-specific T cells 
concurrently with an intravitreal injection of OVA into one eye and a control intravitreal 
injection into the other eye of each recipient showed selective recruitment to the OVA 
injected eye. Several studies have described the disappearance of antigen-specific 
effector/memory T cells from the periphery and their accumulation within antigen-challenged 
sites (219, 223). Accumulation of autoantigen specific T cells was observed in these studies in 
lymphoid organs that specifically expressed the autoantigen (219). It has been further 
demonstrated that antigen-specific CD4 T cells also migrate to non-lymphoid organs in large 
numbers after systemic exposure to antigen (224, 225) but here it was not possible to 
determine whether T cells migrated preferentially to the antigen-containing organs (225). 
Data presented in chapter 4 supports the accumulation of CD4+ T cells to non-lymphoid 
organs and suggests that the transferred auto-antigen specific T cells were selectively 
recruited to the eye which contains the target antigen, as well as being retained in lymphoid 
tissues such as the spleen and lymph nodes.  
In a study by Reinhardt et al (225) the group were able to confirm by confining antigen to a 
local site injection of OVA peptide/IFA subcutaneously to mouse tails with a concurrent 
transfer of OVA specific T cells, that by day 5 after subcutaneous injection of OVA peptide 
large numbers of OTII cells were present within the tail tissue (225). In the data presented in 
this chapter, at day 4 after adoptive transfer of OTII cells with an intravitreal injection of OVA, 
transferred OTII cells can be detected within the eyes of recipients providing evidence that 
the local site of antigen deposition is the major non-lymphoid tissue in which activated 
antigen-specific CD4 T cells accumulate during a primary response. A small population of 
transferred OTII cells is also observed in lymphoid and non-lymphoid tissues such as spleen, 
lymph node, liver and kidney suggesting that local antigen presentation is not the only factor 
that determines the distribution of antigen-specific T cells in lymphoid and non-lymphoid 
tissue, also in agreement with the results of the Reinhardt study (225).  
When activated TCR transgenic OVA specific OTII cells are transferred into recipients with no 
pathogenic stimulus, endogenous cells do not stick in the eye in greater numbers than just a 
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PBS injection alone and very low levels of transferred cells stick non-specifically in the eye 2 
days after transfer. When OVA antigen is then injected into one eye of each recipient an 
antigen-specific recruitment was observed to the OVA injected eye over the control injected 
eye, inducing an increase in the endogenous compartment and clinical disease by OCT. Within 
the control eye, no increase in endogenous cells compared to a PBS intraperitoneal injection 
is observed, increased numbers of transferred OTII cells stick non-specifically in the eye in 
comparison to the activated OTII cell transfer. This non-specific sticking of OTII cells within 
the eye that received no antigen could be due to cells recirculating after encountering the 
OVA antigen within the contralateral eye. 
The recruitment of endogenous cells to the eyes of pathogenic transfer recipients at day 2 is 
not significantly increased in comparison to the mice that received an OTII cell transfer or OTII 
transfer with intravitreal OVA injection. However, the recruitment of pathogenic transferred 
cells to the eyes of recipients by day 2 is significantly increased (p<0.001****) in comparison 
to the OTII transfer and the OTII transfer with intravitreal OVA injection. Thus, suggesting that 
the retinal antigen present in the eye is facilitating the recruitment of the transferred 
population and by injecting OVA into the eye does not induce transferred cell recruitment this 
early after cell transfer which could be due to the APCs not presenting the antigen to the CD4+ 
T cells by this time point. 
The adoptive transfer of a mixture of pathogenic and non-pathogenic activated T cells at a 
ratio of 1:1 allowed further assessment of the recruitment of these cells to the eye. Several 
studies have shown that T cells were recruited irrespective of their antigen-specificity, into 
acute T-cell dependent inflammatory sites (219, 226, 227). Activated OTII cells behave 
differently in tissues that are ‘vulnerable’ due to an ongoing antigen specific response, which 
could have the effect of focussing recently activated cells to a target tissue increasing the 
likelihood of them catching the infection.  
The data presented in this chapter illustrates a recruitment of antigen-specific pathogenic 
cells to the eye to initiate clinical disease, when non-pathogenic (OVA specific) activated cells 
are transferred with no OVA peptide injection there is low levels of recruitment in the 
endogenous compartment but not significantly different from recipients who received a PBS 
intraperitoneal injection along with minimal numbers of transferred cells are detected within 
the eye. Therefore, the recruitment of large numbers of OVA specific cells to the eye occurs 
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when a pathogenic stimulus is present or if the antigen has been introduced into the ocular 
tissue. 
In conclusion, intraperitoneal injection alone causes changes in the number of CD4+ T cells 
retained in ocular tissue, this number is not significantly increased if the injection includes 
activated non-ocular-antigen specific T cells. The data that co-transfer of pathogenic and non-
pathogenic cells together leads to much greater retention of both populations suggests that 
an antigen specific signal from the pathogenic cell transfer induces a qualitatively different 




























































Leukocyte trafficking is a thoroughly regulated process, the breakdown of the fundamental 
control mechanisms can contribute to conditions such as immunodeficiency and autoimmune 
disease (228). Migration profiles can greatly vary between types of leukocytes and are known 
to have a direct effect on leukocyte retention at sites of immune defence and inflammatory 
diseases, it is now recognised that chemokines and chemokine receptors working alongside 
adhesion molecules are the main controllers of leukocyte migration and are critical to 
fundamental biological processes including embryonic development early in life, immune 
surveillance, host defence and wound repair throughout life (228, 229). 
 
6.1.1 Chemokines 
Chemokines are a family of small, highly conserved proteins involved in numerous biological 
processes including chemotaxis, leukocyte degranulation, haematopoiesis and angiogenesis 
and are the largest family of cytokines in human immunophysiology (230-235). The proteins 
are sized roughly 8 to 12 kDa, and are able to induce chemotaxis in a variety of cell types 
including, neutrophils, monocytes, lymphocytes, eosinophils, fibroblasts and keratinocytes 
(236). Chemokines provide a wide range of functions and can be naturally inclined to create 
a homeostatic environment. They are produced constitutively and secreted to mediate 
lymphocyte trafficking to lymphoid tissues, and are also known to play a role in 
immunosurveillance (237). The role chemokines play in immunosurveillance involves T and B 
cell localisation with APCs from the lymphatic system presenting antigen, however not all 
chemokines are produced in a resting state some chemokines are considered to be 
inflammatory in nature and are only secreted when infection is present or due to a pro-
inflammatory stimulus (237). In order to mount an immune response chemokines induce 
leukocytes to migrate to the site of inflammation where injury or infection is present and 
inflammatory cytokines are aiding in mounting an immune response by activating cells (237). 
 
6.1.2 Chemokine receptors 
Chemokines are secreted proteins that travel in the circulation, they move through the 
parenchyma and extracellular matrix of tissues and bind to and activate the extracellular 
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domain of their cognate receptors present on individual cell types (237, 238), they act on 
leukocytes by interactions with seven-transmembrane G protein-coupled receptors which are 
localised on target cells (239). Chemokine activity is initiated by the binding of the chemokine 
against the specific corresponding G protein-coupled receptor, in order to activate a 
chemokine receptor two steps need to be undertaken, firstly binding of the receptor to the 
specific chemokine agonist it recognises, followed by the flexibility of the N terminus allowing 
a conformational change to take place. This change is necessary to allow the N terminus to 
form interactions with the specific chemokine receptor to induce activation (240). After the 
receptor has been activated, GDP bound to the α sub-unit of the G proteins is changed for 
GTP (240). Chemokines interact with both chemokine receptors  and with glycosaminoglycans 
to promote migration and impact directionality to cell movement (241).  
Ten CC-receptors and six CXC-receptors have been identified, single XCR1 and CX3CR1 
receptors have also been described (239). Most chemokine receptors recognise several 
ligands and multiple chemokines are able to bind to more than one receptor, additionally, 
some chemokines act as natural antagonists of specific receptors (239). 
The functions of chemokine receptors are vast but they can be grouped depending on if they 
are predominantly involved in response to infection and inflammation or maintaining 
homeostasis within the host (242). By inducing chemotaxis and therefore directing cells to 
the source of chemokine gradients, allows chemokines to control the position and trafficking 
of leukocyte within the host. Specifically, mobilisation of leukocytes to the site of 
inflammation in response to chemokine secretion is due to the significant role inflammatory 
chemokine receptors play in the hosts defence and their ability to trigger leukocyte 
movement (242).  
 
6.1.3 Chemokine interactions with chemokine receptors 
Mechanisms affecting the chemokine or chemokine receptor modulate a leukocytes ability to 
respond to chemokines. Modulation of levels of the receptor molecules on a cellular basis or 
functionally active receptors being presented at the cell surface are methods of control 
exerted on the chemokine receptor (242).  By affecting the activation state, cellular location 
or signalling ability of a functional chemokine receptor at the cell surface tight control is 
188 
 
achieved, an essential method of rapid control in response to cross-talk from other receptors 
or due to ligand binding (242).  
 
6.1.4 Fractalkine (CX3CL1)  
CX3CL1 also known as fractalkine is the only known member of the CX3C chemokine subclass 
(150, 243). Fractalkine is unique within the chemokine family due to its synthesis as a 
transmembrane molecule, it is made up of 373 total amino acids including: at residues 1-76 
an extracellular terminal domain, 77-317 a mucin like stalk, 318-336 a transmembrane helix 
and at 337-373 a short cytoplasmic tail (150). Fractalkine can exist in a membrane bound or 
soluble form. The soluble form of fractalkine has chemoattractive functions that act on T cells, 
NK cells and monocytes, it is generated by disintergrin-like metalloproteinases ADAM 10 and 
ADAM 17/TACE, and is made up of a and extracellular mucin-like stalk and the chemokine 
domain. The membrane bound form acts as an adhesion molecule and assists integrin-
independent adhesion induced by IL-1, IFN-γ and TNF-α on primary endothelial cells (150, 
243). The membrane bound form of CX3CL1 also promotes the friction and interlocking of 
CX3CL1 leukocytes (150).  
 
6.1.5 CX3CR1  
The highly specialised receptor for CX3CL1 and CCL26 in humans is known as CX3CR1 (244). 
CX3CR1 can be found on the surface of cytotoxic effector lymphocytes including CD8 T cells, 
NK cells and γδ cells as a marker due to the expression of large amounts of granzyme B and 
perforin no matter what the mode of target recognition or cell lineage (150).  
During inflammation fractalkine is expressed by monocytes within the peripheral blood, it can 
also be expressed on endothelial cells, fibroblasts, dendritic cells, and macrophages during 
autoimmune inflammation such as during the autoimmune disease rheumatoid arthritis (150, 
245). A role for interactions between fractalkine and its specific receptor have been suggested 
in immune-related inflammatory disease due to their presence on lymphocytes and increased 
cellular expression during inflammatory conditions (150). In both humans and mice CX3CR1 
is expressed on monocytes, macrophages, mucosal dendritic cells , natural killer cells, mast 




6.1.6 CX3CR1 expression on CD4+ T cells 
Chemokine receptors expressed on lymphocytes can vary based on different subtypes and 
specific development stage so as to facilitate chemotaxis to different tissues (246). Studies 
have illustrated in humans that expression of CX3CR1 is predominantly seen in Th1 cells that 
respond chemotactically to fractalkine (246), CX3CL1 upregulation during inflammation is 
suggested to be a contributing factor of inflammatory disease by the promotion of 
transmigration of CX3CR1 expressing cells to sites of inflammation (151).  
In a study by Mionnet et al (151), CX3CR1-associated survival was observed on Th1 cells upon 
airway inflammation but not under homeostatic conditions or peripheral inflammation (151). 
In vitro, differentiated Th1 cells did not express CX3CR1 unless incubated with lung cells or 
injected into sensitised mice exposed to aerosols of their cognate antigens, therefore CX3CR1 
expression in T helper cells is inducible under specific conditions in vivo and in vitro (151). It 
was also shown that CX3CR1 does not play an integral role in T cell migration to the lung but 
is instead required for maintenance and survival within inflamed airways (151). Whereas in a 
study by Staumont-Sallé (247) in an adoptive transfer model of atopic dermatitis CX3CR1 Th1 
cells are established as a key regulator of CD4+ T cells retention at the inflamed site, which 
indicates a new function for the fractalkine ligand and receptor (247).  
 
6.1.7 CX3CR1 in EAU 
The role of CX3CR1 in EAU is not yet defined. Dagkalis et al has suggested CX3CR1 deficiency 
generates a more severe EAU disease phenotype (47). To understand the role of CX3CR1 in 
regulating function of monocytes and microglia, using CX3CR1 deficient mice (47) it was found 
that in comparison to CX3CR1 positive mice, CX3CR1 negative mice had a more severe disease 
phenotype 23 days post immunisation, based on increased cellular infiltrate and increased 
monocyte/macrophage clustering (47). 
In contrast, Kezic et al (248), reported no impact on the pathogenesis of EAU when comparing 
CX3CR1 positive and CX3CR1 negative mice, demonstrating the lack of a significant role for 
CX3CR1 in this particular study compared to previous studies suggesting a role in other retinal 
and neurodegenerative conditions (248). This perhaps may reflect a differential role for 
CX3CR1 expression on different cell types such as T cells versus macrophages. These studies 
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highlight a need to investigate soluble mediators in various disease states and tissue 
microenvironments (248). 
 
6.1.8 CX3CR1 Knockout mice  
CX3CR1+/GFP mice were produced by targeted inactivation of the CX3CR1 gene with cDNA 
encoding EGFP (Clontech) (152). In the construct (and mutant locus) the EGFP gene replaces 
the first 390 bp of the second CX3CR1 exon encoding the N-terminus of the seven-
transmembrane receptor specific for CX3CL1 (152). Germ line transition of the mutant allele 
yielded heterozygous CX3CR1+/GFP mice, which were inter-crossed to generate CX3CR1GFP/GFP 
mice (152) on a C57BL/6 background screened for rd8 mutations. 
CX3CR1+/GFP mice can serve as a source of unmanipulated, in vivo labelled cell populations 
that could be instrumental in high-resolution studies on the development and dynamic 
properties of CX3CR1 (152), whereas CX3CR1GFP/GFP mice are usual to understand what effect 
deleting CX3CR1 has on disease course. 
This chapter focuses on utilising the adoptive transfer technique to induce EAU using C57BL/6 
CX3CR1+/GFP (CD45.2) or CX3CR1GFP/GFP (CD45.2) as donors or recipients to analyse the role 
CX3CR1 plays on disease pathogenesis in donor CD4+ T cells and within recipient tissue. 
Secondly, the use of CX3CR1+/GFP mice allows tracking of the transferred population and using 
GFP expression to monitor CX3CR1 expression on CD4+ T cells throughout clinical disease. In 
the early sets of experiments presented in this chapter minimal effects of CX3CR1 on disease 
course is observed but work later in the chapter marks an important phenotype change of 












6.2 Materials and Methods 
 
6.2.1 Adoptive transfer technique 
EAU was induced in C57BL/6 CX3CR1+/GFP (CD45.2) or C57BL/6 CX3CR1GFP/GFP (CD45.2) using 
RBP3 peptide, these donor cells were then transferred using i.p injection into C57BL/6      
RAG2-/-  to analyse differences in disease through donor cells. 
C57BL/6 Ly5 (CD45.1) were immunised and donor cells were then transferred using i.p 
injection into C57BL/6 CX3CR1+/GFP (CD45.2) or C57BL/6 CX3CR1GFP/GFP (CD45.2) mice to 
analyse differences in disease in recipient tissue.  
C57BL/6 CX3CR1+/GFP (CD45.2) were immunised and donor cells were then transferred using 
i.p injection into or C57BL/6 Ly5 (CD45.1) mice to analyse expression of CX3CR1 on CD4+ T 
cells during clinical disease.  
 
6.2.2 Clinical imaging 
OCT was used to acquire clinical imaging for a disease time course from day 0 to day 25 using 
the standardised method developed during data chapter 3.   
 
6.2.3 Flow cytometry 
At predefined time points after adoptive transfer, retinas were analysed by flow cytometry to 
quantify total cell number for each leukocyte population. Allelic markers were used as seen 
previously to identify transferred and endogenous populations including CD45.1, CD45.2 and 
expression of GFP denoting CX3CR1 expression. 
 
6.2.4 Absolute numbers quantification 
Splenocytes were counted to form a 7-fold serial dilution from 20x106-312,500. All samples 
including the standard curve are resuspended in the same volume and acquired at the same 
speed for the same amount of time. Unknown sample numbers were then interpolated from 






6.2.5 Statistical analysis 
Data is presented as log transformed  to normalise the data(ln (1+)) and expressed as Mean 
+ SEM. Statistical analysis such as a Mann Whitney test (for 2 sample groups) or a one-way 
































6.3.1 CX3CR1 deficiency on donor cells affects initiation of disease in RAG2-/- 
mice 
In order to investigate the effect of CX3CR1 on donor T cells on EAU disease course, we used 
the adoptive transfer technique to transfer uveitogenic T cells into RAG2-/- recipients using 
cells with different CX3CR1 expression.  
Cells were transferred from either Ly5 (Wild type mice), CX3CR1+/GFP (CX3CR1 heterozygous) 
or CX3CR1GFP/GFP (CX3Cr1 Knockout) into RAG2-/- (CX3CR1 WT) recipients. RAG2-/- recipients 
do not have endogenous T or B cells so the effect of changing CX3CR1 expression on the donor 
T cells on the recipient, can be analysed based on disease initiation, disease severity and 
quantification of retinal infiltrate. 
Ly5 CD4+ transferred cells induced disease at day 7, as seen by OCT imaging (Figure 6.1) in 
comparison to the CX3CR1 heterozygous and CX3CR1 knockout transfers (Figure 6.1c and 
6.1g). By day 13 all cell transfer groups have clinical disease by OCT at reasonably consistent 
severity across the three groups (Figure 6.1b, 6.1d and 6.1h).  
In the CX3CR1 heterozygous and CX3CR1 knockout group, disease was monitored through to 





























Figure 6.1: OCT clinical imaging of disease of each group of recipients Ly5, CX3CR1 
heterozygous and CX3CR1 knockout. A+B Disease course from day 6 to day 14 in RAG2-/- mice that 
received a Ly5 wildtype transfer of uveitogenic cells. C-F Disease course from day 0 to day 28 in      
RAG2-/- mice that received a CX3CR1 heterozygous transfer of uveitogenic cells. G-J Disease course 
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Figure 6.2: Average OCT disease scoring across all three recipient groups during active 
disease. Fundal images were acquired with OCT at various time points throughout disease course. 
The images were then collated and scored blind using the clinical disease scoring criteria presented in 















6.3.2 CX3CR1 deficiency on donor cells does not affect disease phenotype after 
disease initiation  
Analysis of retinas during clinical disease allowed quantification of retinal infiltrate. Due to 
the lack of endogenous B and T cells, the cells driving the disease are from the transferred 
population. 
At day 7 after adoptive transfer (as highlighted previously in figure 6.1), severe clinical disease 
is present in the imaging of the wildtype Ly5 transfer eyes of the RAG2-/- mice. This is 
confirmed by the flow cytometry quantification of CD4+ T cells (figure 6.3a). There is a 
statistically significant difference between the total CD4+ T cells present in the retinas of the 
Ly5 wildtype transfer and the retinas of the two other groups; CX3CR1 heterozygous and 
CX3CR1 knockout (Figure 6.3a). In the CD8 compartment, the transferred cells have survived 
and been recruited to the retinas of all groups of animals (figure 6.4a) and in similar numbers 
across the groups. The CD11b+ endogenous infiltrate illustrated a statistically significant 
(****p<0.0001) increase between the Ly5 wildtype RAG2-/- recipients and the RAG2-/- 
recipients that received a CX3CR1 heterozygous or CX3CR1 knockout groups (figure 6.5a).  
By day 14, the total number of CD4+ T cells in the retinas of each group has reached similar 
levels (figure 6.3b), similarly observed in the OCT imaging at day 13 in figure 6.1. This pattern 
is also observed within the CD8+ and CD11b+ cell numbers (figure 6.4b and 6.5b) 
At day 21, only the CX3CR1 heterozygous and CX3CR1 knockout RAG2-/- recipients remain and 
disease between the two groups is still comparable (figure 6.1), this observation is backed up 
by the retinal infiltrate in CD4, CD8 and CD11b cell number (figure 6.3c, 6.4c and 6.5c). 
Disease still has not resolved by day 28 the pattern follows from day 21 with equal disease 
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Figure 6.3: Analysis of total CD4+ T cell number within the retinal infiltrate at different time 
points throughout clinical disease. RAG2-/- recipients received an intraperitoneal transfer of 
uveitogenic cells from one of three donor types Ly5, CX3CR1 heterozygous or CX3CR1 knockout. As 
seen in figure 6.1 clinical disease was monitored using OCT clinical imaging throughout clinical disease. 
To correlate with the clinical imaging at each time point retinas were dissected and prepared for flow 
cytometric analysis and CD4+ T cells numbers were quantified. Data expressed as Mean +SEM. 
Statistical analysis performed: One-Way ANOVA multiple comparisons compared to wildtype transfer 
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Figure 6.4: Analysis of total CD8+ T cell number within the retinal infiltrate at different time 
points throughout clinical disease. RAG2-/- recipients received an intraperitoneal transfer of 
uveitogenic cells from one of three donor types Ly5, CX3CR1 heterozygous or CX3CR1 knockout. To 
correlate with the clinical imaging at each time point retinas were dissected and prepared for flow 
cytometric analysis and CD8+ T cells numbers were quantified. Data expressed as Mean +SEM. 
Statistical analysis performed: One-Way ANOVA multiple comparisons compared to wildtype transfer 
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Figure 6.5: Analysis of total CD11b+ cell number within the retinal infiltrate at different time 
points throughout clinical disease. RAG2-/- recipients received an intraperitoneal transfer of 
uveitogenic cells from one of three donor types Ly5, CX3CR1 heterozygous or CX3CR1 knockout. To 
correlate with the clinical imaging at each time point retinas were dissected and prepared for flow 
cytometric analysis and CD11b+ cell numbers were quantified. Data expressed as Mean +SEM. 
Statistical analysis performed: One-Way ANOVA multiple comparisons compared to wildtype transfer 


















6.3.3 CX3CR1 deficiency in recipient tissue does not affect EAU disease onset 
The transfer of CX3CR1 deficient cells into RAG2-/- recipients saw a late onset of EAU in 
comparison to wildtype transfers (figure 6.1 and 6.3). 
From this we wanted to understand if CX3CR1 deficiency within recipients had a similar effect. 
In order to investigate the affect CX3CR1 deficiency within the recipient tissue has on disease 
initiation, wildtype (Ly5) cells were transferred into CX3CR1 heterozygous (CX3CR1+/GFP) or 
CX3CR1 (CX3CR1GFP/GFP) knockout recipients. In previous studies using active immunisation of 
CX3CR1 heterozygous mice or CX3CR1 knockout mice, CX3CR1 was found to not have an 
effect on disease onset (248).  
At day 0, the fundus and OCT images are both similar and normal before disease induction 
(figure 6.6a and 6.6f). At day 2, clinical disease cannot be observed by OCT imaging in both 
groups of recipients (figure 6.6b and 6.6g).  
By day 7, severe clinical disease can be seen in both groups by OCT (figure 6.6c and 6.6h), 
severe retinal infiltrate (vitritis) is present within the vitreous of the animals in both groups. 
Obvious swelling of the retina and optic disc is also observed within the OCT image and a 
vitreal haze is present within the fundus image with obvious swelling around the optic disc. 
At day 14, active clinical disease has begun to resolve (figure 6.6d and 6.6i). In the OCT image 
swelling of the retina and optic disc has resolved but retinal infiltrate is still seen within the 
vitreous. The fundus images still show a swelling around the optic disc and some perivascular 
sheathing but the vitreal haze has subsided.  
At day 21, active disease has further resolved with minimal retinal infiltrate present within 
the OCT. Although active disease appears to be resolving within the OCT image in the fundal 
imaging retinal scarring remains and mild inflammation is observed around the optic disc 






















Figure 6.6: OCT imaging of clinical disease course using a Ly5 transfer of uveitogenic cells 
into CX3CR1 heterozygous or CX3CR1 knockout mice. Clinical imaging was taken throughout 
clinical disease to observe disease initiation and progression within the two groups. Day 0 baseline 
illustrates the two groups of recipients have similar characteristics as other wildtype naives (A+F). At 
day 2, clinical disease is not observed, and the OCT and fundus imaging is comparable to the baseline 
at day 0 (B+G). From day 7, clinical disease is observed in both the fundal images and OCT (C+H). By 
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Figure 6.7: Average OCT scores of CX3CR1 heterozygous and CX3CR1 knockout recipients 
after adoptive transfer. Fundal images were obtained throughout clinical disease from both 
recipient groups. Images were then scored blind using the criteria described in chapter 2. Average 













6.3.4 CX3CR1 deficiency in recipient tissue does not affect leukocyte 
recruitment to the eye throughout disease  
CX3CR1 deficiency on recipient tissue does not affect disease induction and by OCT imaging 
does not appear to affect the disease course within the two groups.  
To further analyse the differences in disease course across the two groups of recipients that 
received Ly5 uveitogenic cells (CX3CR1 heterozygous and CX3CR1 knockout) flow cytometric 
analysis was performed at several time points throughout clinical disease course to support 
the OCT imaging collected. 
At day 2, endogenous recruitment of CD4+ T cells to the eye is similar between the two groups 
this is also seen within the transferred population at this time point (figure 6.6a and 6.6d). 
Within the CD8 T cell compartment endogenous recruitment and transferred recruitment is 
comparable across the two recipient groups (figure 6.8b and 6.8e), this is also seen within the 
CD11b+ cell compartment (figure 6.8c and 6.8f).  
As observed within the OCT imaging in figure 6.6 and 6.7 clinical disease has developed in the 
recipients of both groups illustrated by severe retinal infiltrate, made up of several different 
leukocyte populations including CD4+ T cells, CD8+ T cells and CD11b+ cells. CD4+ T cell 
recruitment has increased in both groups to mediate disease. Transferred CD4 T cell number 
has increased and the ratio of endogenous to transferred cells is ~1:1 illustrating recruitment 
of both uveitogenic transferred CD4+ T cells and endogenous CD4+ T cells (figure 6.8a and 
6.8d). At peak disease, endogenous CD8+ T cells are found in increased numbers in the retinal 
infiltrate (figure 6.8a), but in contrast transferred CD8+ T cells have a small increase in number 
at peak disease which has also been observed in previous chapters (chapter 4) (figure 6.8b). 
The same pattern is observed in the CD11b+ compartment, many endogenous cells within the 
retinal infiltrate but minimal transferred cells (figure 6.8c and 6.8f). 
At day 14 total CD4+ retinal infiltrate in the endogenous compartment has remained from 
day 7 (figure 6.8a) but within the transferred compartment there is now a statistically 
significant difference between the transferred CD4+ T cell population within the eyes of the 
CX3CR1 heterozygous recipients and the CX3CR1 knockout recipients. This is due to a 
decrease in transferred cells in the CX3CR1 knockout recipients in comparison to the CX3CR1 
heterozygous recipients (figure 6.8d). Endogenous CD8+ T cells have persisted through to day 
14 in the CX3CR1 heterozygous group (figure 6.8b), whereas in the CX3CR1 knockout group a 
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drop in endogenous CD8+ numbers is observed (figure 6.6b). In the transferred CD8+ 
population a minimal population is still observed in both groups of recipients (figure 6.8e). 
CD11b+ cell number is reduced in both groups in the endogenous compartment, but no 
statistical difference is observed between the two groups (figure 6.6c). As seen at day 7, the 
transferred CD11b+ cell number continues to be minimal through peak disease with very little 
recruitment of transferred cells (figure 6.8f).  
Finally, at day 21 when active disease has begun to resolve based on OCT clinical imaging 
(figure 6.6).  Endogenous CD4+ T cell numbers have dropped in both groups in comparison to 
day 14 but no statistically significant difference between the two groups is observed (figure 
6.6a). Whereas in the transferred CD4+ T cell population a reduction in cell number in both 
groups of recipients is observed but a statistically significant difference between the two 
groups based on cell number is present. Similarly, to day 14 a statistically significant difference 
between the two recipient groups based on transferred CD4+ T cell number due to a larger 
decrease of transferred CD4+ cells in the CX3CR1 knockout group when compared to the 
CX3CR1 heterozygous group (figure 6.8d). 
CD8+ T cell number at the day 21 time point appears to be similar in total endogenous cell 
number across the two recipient groups (figure 6.8b). As seen throughout clinical disease, 
very little recruitment of the transferred CD8+ population is seen. This pattern continues 
through to day 21 (figure 6.8e). 
Endogenous CD11b+ cell number decreases at day 21 back to a similar number that is seen at 
day 2 (figure 6.c8). Transferred CD11b+ cells were recruited in small numbers throughout the 
disease and this persists through to day 21 (figure 6.8f). 
Overall, the only difference between disease in the two recipient groups is observed in the 
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Figure 6.8: Flow cytometric analysis of retinal infiltrate throughout clinical disease in 
CX3CR1 heterozygous or CX3CR1 knockout recipients that received a Ly5 uveitogenic cell 
transfer. Retinas from CX3CR1 heterozygous recipients or CX3CR1 knockout recipients were taken 
and processed at each clinical imaging time point to analyse leukocytes present within the retinal 
infiltrate. Time course of endogenous CD4+ retinal infiltrate through clinical disease (A). Time course 
of transferred CD4+ retinal infiltrate through clinical disease (D). Time course of endogenous and 
transferred CD8+ T cell number through clinical disease (B+E). Time course of endogenous and 
transferred CD11b+ cell number through clinical disease (C+F). Data expressed as Mean +SEM. 













6.3.5 CX3CR1 upregulation on CD4+ T cells in the eye during EAU  
In a model studied by Mionnet et al, expression of CX3CR1 on CD4+ T cells is required for the 
development of clinical asthma, suggesting that expression by Th2 cells is required for airway 
disease (151). Further to this, expression of CX3CR1 denoted by GFP is highly increased on T 
cells in the inflamed lung (20-30%) in comparison to T cells in naïve CX3CR1 heterozygous 
mice (0.5%) (151). The studies further highlighted that CX3CR1 gives a selective advantage to 
Th2 cells, inflammation was not enough to induce infiltrating Th2 cells to express CX3CR1 but 
also required TCR engagement (151). And finally, CX3CR1 provided a survival signal to lung 
Th2 cells (151). 
To analyse the role of expression of CX3CR1 on CD4+ T cells in EAU, uveitogenic CX3CR1 
heterozygous cells were adoptively transferred into Ly5 recipients. Disease course was 
monitored using OCT imaging (figure 6.9) and CX3CR1 expression quantified by flow 
cytometric analysis at each time point by GFP expression on CD4+ T cells. Leukocyte infiltrate 
data and OCT imaging and scoring was previously presented in chapter 4. 
Figure 6.10a illustrates the frequency of transferred CD4+ cells expressing CX3CR1 from pre-
clinical disease at day 2 through peak disease to day 21. At day 2 GFP therefore CX3CR1 
expression was at 10% on the small number of recruited transfer cells at this time point. By 
day 7, CX3CR1 expression on CD4 T cells has increased slightly to ~20%. Peak frequency of 
transferred CD4+ T cells expressing CX3CR1 occurs at day 14 where 40% of the transferred 
population is GFP+ which then plateaus off at day 21. 
To support the large CX3CR1 CD4+ T cell population present within the eye during clinical 
disease figure 6.10b illustrates an increased population of CX3CR1 CD4+ T cells present within 
the eye in comparison to the other organs analysed including blood and liver. 
Throughout clinical disease, CX3CR1 expression on CD4+ T cells present within the liver and 








































Figure 6.9: Clinical imaging of disease course after CX3CR1 heterozygous transfer of 
uveitogenic cells into Ly5 mice. As previously described in figure 4.5, clinical disease course after 
uveitogenic cell transfer. Peak disease is present at day 7-10, but by day 14 infiltrate has reduced and 
































Figure 6.10: Frequency of CX3CR1+ CD4+ T cells in the eye throughout disease, and total 
number of CX3CR1+ CD4+ T cells in the eye in comparison to blood and liver. (A) CD4+ 
CX3CR1+ transferred cells as a fraction of the total CD4+ transferred population recruited to the eye 
at each time point through EAU. (B) Comparison of CD4+ CX3CR1+ cells present within the eye, blood, 
and liver throughout EAU. (A) frequency calculated by dividing total CD4+ CX3CR1+ cell number by 
total transferred CD4+ T cell number at each time point. (B) Total CX3CR1+ CD4+ cell number (log 














6.3.6 Pathogenic cells express CX3CR1 during EAU but when transferred 
together non-pathogenic cells do not express CX3CR1 during EAU 
As illustrated in figure 6.10, CX3CR1 is expressed on transferred uveitogenic CD4+ T cells 
during EAU. As peak disease progresses, the frequency of CX3CR1 expression on CD4+ T cells 
increases to ~40% (figure 6.10a).  
To further investigate if the upregulation of CX3CR1 on CD4+ T cells is observed solely on 
pathogenic transferred CD4+ T cells, CX3CR1 expression was quantified from the double cell 
transfer (described in figure 5.13).  Pathogenic CX3CR1 heterozygous leukocytes and OTII 
activated non-pathogenic leukocytes were transferred in a 1:1 mixture into Ly5 recipients. 
Leukocyte infiltrate data and OCT imaging was previously presented in chapter 5. 
OCT imaging (figure 6.11) shows a similar clinical disease course as the CX3CR1 heterozygous 
transfer alone into Ly5 recipients (figure 6.9). From data presented in chapter 5, CD4+ 
infiltrate during peak disease was quantified and 3 populations were observed: endogenous, 
antigen-specific (pathogenic) and non-antigen specific OTII (TCR transgenic activated with 
OVA peptide). In both the transferred antigen-specific and the activated non-antigen specific 
OTII populations there is a heterozygous CX3CR1 GFP tag present. Using GFP expression as a 
measure of CX3CR1 expression on both these populations total CD4+ CX3CR1+ retinal 
infiltrate is quantifiable in each recipient.  
At day 5-7, peak disease is observed by OCT clinical imaging (figure 6.11b), retinas were then 
isolated from recipients and CX3CR1 expression on CD4+ T cells quantified in the antigen-
specific and non-antigen specific OTII transferred populations. Figure 6.12 shows a difference 
in the frequency of CX3CR1 expression on CD4+ T cells on the transferred antigen-specific 
pathogenic cells in comparison to the activated non-antigen specific OTII transferred cell 
population.  
At day 14, active disease appears to have begun to resolve by OCT imaging (figure 6.11c). But 
a statistically significant difference between CX3CR1 expression on CD4+ T cells is observed 
between the transferred antigen-specific and the transferred non-antigen specific OTII cells 















Figure 6.11: OCT Clinical imaging of EAU disease course after double transfer of antigen -
specific and non-antigen specific leukocytes. Recipients were imaged from day 0 to day 14 to 
monitor clinical disease course. Peak clinical disease was observed by day 5, denoted by swelling of 
the retina and optic disc combined with high levels of retinal infiltrate (B). At day 14, active disease is 
still present within the eyes of recipients, but disease is post-peak so retinal infiltrate is mildly reduced 

















































Figure 6.12: Flow cytometric analysis of retinal infiltrate at day 7 and day 14 quantifying 
CX3CR1+ CD4+ cells as a frequency of total transferred RBP3 antigen specific or RBP3 non-
specific (OVA specific) populations. CX3CR1 expression was measured using the GFP tag on the 
CX3CR1 heterozygous antigen-specific (pathogenic cells) and the CX3CR1 knockout cross onto OTII 
TCR transgenic mouse OVA specific (Non-pathogenic cells). The frequency of CD4+ CX3CR1+ was 
calculated for both the RBP3 specific (pathogenic) cell population and the OVA specific (activated) cell 
population. Data expressed as Mean + SEM. Statistical analysis performed unpaired non-parametric 




















6.3.7 CX3CR1 upregulation on CD4+ T cells is due to an antigen-specific signal 
to the cells in vivo 
As seen in figure 6.12, more than 35% of antigen specific, pathogenic transferred CD4+ T cells 
express CX3CR1 during clinical disease, in comparison ~4% of the transferred non-pathogenic, 
OVA specific CD4+ T cells expressed CX3CR1 during clinical disease.  
To further investigate this observation that an antigen specific component is involved in 
CX3CR1 expression on CD4+ T cells. CX3CR1 expression was measured using the OVA 
intravitreal transfers described previously into C57BL/6 CX3CR1 heterozygous knockout mice. 
Leukocyte infiltrate data and OCT imaging was previously presented in chapter 5. 
Recipients firstly received an intravitreal injection of ovalbumin into the left eye and a PBS or 
L144 intravitreal control injection into the right eye. OTII TCR transgenic leukocytes were then 
transferred by intraperitoneal injection after activation by ovalbumin. Recruitment of 
leukocytes to both eyes were then monitored by OCT and endogenous and transferred 
leukocytes quantified by flow cytometry.  
At day 2, by clinical imaging no infiltrate is observed by OCT and overall, the fundus and OCT 
images look normal (figure 6.13a and 6.13b). By flow cytometry, endogenous recruitment to 
both eyes are comparable with low numbers of CX3CR1 expression, minimal transferred cell 
recruitment is observed at this time point.  
At day 4, some retinal infiltrate is observed by OCT in the left eye but not within the right 
(figure 6.13c and 6.13d), when CX3CR1 expression is analysed in the infiltrate from both eyes, 
no difference is observed in the total number of CX3CR1 CD4+ T cells expressing in both eyes 
at this time point (figure 6.14a and 6.14b). 
By day 8 after intravitreal injection of ovalbumin peptide and cell transfer, peak disease is 
present within the left eye (that received the OVA peptide) of the recipients, whereas in the 
right eye minimal infiltrate is observed (figure 6.11e and 6.11f). This continues to day 15 
where obvious infiltrate and retinal swelling is present within the left eye but not within the 
right eye (figure 6.13g and 6.13h). Total CD4+ CX3CR1+ T cells were increased in the 
endogenous and transferred compartment of the left eye, but in the right eye remained at 
similar reduced numbers as at day 4 (figure 6.14a and 6.14b). 
At day 25, retinal infiltrate is still observed within the left eye, but disease is past peak at this 
time point (figure 6.13i). The right eye of each recipient has not changed throughout the 
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disease course of the left eye by clinical imaging (6.13j). CX3CR1 is also still increased in the 
left eye over the right eye, although total CX3CR1+ CD4+ T cells does decrease after peak 
disease (figure 6.14a and 6.14b). CX3CR1 expression on CD4+ T cells is increased in the left 
eye in comparison to the right eye throughout the whole disease course.  
CX3CR1 expression on CD4+ T cells during EAU is observed when an antigen-specific 
interaction in vivo has taken place and therefore activation alone with a non-specific antigen 























Figure 6.13: OCT clinical imaging of disease course after cell transfer and intravitreal 
injection of OVA or L144 control peptide Disease was monitored in both eyes from day 2-day 25. 
Disease was observed in the left eye (A,C.E,G,I). But no clinical disease was seen in the right eye (B, D, 
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Figure 6.14: Total CX3CR1+ CD4+ T cells within the retinal infiltrate at each time point. Flow 
cytometric analysis at each time point during clinical disease of total CD4+ CX3CR1+ T cells present 
within the endogenous compartment of each eye (A) and transferred CX3CR1+ CD4+ T cells (B). (Left 
eye received OVA intravitreal injection, Right eye received control peptide L144 or PBS) Data 

































The role of CX3CR1 in EAU is controversial. A study by Kezic et al (248) suggests that the 
CX3CR1 receptor does not play a significant role in the pathogenesis of EAU (248), this was 
based on disease scores following active induction of disease between wildtype, CX3CR1 
heterozygous and CX3CR1 knockout mice not being significantly different at disease onset 
(248). Conversely, a study by Dagkalis et al (47)  defined an association between CX3CR1-
deficiency and increased severity of disease in EAU in the active immunisation model. CX3CR1 
knockout mice had increased disease severity at day 23 post-immunisation in comparison to 
CX3CR1 heterozygous mice, with increased recruitment of monocytes to the retina in 
response to EAU induction (47). 
The studies presented in this chapter extend these findings by illustrating a role for CX3CR1 
expression on CD4+ T cells during EAU using the adoptive transfer technique of disease 
induction, showing that there is a selective retention or recruitment of CX3CR1+ CD4+ T cells 
during active clinical disease. 
To investigate the role of CX3CR1 expression has on disease initiation and progress in the 
adoptive transfer model of EAU, cells of different CX3CR1 expression (wildtype, CX3CR1 
heterozygous and CX3CR1 knockout) were transferred into RAG2-/- mice. These experiments 
allow the analysis of the effect of CX3CR1 deficiency on donor cells with CX3CR1 intact in the 
recipient tissue.  
Wildtype cells initiate disease within the RAG2-/- recipients by day 7, whereas disease 
initiation within the CX3CR1 heterozygous and CX3CR1 knockout transfer recipients occurred 
at the later time point of day 14. The delay in disease induction in the CX3CR1 deficient 
transfers (figure 6.1 and 6.2) is consistent with a role for CX3CR1 on the transferred 
population that even in the heterozygote animals influences efficacy of recruitment during 
disease initiation but does not limit maximum severity of the disease. Because normal Treg 
function is deficient, it is not possible to interpret disease duration. 
To complement this set of experiments, CX3CR1 deficiency in recipient tissue was 
investigated.  Wildtype cells were transferred into CX3CR1 heterozygous and CX3CR1 
knockout mice. No difference was observed in disease initiation or course by OCT imaging 
(figure 6.5) but there was a statistically significant difference in the transferred WT CD4+ T 
cell number within the retinal infiltrate at day 14 and day 21 (figure 6.6). Which indicates that 
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CX3CR1 expression within the tissue can have an effect on CD4+ T cell recruitment throughout 
active clinical disease. 
These data sets illustrate a role for CX3CR1 in disease initiation in donor uveitogenic cells, but 
not disease severity. Further to this the wildtype transferred cells preferentially survived 
during clinical disease in CX3CR1 heterozygous mice over the CX3CR1 knockout mice.  
As demonstrated in chapter 4, within the leukocyte population that is transferred into naïve 
recipients the surviving population is CD4+ T cells. This suggests that the effect on disease 
within donor CX3CR1 deficient cells is based on CX3CR1 being expressed on CD4+ T cells 
during EAU. 
Mionnet et al (151), suggested a role for CX3CR1 expression on CD4+ T cells in survival and 
maintenance during airway inflammation (151). Further to this, a study conducted by 
Staumont-Sallé et al concluded that CX3CR1 deficiency does not affect antigen presentation 
or T cell proliferation upon skin sensitisation in experimental models of atopic dermatitis and 
that expression of CX3CR1 by both Th1 and Th2 cells was required for induction of disease 
(247). The study also used adoptive transfer experiments to establish CX3CR1 as a key 
regulator of CD4+ T cell retention in inflamed skin (247). However, the role of CX3CR1 on CD4+ 
T cells in EAU has not yet been published. 
Adoptive transfer of CX3CR1 heterozygous cells into Ly5 (wildtype) C57BL/6 recipients 
investigated expression of CX3CR1 using the GFP on CD4+ T cells. At day 7 which is considered 
to be peak disease, CX3CR1 expression is observed on transferred CD4+ T cells recovered from 
the eye at a frequency of ~0.2 on total transferred CD4+ T cells, when followed to day 14 the 
frequency increases to ~0.4 showing an increase in the relative frequency of transferred CD4+ 
T cell expressing CX3CR1 within the ocular tissue. The increase in CX3CR1 expression could be 
due to a selective recruitment of transferred CX3CR1 expressing cells, specific retention, and 
survival of CX3CR1 expressing CD4+ T cells or stimuli within the eye causing local CX3CR1 
upregulation.  
To investigate if the local environment was sufficient to drive CX3CR1 expression by recruited  
CD4+ T cells, experiments were performed using pathogenic antigen specific cell transfers 
mixed  with an activated non-antigen specific OTII transfer (non-pathogenic cells that do not 
cause uveitis alone as described in chapter 5). Both transferred cell populations were CX3CR1 
heterozygous, so CX3CR1 expression was monitored on both antigen specific and non-antigen 
specific CD4+ T cells recruited to the ocular tissue during active disease using GFP expression. 
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CX3CR1 expression on the antigen-specific population is at a frequency of ~0.2 of the 
pathogenic transfer population at day 7 but increases to >0.4 by day 14. Confirming as 
previously observed that there is a local enrichment of CX3CR1 CD4+ transferred T cells. In 
contrast, the non-antigen specific transferred cell population had minimal CX3CR1 expression 
on CD4+ T cells at both time points. These findings demonstrate that the local environment 
alone is not sufficient to stimulate CX3CR1 on CD4+ T cells during the disease course. 
To determine if expression of CX3CR1 on CD4+ T cells is due to antigen-specific stimulus within 
the tissue, ovalbumin peptide was injected intravitreally into the eye (described in chapter 5) 
TCR transgenic ovalbumin specific leukocytes (OTII) were then transferred intraperitoneally.  
As shown in chapter 5 figure 5.2 activated OTII cells do not localise to the retina following 
transfer in the absence of uveitis, however, when the antigen is present within ocular tissue, 
recruitment of the ovalbumin-specific T cells is observed to the eye that received the 
ovalbumin peptide compared with the eye that received PBS or L144 (data presented in 
chapter 5, figures 5.6-5.10). CX3CR1 expression was then quantified on the endogenous and 
transferred recruited CD4+ T cells using GFP expression. There is a significant difference 
between the two eyes both in terms of recruitment of endogenous and transferred cells and 
also in CX3CR1 expression on CD4+ T cells between the endogenous and transferred 
population. A significant increase in CD4+ T cell recruitment is observed in the eye that 
received the OVA intravitreal injection throughout disease course and an increase in CX3CR1 
expression is also observed, whereas in the contralateral eye where no disease progression is 
observed and no OVA antigen is present CX3CR1 expression is minimal within the CD4+ T cells 
that are present. The data produced further supported the hypothesis that an antigen-specific 
stimulus is involved in the expression of CX3CR1 on CD4+ T cells.  
In conclusion, as expected from previous studies, CX3CR1 expression is not necessary either 
for CD4+ uveitogenic cells to cause uveitis or to provide an ocular environment in which it can 
develop. Partial or complete CX3CR1 deficiency in donor T cells delays disease initiation in 
comparison to WT cells but does not then affect disease course. While deficiency of CX3CR1 
in the recipient animals supports greater persistence of the WT cell population in the 
heterozygous background (figure 6.8). This is consistent with the findings Dagkalis et al (47) 
that the knockout background had more severe disease. However, before cells are transferred 
the culture supernatant of the CX3CR1 heterozygous and CX3CR1 deficient mice show similar 
levels of IFN-γ production whereas the wildtype supernatant shows an increase in IFN-γ 
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production and therefore a more Th1 phenotype is present within the cell culture (figure 3.7). 
Due to the transferred CD4+ population being the sole surviving population this data 
suggested a role for CX3CR1 on CD4+ T cells.  
To investigate the mechanism of CX3CR1 expression within the uveitogenic antigen specific 
transferred population. The double transfer of antigen specific and non-antigen specific cells 
suggested an antigen specific mechanism and TCR engagement is involved in CX3CR1 
expression on CD4+ T cells. This was further confirmed by the transfer of non RBP specific TCR 
transgenic OTII leukocytes concurrently with an intravitreal injection of ovalbumin peptide 
illustrating CX3CR1 expression on transferred CD4+ T cells recruited to the ovalbumin injected 
eye. This data demonstrates that bystander activation in the target tissue is not sufficient to 
induce CX3CR1 expression on CD4+ T cells, but instead it requires an antigen specific signal. 
However, before transfer antigen specific in vitro activation leads to only very  limited CX3CR1 
expression (less than 5%), it is only when the cells come back into contact with the same 
antigen during active clinical disease that CX3CR1 expression is seen at higher frequencies on 
CD4+ T cells. Together this data illustrates the maintenance of CX3CR1 expressing CD4+ T cells 


























Chapter 7. The effect of IL-27Rα on 





















Cytokines are involved in most biological processes including disease pathogenesis, non-
specific response to infection, specific responses to antigen, embryonic development, 
changes in cognitive function and the degenerative process of ageing (249). Cytokines can be 
divided into functional classes such as lymphocyte growth factors, pro-inflammatory 
cytokines, anti-inflammatory cytokines or cytokines involved in polarising the response to a 
specific antigen (249).  
Polymorphisms in cytokines and cytokine receptors are associated with susceptibility to 
disease in many autoimmune conditions (249). After autoimmunity is initiated, it results in a 
persistent inflammatory response against self-tissue with the release of inflammatory 
mediators such as cytokines, the production of autoantibodies, the formation of immune 
complexes and the extravasation and activation of cytotoxic T cells, natural killer cells, 
macrophages and polymorphonuclear leukocytes (250).  
 
7.1.1 Cytokines in Experimental Autoimmune Uveitis 
T cell cytokines in uveitis 
Th1 cells can be defined by their expression of the transcription factor T-bet and secretion of 
IFN-γ (251). IL-12 produced by dendritic cells and macrophages, plays a key role in inducing 
Th1 cells, the roles of IL-12 and IFN-γ (the main signature cytokine of the Th1 lineage) have 
been intensively studied in models of EAU (252).  
Th2 cells are defined by the transcription factor GATA binding protein 3 and secretion of IL-4, 
IL-13 and IL-5 and are responsible for developing the humoral response, the timing and 
cellular source of Th2 cytokines can determine whether Th2 cells play a pathogenic or 
protective role in the progression of uveitis (251, 252).  
Tregs are important for peripheral tolerance and the control of autoimmune disease and are 
identifiable by forkhead box P3 (FoxP3) transcription factor expression and production of 







Th17 cells and IL-17 in uveitis 
IL-17 is part of the IL-17 family of cytokines, including IL-17 (IL17A), IL-17B, IL-17C, IL-17D, IL-
25 and IL-17F. In uveitis Th17 cells produce IL-17A and IL-17F and have an important role for 
driving inflammation. Pathogenic Th17 cells are capable of inducing uveitis alone and 
treatment with anti-IL-17 antibody can block development of EAU (251, 253). 
IL-23 and its roles in uveitis 
The IL-12 superfamily of cytokines consists of ; IL-12, IL-23, IL-27 and IL-35 (251). IL-23 is made 
up of the unique subunit p19 (only found in IL-23) and the shared subunit p40 (also comprising 
IL-12). Due to IL-23 comprising of two subunits it is known as a heterodimeric protein (251, 
254). In the maturation and development of a population of pathogenic Th17 cells IL-23 is a 
very important checkpoint, if IL-23 is not present the population will not be pathogenic when 
developed (251, 254). Lack of the IL-12p40 or IL-23p19 subunits in mice has shown protection 
against the development of EAU (255). Increased serum levels of IL-23 in humans has been 
linked to increased risk of uveitic disease (251). 
IL-6 and its roles in uveitis 
IL-6 is an established innate cytokine and a principal mediator of autoinflammatory disease 
which includes uveitis. IL-6 family cytokines include cardiotrophin-1 (CT-1), ciliary 
neurotrophic factor (CNTF), leukaemia inhibitory factor (LIF), oncostatin M (OSM), 
osteopontin (OPN), IL-11 and IL-31 (251, 256).  
In EAU, IL-6 deficient animals have a significantly attenuated disease phenotype and 
treatment with intravitreal anti- IL-6 reduces inflammation (251, 256). Elevated IL-6 levels in 
humans have been detected in the aqueous humor, similarly to the mouse model intravitreal 
anti-IL-6 is capable of reducing inflammation (251).  
 
7.1.2 Interleukin 6 and Interleukin 12 family of cytokines  
Interleukin 6 (IL-6) 
Type-I cytokines include IL-6 and IL-12 families that are both made up of proteins related 
structurally due to the presence of four-helix proteins. Members of the IL-6 family of 
cytokines are secreted in the form of single-subunit monomers (257). The dimeric IL-12 family 
α subunits, including p19, p28 and p35 pair with potential β subunits for example p40 and 
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EBI3. The α subunits are structurally homologous to IL-6 cytokines while the β subunits can 
be compared structurally to membrane-bound receptors of IL-6 cytokines (257).  
The IL-6 cytokine family comprises of a number of cytokines including IL-6 and IL-11, these 
cytokines have been implicated to play important roles in autoimmunity, cancer, chronic 
inflammation and infectious diseases (258). The defining characteristic of this family of 
cytokines is many of the cytokines share the common cytokine receptor subunits. Further to 
this, phylogenetic analysis suggests a close relationship between the IL-6 and IL-12 cytokine 
families  (257, 258).  
Interleukin 12 (IL-12)  
IL-12 was first purified in 1989, it was discovered to have the unique molecular structure of a 
covalently linked heterodimer composed of p40 and p35 (259, 260).  The sequence of p35 is 
homologous to that of IL-6 and G-CSF  comprised of a four-α- helix structure that is typically 
seen in cytokines (260). The sequence of the p40 chain is structurally similar to the IL-6 
receptor-α chain and ciliary neurotrophic factor receptor which are both members of the 
hemopoietin family. The similarities found in these chains are present in the extracellular 
portion of specific members of the hemopoietin family (260). The extracellular portion of the 
receptor α chain of the IL-6 family is capable of being secreted as a soluble molecule to form 
complexes with cytokines, these complexes can bind to transmembrane chains of the 
receptor complex to induce signal transduction. The membrane receptor complex of IL-12 is 
composed of two chains IL-12Rβ1 and Il-12Rβ2 that are both homologous to gp130, IL12Rβ1 
binds to IL-12p40 and is associated with Tyk2, whereas IL-12Rβ2 recognises the heterodimer 
or the p35 chain and is associated with Jak2 (260). The production of IL-12 is mostly found by 
activated innate cells such as neutrophils and dendritic cells and adaptive immune cells 
including macrophages and monocytes. The production of IL-12 by these activated cell types 
is capable of inducing IFN- γ  production in populations of T cells including Th1 cells and NK 
cells (260). Most biological responses to IL-12 are mediated by STAT4 but signalling through 
the IL-12 receptor complex also includes a number of STAT transcription factors such as: 
STAT1, STAT3 and STAT5 inducing nuclear translocation, phosphorylation and dimerisation in 
these transcription factors (260).  
IL-12 was originally thought to be the only heterodimeric cytokine, however IL-23, IL-27 and 
IL-35 have been determined to have a similar structure to form part of the family of 
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heterodimeric cytokines (260). IL-23 and IL-27 affect the production of IFN-γ by T and NK cells, 
and in the case of IL-23 share part of the IL-12 receptor complex (figure 7.1) 
 
Figure 7.1: IL-12 family of cytokines and their receptors. Architecture of the IL-12 family of 
cytokines and their receptors. Figure adapted from Vignali et al (2012) (261). 
 
7.1.4 Role of interleukin 27 (IL-27) and Interleukin 27 Receptor (IL-27R) in vivo 
IL-27 is a heterodimeric cytokine made up of EBI3 and IL-27p28. Receptors of class I cytokines 
are made up of α and β heterodimers. The α subunit being a primary cytokine in the case of 
IL-27 receptor (IL-27R) this is the IL-27Rα (also known as WSX-1 or TCCR) and a β subunit that 
is used for high affinity binding and signal transduction which in the case of IL27R is gp130 
(39).  
WSX-1 consists of 2 tyrosine residues that can be phosphorylated in humans whereas in mice 
there are 3 tyrosine residues including one residue that is conserved (39). WSX-1 contains a 
Trp-Gly-Glu-Trp-Ser (WGEWS) fitting with other proteins from the same family (WSXWS 
motif) (262). IL-27Rα is expressed highly in spleen, thymus, and lymph nodes, specifically in 
the CD4+ T cell compartment.  
The IL-6 receptor family of cytokines shares the gp130 subunit with several other receptor 
partners (39), IL-27Rα is capable of forming homodimers that are capable of activating the 
JAK-STAT pathway that is associated with myeloid cell transformation but gp130 is considered 
to be the main partner of the IL-27Rα (40, 263). In memory B cells IL-27 mainly signals through 
STAT1 in humans whereas activated T cells signal mainly through STAT3 (39, 264).  
Upon activation of CD4+ T cells increased surface expression of Il-27Rα has been observed 
this is significantly different to naïve T cells where minimal expression is present (40).  
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Studies have illustrated both naïve and activated CD8+ T cells are responsive to IL-27, however 
downregulation of gp130 expression render memory CD8+ T cells non-responsive to IL-27 and 
therefore do not produce an IL-10 response(265). A study by Perona-Wright et al (265), 
showed mice lacking in IL-10 down regulated the cytokine receptor gp130 due to the 
persistent loss of IL-27 responsiveness in memory CD8+ T cells. Impaired IL-27 responsiveness 
on human memory CD8+ T cells has shown the same effects as the mouse models (265). 
In order to study the effect of IL-27Rα in vivo, IL-27Rα knockout mice were generated.  
A study by Wang et al (266) have shown when administered in recombinant heterodimer form 
to mice with EAU it was able to inhibit cellular infiltrate including Th1 and Th17 responses and 
stimulated an expansion in the Treg population to decrease disease (40, 266). Dominant 
cellular sources of IL-27 include myeloid cell populations such as; macrophages, inflammatory 
monocytes, microglia and dendritic cells but it has also been observed to be expressed by 
plasma cells, endothelial cells and epithelial cells (40). Specifically, within the eye, IL-27 is 
produced by the microglia, retinal ganglion cells and throughout the neuroretina especially 
during peak EAU (267).  
 In a study by Chihara et al (268), the co-inhibitory receptor protein C receptor and podoplanin 
were functionally validated and are co-expressed in both CD4+ and CD8+ T cells, that forms 
part of a larger programme that is driven by IL-27 of a co-inhibitory nature shared by non-
responsive T cells in many physiological contexts(268), illustrating the role of IL-27 as an 
immunoregulatory cytokine.  
The immunoregulatory properties of IL-27 centre around the idea of its ability to induce T 
cells to perform functions necessary for suppressing ongoing inflammation (40). Il-27 
promotes Th1-type immune responses while inhibiting Th17 responses, inducing Il-10 
expression and the promotion of a Treg specific population specialised to limit the Th1 
response. Further to this IL-27 is also capable of limiting IL-2 production while increasing IFN-
γ production during an immune response (40). 
 
7.1.5 IL-27Rα-/-/ WSX-1-/- mice 
IL27Rα-/- mice were generated in 2001 by Yoshida et al. (262). The mice were produced by 
homologous recombination and have been used in studies to define the role of IL-27Rα-/- in 
vivo (262).  
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Development of hematopoietic and lymphoid systems in the mice appeared normal but 
isolated T cells from the knockout animals produced reduced levels of IFN-γ when treated in 
vitro with IL-12 and concanavalin A (ConA) or anti-CD3 antibody (262). When fully 
differentiated, if cells from IL-27Rα-/- are subjected to a secondary stimulation they produce 
similar levels of IFN-γ to wild type mice (262). 
Studies in arthritis using this mouse model in the experimental model adjuvant induced 
arthritis (AIA) have illustrated that IL-27Rα-/- mice displayed a more severe inflammatory 
arthritis indicated by increased leukocyte infiltration, synovial exudate, hypertrophy and 
hallmarks of cartilage and bone erosion (269).  
Along with a more severe inflammatory arthritis, IL27Rα-/- mice with AIA showed heightened 
synovial T cell infiltration and the presence of discrete CD3+ aggregates (ectopic lymphoid 
structures (ELS)) within the synovium (269). In this study by Jones et al (269), at day 3 after 
AIA induction a small portion of the IL-27Rα-/- mice presented with small CD3+ aggregates but 
by day 10 all IL-27Rα-/- mice had developed multiple CD3+ aggregates throughout the 
synovium, in contrast wildtype mice developed fewer lymphoid aggregates and a less severe 
infiltrate in the synovium (269).  
These studies have suggested a role for IL-27 in regulating autoimmune disease, further 
studies in the EAE model using the IL-27Rα-/- mouse gave severe neuroinflammation and a 
more severe Th17 response (270). Further studies support this hypothesis when autoimmune 
disease is treated with IL-27, limited immunopathology associated with a Th17 response is 
present. This occurs in models of uveitis including EAU, collagen induced arthritis (CIA),EAE 
and colitis (270). 
IL-27Rα-/- mice are a useful tool to study interactions and properties of IL-27 receptor in vivo, 
and the role of IL-27 in disease processes in autoimmune models such as models of arthritis 
(AIA) and uveitis (EAU). 
 
7.1.6 Anti-inflammatory properties of IL-27 
A role for IL-27 in the promotion of Th1-type immunity has been suggested in early studies of 
the cytokine but further studies have instead highlighted a function for IL-27 in limiting 
immune hyperactivity (40). One report that illustrated this was using IL27Rα-/- mice that were 
infected by Toxoplasma gondii. Parasite replication was efficiently controlled but was not 
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capable of downregulating the response of CD8+ and CD4+ T cells induced by infection and 
instead the mice developed increased levels of IFN-γ and a lethal CD4+ T cell mediated 
immune pathology (40, 271). Similarly, in a model of Trypanosoma cruzi infection IL27Rα-/- 
mice had exacerbated IFN-γ production and lethal inflammatory disease (40, 272).   
 
7.1.7 Pro-inflammatory properties of IL-27 
IL-27 is considered a growth and survival factor for T cells that has a positive affect on many 
aspects of T cell function (40, 273). Upregulation of expression of lymphocyte function-
associate antigen-1, ICAM-1 and sphingosine-1-phosphate has been linked to IL-27 but 
inhibition of CCR5 expression has also been observed, this illustrates a need for further study 
of IL-27 on trafficking and behaviour of lymphocyte populations (40).  
Using IL-27Rα-/- mice this chapter aims to compare disease course assessed using OCT and 
total retinal infiltrate in groups of animals that have received either wildtype pathogenic cell 
transfer or IL-27Rα-/- pathogenic cell transfer. The fate of transferred IL27Rα-/- and wildtype 
cells will be analysed using allelic markers. The adoptive transfer model was used as a way of 
specifically studying the effect of the knockout phenotype on T cells in an environment where 

















7.2 Materials and Methods 
 
7.2.1 Adoptive transfer technique 
EAU was induced in C57BL/6 or IL-27Rα-/- CD45.2 donors using RBP3 peptide,  donor cells 
were then transferred using i.p injection into C57BL/6 CD45.1 recipients at variable cell 
concentrations to determine the optimum number of cells needed to induce a disease. 
 
7.2.2 Flow cytometry analysis 
Flow cytometry was used to identify subsets of cells within the endogenous and transferred 
cell population present in the retinal infiltrate using extracellular and intracellular staining. 
Within transferred recipients, allelic markers CD45.1 and CD45.2 were used to identify 
endogenous and transferred populations of cells within the retina. 
 
7.2.3 Clinical imaging 
OCT scans and fundus images standardised across recipients during transfer optimisation 
were taken weekly for both groups to study disease course. 
 
7.2.4 Immunohistochemistry  
Eyes were frozen in OCT and kept at -80°C before being sectioned at ~20 microns. Sections 
were then stained for CD3, CD4 and CD8 or CD3, CD4 and CD19 to identify leukocyte infiltrate. 
 
7.2.5 Fluorescence Microscopy 
Whole retina mounts were isolated and fixed for analysis by light sheet fluorescence 










7.3.1 Flow cytometric analysis of naïve mice 
As previously discussed in chapter 4 naïve baseline quantification of leukocytes in 
unmanipulated mice is a useful tool in understanding leukocyte presence in the eye before 
induction of EAU. 
IL27Rα-/- mice do not display major defects in mounting a Th1 response, but in a limited 
number of scenarios the Th1 response is delayed in these animals (274). These mice have 
exacerbated inflammation in response to a wide variety of immune challenges, including 
pathogens that cause a Th1 and Th2 response in models of inflammation that rely on Th2 and 
Th17 activity (274). Several mechanisms have been suggested to be linked to the role of IL-27 
in immunomodulatory activities including; IL-27 is known to antagonise Th17 development 
(275), induce IL-10 production (276) and suppress IL-6-induced T cell proliferation under 
inflammatory conditions (275).  
To determine at baseline if there are any changes within leukocyte recruitment to the eyes of 
IL27Rα-/- mice, leukocyte infiltration was quantified in naïve IL27Rα-/- mice. This data was then 
compared to the C57BL/6 naïve leukocyte data previously presented in chapter 4 figure 4.1. 
The CD4+ T cells present within the naïve eyes of both the C57BL/6 and Il27Rα-/- mice are 
similar in number (figure 7.2a). However, there is a statistically significant increase in CD8+ T 
cell number and CD11b+ cell number present within the eye in the Il27Rα-/- mice in a naïve 
state in comparison to the naïve C57BL/6 group (figure 7.2b and 7.2c). No effect is seen 
between the two groups when looking at Ly6G+ cell number and Ly6C+ cell number (figure 

















Figure 7.2: Quantified leukocyte cell number in naïve eyes of unmanipulated C57BL/6 or 
C57BL/6 IL-27Rα-/- mice. Using a standard curve acquired by flow cytometry leukocytes present 
within the eyes of naïve mice were quantified. CD4+ T cell number within the two groups is 
comparable (A). A statistically significant difference is observed between the two groups in the CD8+ 
and CD11b+ cell compartment (B+C). The final leukocyte populations quantified, Ly6C+ and Ly6G+ cell 
number in the two groups are also similar (D+E). Numbers expressed as Mean +SEM. Unpaired non-













IL-27RΑ-/- LOWER LIMIT UPPER LIMIT MEAN 
CD4 3 102 41 
CD8 22 204 106 
CD11B 598 3028 1786 
LY6G 4 35 12 
LY6C 9 103 55 
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7.3.2 Analysis of adoptive transfer donor C57BL/6 eyes vs C57BL/6 IL-27Rα-/- 
eyes at day 11 after active immunisation. 
In order to perform the adoptive transfer of uveitogenic leukocytes into naïve recipients, 
donors are immunised using RBP3 peptide emulsified in CFA administered subcutaneously 
with a concurrent intraperitoneal injection of pertussis toxin. After 11 days, spleen and lymph 
nodes were isolated for cell culture to produce leukocytes for adoptive transfer. 
To quantify disease severity of the donors at cell harvest, donor eyes were analysed across a 
number of experiments to quantify total leukocyte populations present within the eye at day 
11 after immunisation and intracellular cytokine staining in the two groups immunised 
(C57BL/6 mice and the C57BL/6 IL-27Rα-/- mice).  
Eyes from donor mice 11 days after immunisation were analysed by extracellular staining to 
isolate the CD4+ T cell population then further analysed based on cytokine secretion within 
the isolated CD4+ T cell population (figure 7.3). Overall in the Il-27Rα-/- immunised donors 
have an increase in cytokine production in comparison to the C57BL/6 immunised donors and 
a statistically significant increase in IFN-γ secretion within the Il-27Rα-/- is also observed (figure 
7.3). The increase in IFN-γ production is accompanied by an increased percentage of IFN-γ in 
the eyes of the donors (presented underneath) an increased overall percentage of IL-17 
production is also observed in the IL-27Rα-/- donor mice. 
CD4+, CD8+ and CD11b+ cells were quantified to determine disease stage in both groups of 
immunised animals (figure 7.4). Overall, there is a statistically significant increase in the 
number of leukocytes present within the eyes of the IL-27Rα-/- in comparison to the C57BL/6 
control group. Specifically, a statistically significant increase in CD4+, CD8+ and CD11b+ cell 
number is observed in the IL-27Rα-/- mice in comparison to wildtype, suggesting a more severe 
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Figure 7.3: Intracellular staining of CD4+ T cells to detect cytokines expressed at day 11 after 
immunisation. Extracellular staining was performed on retinal and vitreous infiltrate, gating through 
CD4+ cells to analyse cytokine production in this compartment. IFN-γ, IL-17 and double positive 
expression was analysed in both sets of eyes from the donor groups. Numbers expressed as Mean 















C57BL/6 LOWER LIMIT UPPER LIMIT MEAN 
CD4 219 9096 2542 
CD8 79 910 327 
CD11B 1586 47396 13821 
 
IL-27RΑ-/- LOWER LIMIT UPPER LIMIT MEAN 
CD4 7434 62711 21655 
CD8 703 6955 2321 
CD11B 41414 242324 91789 
 
Figure 7.4: Quantified leukocyte numbers present within the eyes of the donor mice at day 
11. At day 11, 8-10 eyes were analysed from both donor groups and leukocytes quantified. CD4+ T 
cell number was quantified and compared across the two donor groups (A). CD8+ T cell number was 
quantified and compared across the two donor groups (B). CD11b+ cell number quantified and 
compared across the two donor groups (C). Numbers expressed as Mean +SEM. Unpaired non-














7.3.3 Clinical disease onset in IL-27Rα-/- mice  
Because the clinical disease within the immunised IL-27Rα-/- adoptive transfer donors was 
more severe when analysed by leukocyte quantification in comparison to the control C57BL/6 
donor this suggested that disease induction in the IL-27Rα-/- mice has an earlier onset when 
compared to other C57BL/6 mice. This contrasts with EAE studies which reported that the 
induction of disease in IL-27Rα-/- mice is not accelerated. 
To characterise the initiation of clinical disease in IL-27Rα-/- mice, IL-27Rα-/- were immunised 
and analysed by clinical imaging and flow cytometry at day 7 after immunisation.  
A statistically significant increase in leukocyte number is observed by day 7 in the eyes of the 
IL-27Rα-/- mice. When quantified, CD4+ T cell number is significantly increased in the                    
IL-27Rα-/- mice after immunisation in comparison to the baseline obtained from mice of the 
same phenotype (figure 7.5a).  
The same affect is observed within the CD8+ compartment, where a  significant increase is 
observed in comparison to a naïve baseline (figure 7.5b), similarly in CD11b+, Ly6G+ and 
Ly6C+ cell number is also  increased (figure 7.5c, 7.5d and 7.5e).  
The statistically significant increase shows that initiation of clinical disease occurs earlier 
















Figure 7.5: Early onset of EAU in actively immunised IL-27Rα-/- mice. To further analyse onset 
of clinical disease in IL-27Rα-/- mice, active immunisation was performed. 8 eyes were analysed by flow 
cytometry at day 7. Overall leukocyte recruitment appeared to be increased in comparison to baseline 
(day 0). (A-E) Quantified leukocyte cell number at day 0 and at day 7 after active immunisation. 













IL-27RΑ-/- LOWER LIMIT UPPER LIMIT MEAN 
CD4 176 534 400 
CD8 135 745 320 
CD11B 1725 4574 3445 
LY6G 78 581 226 
LY6C 64 611 256 
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7.3.4 Analysis of donor supernatant and donor cells before adoptive transfer  
Due to the early onset of clinical disease in IL-27Rα-/- and statistically significant differences 
between leukocyte recruitment in the donor IL-27Rα-/- mice in comparison to the C57BL/6 
control group, analysis of the leukocyte population used for adoptive transfer was carried out 
using a Legendplex assay. 
At day 11 after active immunisation, spleen and lymph nodes were processed for cell culture 
to prepare for adoptive transfer into naïve recipients. At this time point, eyes were also 
obtained from the donors and analysed by flow cytometry (figure 7.3 and figure 7.4). The 
differences in leukocyte infiltration suggested differences in clinical disease course.  
To determine the cytokine secretion of the whole culture supernatants, supernatant was 
taken at the end of the 72-hour cell culture before transfer. Cytokine secretion was then 
measured using a LegendPlex assay to determine differences between the two cultures. 
Overall, the IL-27Rα-/- culture was determined to be secreting increased levels of cytokines. 
Specifically, a statistically significant increase in IL-1α, IFN-γ, TNF-α, MCP-1, IL-10, IL-6, IL-17A 
and GM-CSF (figure 7.6b, 7,6c, 7.6d, 7.6e, 7.6h, 7.6i, 7.6k, 7.6m) is observed in the IL-27Rα-/- 
cultures suggesting a more potent cell phenotype present within the cell cultures denoted by 
increased cytokine expression per cells and in the fraction of cells present within the culture 
expressing cytokine. Although a statistically significant increase in specific cytokines 
quantified within the IL-27Rα-/- cultures in comparison to the control C57BL/6 cultures, other 
cytokines analysed including: IL-23, IL-12p70, IL-1β, IL-27 and IFN-β (figure 7.6a, 7.6f, 7.6g, 
7.6j and 7.6l) although not statistically significant has a general effect of increased cytokine 
secretion within the IL-27Rα-/- cultures raising the possibility that a more pathogenic type of 
cell is present within the culture. 
Another observation made about the difference in the IL-27Rα-/- cultures in comparison to 
the C57BL/6 culture is the difference in total cell number yield from the cultures. Comparable 
numbers of mice were originally immunised to create the same number of flasks at the same 
cell density at 0 hours of cell culture. After leukocytes were isolated using Ficoll density 
centrifugation at 72 hours of cell culture a large difference in leukocyte number obtained from 
the two cell cultures is observed. The IL-27Rα-/- cultures yield more than double the cell 
number of the C57BL/6 cultures. 
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For cell transfer we used equivalent numbers of CD4+ T cells , so it was important when 
analysing the transferred leukocyte population to determine the percentage of a number of 
leukocyte populations present within the transferred populations including; CD4+ T cells, 
CD8+ T cells, CD11b+ cells and other leukocytes (figure 7.7). Despite the overall increase in 
cell numbers, the transferred CD4+ T cell population isolated from each cell culture is 
comparable in percentage in both C57BL/6 and IL-27Rα-/- leukocyte populations (figure 7.7). 
The same is also seen within the CD8+ and CD11b+ cell compartment (figure 7.7). Thus 
suggesting that although the leukocytes present within the IL-27Rα-/- cultures expand more 
than the C57BL/6 control, the total percentage of CD4+ T cells present within each culture is 




































Figure 7.6: Analysis of supernatant obtained from cultures of C57BL/6 leukocytes or               
IL-27Rα-/- leukocytes. To analyse cytokine secretion within both cultures a sample of supernatant 
was obtained from each culture and analysed using LegendPlex analysis. Overall, increased levels of 
cytokines are observed with the analysed IL-27Rα-/- culture in comparison to the C57BL/6 cultures. (A-
L) Cytokine expression within the supernatant of the C57BL/6 culture in comparison to the IL-27Rα-/-. 
























Figure 7.7: Flow cytometric analysis of transferred leukocyte populations from C57BL/6 
cultures and IL-27Rα-/- cultures. After leukocytes were isolated for adoptive transfer a sample was 
analysed by flow cytometry to determine the percentage of CD4+ T cells, CD8+ T cells and CD11b+ 
cells transferred into the naïve recipients by extracellular staining. Data expressed as Mean 















7.3.5 OCT imaging throughout clinical disease in the C57BL/6 and IL-27Rα-/- 
adoptive transfer recipients  
At day 7 both groups of recipients have peak disease, but differences are observed in the 
severity of the peak disease in each group of recipients that received either the C57BL/6 
leukocyte transfer or the IL-27Rα-/- leukocyte transfer. The disease within the recipients that 
received C57BL/6 cells (figure 7.8c) is severe with obvious retinal and optic disc swelling 
within the OCT image coinciding with the large cell numbers present in the vitreous stopping 
a clear signal within the OCT image. Within the fundal image cellular infiltrate causes a 
reflection of light also causing the image to be blurry. 
However, in the IL-27Rα-/- recipients the disease is so severe that an OCT image cannot be 
obtained due to the severity of the disease present (figure 7.8d). Due to the severity of the 
cellular infiltrate the OCT cannot give a clean image of the optic disc, retina or vitreous 
including the infiltrate. This is supported by the fundus image which due to the severity of the 
cellular infiltrate the image is unclear, and the optic disc or blood vessels are no longer 
obviously present (as seen in figure 7.8a and 7.8b). 
By day 13, disease is resolving and is less severe in comparison to the disease present at day 
7 but is still active and of a severe phenotype. At this time point the OCT images are 
comparable between the two recipient groups (figure 7.8e and 7.8f), although the thickness 
of the retina has reduced in both groups, the optic disc is still swollen and severe vitreal 
infiltrate is present. When looking at the fundus image there is obvious differences between 
the two groups. In the C57BL/6 recipients the vitreal haze is not obscuring the optic disc and 
blood vessels, whereas, within the IL-27Rα-/- transfer recipients the fundus remains full of 
leukocyte infiltrate and the vessels and optic disc are not clear due to the presence of this 
infiltrate within the vitreous. 
At day 28, active disease has mostly resolved within the C57BL/6 recipients (figure 7.8g) with 
minimal cellular infiltrate present within the vitreous in the OCT image, the retina and optic 
disc has thinned and is now thinner than the OCT images taken  at baseline day 0 (figure 7.8a). 
The fundus image is much clearer due to reduced infiltrate present within the vitreous. In the 
IL-27Rα-/- transfer recipients the OCT image shows continued active disease including severe 
infiltrate present within the vitreous. However, the retina appears to have thinned and 
swelling of the optic disc has resolved (figure 7.8h).  
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Based on the resolution of active clinical disease in the C57BL/6 recipients the OCT disease 
course has been split into two stages the early disease highlighted in figure 7.8 and the later 
stages of disease observed in figure 7.9. 
At day 40, the disease remains inactive in the C57BL/6 recipients (figure 7.9a). In the OCT 
image, there is a lack of infiltrate present within the vitreous, the retina remains thin but the 
optic disc has returned to its original thickness observed at baseline. In the fundus image the 
vitreal haze has completely resolved and the retina, blood vessels and optic disc are now seen 
clearly within the image. In the IL-27Rα-/- recipients, the OCT image shows that active disease 
has persisted to this time point, vitreal infiltrate remains present within the eyes of the 
recipients. Although the retina remains thinned, the optic disc appears slightly swollen (figure 
7.9b). The fundus image is still blurry due to the vitreal infiltrate, the retina and vessels are 
visible but not defined and the optic disc remains swollen with infiltrate. 
By day 51, the disease continues to be quiescent and not active within the C57BL/6 recipients, 
a small amount of infiltrate is observed within the OCT image but not enough to suggest any 
active disease (figure 7.9c). The retina remains thinned due to scarring from disease severity 
and has not returned to a baseline state and the optic disc has remained similar to baseline 
state that was observed at previous time points. In the IL-27Rα-/- recipients active disease 
persists to this time point (figure 7.9d). The infiltrate present within the vitreous has further 
persisted to this stage in disease, the retina remains thinned, but the optic disc is swollen due 
to the infiltrate.  
At day 67, eyes were analysed by flow cytometry to quantify leukocyte infiltrate present 
within the eyes of both groups of recipients. Before the eyes were analysed, they were imaged 
using OCT at this time point to deduce disease severity in the two groups before flow 
cytometric analysis.  
The C57BL/6 group continues to be quiescent in the recipients by studying the OCT image 
(figure 7.9e). The number of leukocytes present within the vitreous is minimal, the retina 
remained thinned and the optic disc consistent with the baseline OCT image. The fundus 
image shows some retinal scarring, but the image is clear, and the optic disc and blood vessels 
are clearly present within the image. The IL-27Rα-/- recipients as seen in previous time points 
still has persistent active disease that has shown no signs of resolution throughout the entire 
disease course. There is obvious swelling of the optic disc and infiltrate present within the 
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vitreous (figure 7.9f). In the fundus image, the fundus remains blurry due to the cells present 

















Figure 7.8: OCT time course of early clinical disease in C57BL/6 transfer recipients and           
IL-27Rα-/- transfer recipients. OCT and fundus imaging from baseline through to day 28 to monitor 
early clinical disease in both recipient groups. (A+B) Baseline day 0 imaging illustrates the naïve eyes 
showing no signs of clinical disease in both groups before disease induction by leukocyte transfer. 
(C+D) Day 7 imaging illustrating peak disease in both groups with severe vitreal infiltrate and swelling 
of the retina and optic disc visible in the OCT. (E+F) Day 14 imaging illustrating early disease resolution 
in both groups but still with severe clinical disease present within both groups. (G+H) Day 28 imaging 
of the recipient groups illustrating further resolving in the C57BL/6 transfer group but active disease 
persisting in the IL-27Rα-/- group. 
(A+C+E+G) C57BL/6 transfer recipients 





























Figure 7.9: OCT time course of late clinical disease in C57BL/6 transfer recipients and               
IL-27Rα-/- transfer recipients. OCT and fundus imaging from day 40 through to day 67 to monitor 
late clinical disease in both recipient groups. (A+B) Day 40 imaging of both groups to illustrate disease 
severity and persistence in each group at this time point. (C+D) Day 51 imaging of both groups of 
recipients to compare disease severity and persistence within the two groups of recipients. (E+F) Day 
67 imaging was obtained before eyes were analysed by flow cytometry to quantify leukocytes present 
within the eye. The imaging allows a final comparison of disease severity to correlate with leukocyte 
numbers obtained by flow cytometry. 
(A+C+E) C57BL/6 transfer recipients 












7.3.6 Flow cytometric analysis of leukocyte infiltrate at day 67 after adoptive 
transfer of uveitogenic leukocytes into C57BL/6 or IL-27Rα-/- recipients 
Disease course was monitored in the two recipient groups using OCT imaging from baseline 
through to day 67 (figure 7.8 and 7.9). At day 67, disease within the IL-27Rα-/- recipients 
remains active in the OCT image with large levels of vitreal infiltrate (figure 7.9f), whereas in 
the C57BL/6 recipients active disease resolved by day 28 (figure 7.8g) and remained in a 
quiescent state through to day 67 (figure 7.9e). Data from the C57BL/6 recipients previously 
presented in chapter 4. 
One eye from each recipient was isolated and prepared for analysis by flow cytometry and 
the corresponding eye was used for light sheet analysis, flat mount analysis by confocal 
microscope or sectioned for staining by immunofluorescence.  
Retinas and vitreous were isolated from one eye from each recipient in both groups. CD4+, 
CD8+, CD11b+, Ly6G+ and Ly6C+ cells were quantified in the endogenous and transferred 
compartment of each eye using allelic markers.  
Figure 7.10a illustrates endogenous and transferred CD4+ T cells present within recipients’ 
eyes at day 67. In recipients that received the C57BL/6 transfer, a small population of 
transferred CD4+ T cells persists within the eye to day 67 which corresponds with a small 
increase in the endogenous population. In the IL-27Rα-/- recipient group a large group of 
transferred CD4+ T cells have persisted through to day 67 driving disease to continue; this is 
accompanied by a large endogenous CD4+ T cell population within the ocular tissue at day 67. 
The large CD4+ T cell number present within the IL-27Rα-/- recipients supports the observation 
made by the OCT images taken at day 67.  
There is a statistically significant difference between the endogenous populations of CD4+ T 
cells within the recipients of each group which coincides with a statistically significant 
difference between the transferred populations present within the eyes of recipients at day 
67 due to differences in disease state. 
Figure 7.10b shows the endogenous and transferred CD8+ T cell number at day 67 in both 
groups of recipients. Transferred CD8+ T cells in both groups do not survive within the eye, 
this was previously observed in chapter 4 from day 14. Due to the transferred cells not 
persisting within the eye there is a statistically significant difference between the endogenous 
and transferred populations. But no statistically significant difference is observed between 
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the endogenous populations of the two groups. This observation suggests that differences in 
disease are driven by the CD4+ compartment by both the endogenous and transferred 
population and other endogenous leukocyte compartments such as macrophages and 
neutrophils. 
Figure 7.10c shows the endogenous and transfer CD11b+ populations present within the eye 
of the two groups of recipients at day 67. Similarly, to the transferred CD8+ T cell population 
the CD11b+ does not persist within the eye in both groups of recipients so there is a large 
statistically significant difference between the endogenous and transferred populations in 
both groups. There is also a small statistically significant increase in the CD11b+ cell number 
present within the eyes of the IL-27Rα-/- recipients in comparison to the C57BL/6 recipients.  
Figure 7.11a represents the Ly6G+ cell number present within the eyes of the recipients in 
both groups at day 67. In both groups the transferred leukocyte population is not present 
within the ocular tissue at day 67, this causes a large statistically significant difference 
between the endogenous and transferred populations in each group of recipients. In the 
C57BL/6 recipients a small population of Ly6G+ cells are observed within the eye, whereas 
within the IL-27Rα-/- a statistically significant increase in the Ly6G+ population is present 
within the eyes of recipients at day 67.  
Ly6C+ and Ly6C- numbers are expressed in figure 7.11b and 7.11c. As observed previously the 
transferred population does not survive within the eye, therefore a statistically significant 
difference between the endogenous and transferred populations is present in both recipient 
groups. There is also a statistically significant increase in the Ly6C+ cell number between the 
two groups, specifically an increase is present within the IL-27Rα-/- recipients in comparison 
to the C57BL/6 recipients. The same effect is also seen within the Ly6C- population present 
within the eyes of the recipients. The IL-27Rα-/- recipients have an increased Ly6C- population 
present within the eye in comparison to the C57BL/6 recipients. 
Overall the IL-27Rα-/- recipients have increased endogenous leukocyte recruitment in 
comparison to the C57BL/6 control group. Transferred CD4+ T cells persist in high numbers 
to drive active disease in the IL-27Rα-/- recipients due to the transferred population not being 
shut down, whereas the transferred CD4+ T cells in the C57BL/6 recipients persist in low 
numbers that do not drive an active disease phenotype which suggests the cells are more 
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Figure 7.10: Leukocytes present within eyes of recipients processed at day 67 after adoptive 
transfer of C57BL/6 cells or IL-27Rα-/- cells. Leukocytes were quantified from retinas and vitreous 
in one eye of each recipient at day 67 after adoptive transfer of C57BL/6 or IL-27Rα-/-leukocytes into 
naïve C57BL/6 recipients. (A) Quantification of CD4+ T cell infiltrate present in eyes of recipients at 
day 67, using allelic markers endogenous and transferred population can be deduced. (B) 
Quantification of CD8+ T cell infiltrate present in eyes of recipients at day 67. Endogenous and 
transferred populations are quantified in each recipient within each group. (C) CD11b+ cell 
quantification at day 67 after adoptive transfer. Endogenous and transferred populations are 
quantified in each recipient within each group. Numbers expressed as Mean +SEM. One-Way ANOVA 
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Figure 7.11: Leukocytes present within eyes of recipients processed at day 67 after adoptive 
transfer of C57BL/6 cells or IL-27Rα-/- cells. Leukocytes were quantified from retinas and vitreous 
from one eye from each recipient at day 67 after adoptive transfer of C57BL/6 or IL-27Rα-/-leukocytes 
into naïve C57BL/6 recipients. (A) Quantification of Ly6G+ cell number present within the eyes of 
recipients at day 67 after disease induction by adoptive transfer. Endogenous and transferred 
populations were quantified individually in each eye. (B) Quantification of Ly6C+ cell number present 
within the eyes of recipients at day 67 after disease induction by adoptive transfer. Endogenous and 
transferred populations were quantified individually in each eye. (C) Quantification of Ly6C- cell 
number present within the eyes of recipients ta day 67 after disease induction by adoptive transfer. 
Endogenous and transferred populations were quantified individually in each eye. Numbers expressed 









7.3.7 Lightsheet, Confocal and EVOS imaging of immunofluorescence staining 
of whole eyes or retinas from C57BL/6 or IL-27Rα-/- recipients 
At day 67, recipient’s eyes were analysed by OCT to determine disease severity. One eye from 
each recipient was then analysed by flow cytometry to quantify differences in cellular 
infiltrate between the two groups.  
Imaging techniques were used to analyse the differences between groups using the remaining 
eye from each recipient. Firstly, one eye from each recipient group was used for analysis by 
Lightsheet fluorescence microscopy (Zeiss Z.1 Lightsheet microscope). 
Lightsheet fluorescence microscopy (LSFM) uses a thin plane of light to optically section 
transparent tissue of whole organisms that have been labelled by a fluorophore (277). An       
IL-27Rα-/- recipient was imaged using lightsheet microscopy, as seen in figure 7.12 the retina 
holds its shape whilst being imaged using the lightsheet and the leukocytes present within 
the retina are visible due to the fluorophore staining. CD4+ T cells (figure 7.12a) are present 
throughout the retinal tissue indicating active clinical disease as previously described in OCT 
and flow cytometry data presented in figures 7.8, 7.9, 7.10 and 7.11. CD8+ T cells are 
dispersed throughout the retina in high numbers (figure 7.12b) as previously highlighted by 
the flow cytometry analysis presented in figure 7.10. The CD3e stain indicates high levels of T 
cell infiltrate present in the retina (figure 7.12c). Figure 7.14d merges the stains together to 
create a complete image of the retina, unfortunately due to the active state of disease the 
vessel stain was not possible to image due to leaking.  
2 eyes from each recipient group were also prepared for flat mount imaging by confocal 
microscopy. Confocal microscopy is capable of providing high-resolution microscopic images 
of cells within tissues under inspection especially using z-axis scans (278). The eyes were 
punctured and placed into fixative for two hours before the anterior was removed and the 
eye placed into fixative overnight. The retina is then removed carefully to keep fully intact. 
The retina was stained with antibodies conjugated to fluorophores to stain for leukocytes 
present within the retina such as CD3e, CD4 and CD8 and a DAPI cellular stain was also used 
to orientate the eye when imaging. The retina is the petallated and mounted onto a slide for 
imaging. 
Figure 7.13 are images taken using a confocal microscope of a retina taken from a C57BL/6 
leukocyte transfer recipient. CD4+ T cells are detected in low numbers within the retina of 
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the C57BL/6 recipient (figure 7.13), this supports the OCT imaging data and the flow 
cytometry data previously presented in figure 7.8, 7.10 and 7.11 that no active disease was 
present in the eyes of the C57BL/6 recipients. Increased CD8+ infiltrate in comparison to the 
CD4+ infiltrate is detected within the flat mounted retina by confocal microscopy (figure 7.13) 
which supports the flow cytometry data obtained and presented in figure 7.10. Figure 7.13 
illustrates the CD3e stain to detect all T cells present within the retina. As the greatest number 
of T cells present within the retina are CD8+ T cells this stain is predominantly staining the 
CD8+ T cells.  
Figure 7.14 contains images taken using a confocal microscope of a retina taken from an          
IL-27Rα-/- leukocyte transfer recipient. As previously discussed, the stains for the flat mount 
are also present in figure 7.13. CD4+ T cells (figure 7.14) are present in high numbers in the 
retina of the IL-27Rα-/- recipients, further indicating active disease that was previously 
suggested in previous figures. CD8+ T cell number is detected in figure 7.14, supporting the 
flow cytometry data previously presented in figure 7.10. The CD8+ T cell number present in 
the retinas of both groups are comparable, this is detected by flow cytometry and confocal 
microscopy. Figure 7.14 also illustrates CD3e staining within the retina to detect all T cells 
present within the retina.  
The final imaging technique used for analysis of eyes at day 67 after adoptive transfer with 
C57BL/6 leukocytes or IL-27Rα-/- leukocytes is by cryostat slicing of the eyes to image using 
the EVOS fluorescence microscope. Firstly, eyes are frozen in OCT medium using liquid 
nitrogen and then stored at -80°C until sectioned. Sections were then obtained from the eyes 
using a cryostat to obtain 20micron sections through the eye. The sections were then stained 
using fluorescently conjugated antibodies specific for CD3e and CD4 along with a DAPI stain 
for orientation of the eye when imaging. Sections were then mounted onto slides for imaging. 
Fluorescence microscopy requires that the objects of interest fluoresce (279). The sections 
were then imaged using a fluorescence microscope.  
Representative images are observed in figure 7.15, figure 7.15a is a section from a C57BL/6 
transfer recipient stained with a CD3e stain to detect all T cells present within the section. 
The CD3e+ cells within the section are low in number which was also illustrated in previous 
figures regarding disease severity and leukocyte infiltrate. 
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Figure 7.15b is a section from an IL-27Rα-/- leukocyte transfer recipient stained with a CD3e 
stain to detect all T cells within the section. The large levels of CD3+ T cells present within the 



















Figure 7.12: Images taken using lightsheet fluorescence microscopy to image a whole retina 
of an IL-27Rα-/- leukocyte transfer recipient. Whole retina imaging using lightsheet fluorescence 
microscopy was used to detect leukocytes throughout the retina. (A) CD4+ AF488 stain to indicate 
disease severity based on CD4+ T cell infiltrate. (Green) (B) CD8+ AF594 stain to determine infiltrate 
within the whole retina (Red)  (C) CD3e AF647 stain to illustrate all T cell infiltrate within the retina at 








Figure 7.13: Images taken by confocal microscopy of a flat mount of a retina obtained from 
a C57BL/6 transfer recipient at day 67. Images obtained using confocal microscopy of a whole flat 
mounted retina. DAPI cellular stain used to orientate the retina to image specific sections of the retina. 
The CD3+, CD4+ and CD8+ stain illustrates total T cell infiltrate within the sections observed to 















Figure 7.14: Images taken by confocal microscopy of a flat mount of a retina obtained from 
an IL-27Rα-/- transfer recipient at day 67. Images obtained using confocal microscopy of a whole 
flat mounted retina. DAPI cellular stain used to orientate the retina to image specific sections of the 
retina. The CD3+, CD4+ and CD8+ stain illustrates total T cell infiltrate within the sections observed to 
























Figure 7.15: Images taken from 40micron sections obtained from frozen whole eyes of 
C57BL/6 or IL-27Rα-/- transfer recipients. Sections from whole eyes frozen in OCT medium were 
obtained from eyes of both groups of recipients. (A) CD3e AF647 stain on sections obtained from 
C57BL/6 transfer recipients. Reduced infiltrate is present in comparison to the IL-27Rα-/- recipients 
due to resolution of active disease within the recipient at day 67. (B) CD3e AF647 stain on sections 
obtained from IL-27Rα-/- transfer recipients. Increased infiltrate is present within the eyes due to 















7.3.8 Analysis of leukocyte transfer recipients by OCT and flow cytometry 
through to day 144 after adoptive transfer. 
After analysis of transfer recipients at day 67 and differences in disease activity observed, 
further recipients were then taken through to day 144 to determine differences in disease 
activity by disease monitoring using OCT imaging and final time point analysis by flow 
cytometry leukocyte quantification. 
C57BL/6 and IL-27Rα-/- recipients were monitored to assess clinical disease across the two 
groups using OCT from day 76 to day 143. Figure 7.16a demonstrates that the active clinical  
disease within the C57BL/6 recipients remains resolved at day 76 as described previously in 
figure 7.9 where active disease resolution occurred within this recipient group at day 28 and 
continued to be in a quiescent state through the time course to day 67. Whereas at day 76 in 
the IL-27Rα-/- recipients (figure 7.16b) some signs of active disease are still present, obvious 
vitreal infiltrate and cells are present around the optic disc. At day 84, disease continues to 
be in a quiescent state in the C57BL/6 recipients (figure 7.16c) that is previously seen in figure 
7.16a. No vitreal infiltrate is observed and no swelling of the retina or optic disc. At day 84 in 
the IL-27Rα-/- recipients (figure 7.16d) obvious vitreal infiltrate is present suggesting active 
disease is persisting. There are obvious cells around the optic disc and retinal folds present 
within the OCT. The fundus image is slightly hazy due to cellular infiltrate. 
At day 123, the disease continues to be in a quiescent state in the C57BL/6 transfer recipients 
(figure 7.16e), in the OCT image no cellular infiltrate is present and there is no obvious 
swelling of the retina or infiltrate present around the optic disc. The fundus image is clear due 
to lack of infiltrate. In comparison, the IL-27Rα-/- recipient mice still show some signs of clinical 
disease in the OCT image such as swelling or fluid accumulation within the retina and vitreal 
infiltrate present. The fundus image remains slightly hazy due to vitreal infiltrate. 
Day 143 is the final OCT time point for both groups of recipients, the C57BL/6 recipients 
remains in a quiescent state (figure 7.16g). The fundus image remains clear due to the lack of 
active disease present in the recipients. As seen throughout the time course, active disease 
persists within the IL-27Rα-/- transfer recipients (figure 7.18h), in the OCT image cellular 
infiltrate remains present within the vitreous and cells are surrounding the optic disc. The 
corresponding fundus image remains hazy due to persistent active disease.  
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At day 144, eyes were dissected to isolate the retina and vitreous to quantify specific 
leukocyte infiltrate within the recipient’s eyes. Total CD4+ T cells were quantified from each 
of the recipient’s eyes (figure 7.19a) and compared to naïve baseline CD4+ T cell number. The 
total number of CD4+ T cells recovered from eyes of C57BL/6 animals at D144 was within the 
normal range established in naïve eyes (3->68) of which transferred cells comprised 25-30% 
in the C57BL/6 recipient transfer suggesting the CD4+ T cell number had returned to naïve 
baseline limits. The transferred population persisted within the C57BL/6 recipients in small 
numbers, a mean of 10 transferred cells per eye (data shown as total CD4+ T cell population).  
In contrast, the IL-27Rα-/- transfer recipients (figure 7.18a) have an increase in total CD4+ T 
cells present within the eyes of the recipients at day 144 in comparison to naïve baseline. 
Active disease was clear in 2/5 animals and CD4+ cells were above normal levels in a further 
2/5 of the recipients with one animal appearing as if infiltrative disease had resolved. 
Transferred cells were present in the majority of eyes. 
The same pattern is also seen in the CD8+ T cell compartment, no significant change is seen 
within the C57BL/6 recipients in comparison to the naïve baseline number (figure 7.19b). But 
as seen in the CD4+ compartment, an increase is observed between the naïve baseline and 
the total CD8+ T cell population present within the IL-27Rα-/- recipients. As previously 
discussed, transferred CD8+ T cells do not persist in either transfer model. 
In the CD11b+ cell compartment, total cell numbers are comparable between the two 
recipient groups. Transferred CD11b+ cells do not survive throughout disease course as 
mentioned in previous figures. 
Overall, transferred IL-27Rα-/- CD4+ T cells cause a more severe clinical disease phenotype and 
drive a more persistent active disease in comparison to the C57BL/6 transfer. Increased 
endogenous leukocyte recruitment is also seen in the IL-27Rα-/- recipients including 
















Figure 7.16: OCT imaging between day 76 to day 143 to monitor disease course between 
the two recipient groups. Disease course was monitored using OCT imaging across the two recipient 
groups that received a C57BL/6 leukocyte transfer or IL-27Rα-/- leukocyte transfer. (A-H) OCT and 








































Figure 7.17: Average clinical scores of recipients over full disease course. OCT imaging was 
used to acquire fundal images of wildtype and IL-27Rα-/- recipients throughout disease course. The 
images were then scored blind using the criteria described in chapter 2 and the average score taken 
from each eye at each time point. Data expressed as Mean +SEM. Area under the curve calculated and 












C57BL/6 LOWER LIMIT UPPER LIMIT MEAN 
CD4 37 59 48 
CD8 43 60 50 
CD11B 2227 3381 2852 
    
IL-27RΑ-/- LOWER LIMIT UPPER LIMIT MEAN 
CD4 10 872 270 
CD8 26 437 182 
CD11B 1761 6068 3607 
 
 
Figure 7.18: Quantification of leukocytes present within the vitreous and retina in transfer 
recipients at day 143 after adoptive transfer of C57BL/6 leukocytes or IL-27Rα-/- leukocytes. 
Quantification of leukocytes present in the eyes of recipients at day 143 after adoptive transfer. (A) 
Total CD4+ T cells present in the eyes of C57BL/6 and IL-27Rα-/- recipients in comparison the naïve 
baseline (B) Total CD8+ T cells present in the eyes of C57BL/6 recipients and IL-27Rα-/- recipients in 
comparison to the naïve baseline (C) Total CD11b+ cells present in the eyes of C57BL/6 recipients and 
IL-27Rα-/- recipients. Total eyes analysed at D143 3 per recipient group. Stats was not performed due 























Studies have shown that IL-27 plays an important role in a variety of autoimmune diseases 
(156). IL-27Rα is quite widely expressed, therefore, to investigate the effect of IL-27Rα 
specifically on T cell pathogenicity and disease the adoptive transfer model was used. 
In mouse models of autoimmune diseases IL-27Rα deficiency has been implicated in a more 
severe disease phenotype. In the murine model of rheumatoid arthritis,  formation of ectopic 
lymphoid tissues has been reported (269) and in the experimental model of multiple sclerosis, 
using a Treg conditional knockout of IL-27Rα-/-, a more severe disease phenotype due to 
dysregulated Tregs was seen (280). 
This chapter presents work showing the effect of the IL-27Rα knockout in EAU, on disease 
induction analysed in the actively immunised model and in disease progression and severity 
analysed in the previously optimised adoptive transfer model. 
In the eyes of unmanipulated IL-27Rα-/- mice total CD8+ T cells recovered (day 0 baseline) are 
significantly increased when compared to naïve C57BL/6 mice. The same effect was observed 
within the kidney of the IL-27Rα-/- mice (appendix 3) but not the liver. This could be caused 
by slower leukocyte trafficking throughout the periphery in comparison to the wildtype 
group, perhaps associated with tight endothelial barriers or potential differences in MHC 
expression within the tissue of the IL-27Rα-/- mice but more study is needed to determine the 
exact cause.  
It has been previously published that in the IL-27Rα-/- mouse a more severe and persistent 
disease is present in comparison to a control C57BL/6 group in models such as AIA and EAE 
(269, 275). Following from this observation, donor eyes from both immunised recipient 
groups at day 11 were analysed by extracellular staining of cell markers and intracellular 
staining of cytokines. In the mouse model of arthritis using the IL-27Rα-/- mice robust Th1 
responses are characterised by IFN-γ and IL-2 production (281). In EAU there is an increase in 
leukocyte number and disease severity in the IL-27Rα-/- mice (figure 7.4) and a statistically 
significant increase in overall IFN-γ production in the IL-27Rα-/- donors is observed. A further 
observation at day 11, is accelerated disease onset in the IL-27Rα-/- donors particularly within 
the CD4+ T cell compartment. This statistically significant increase in CD4+ T cells in the             
IL-27Rα-/- immunised donors in comparison to the C57BL/6 immunised donors demonstrates 
an earlier onset of clinical disease in the IL-27Rα-/- mice in comparison to the C57BL/6 control 
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group. This is further supported by data acquired at day 7 (figure 7.5) showing a more fast-
moving clinical disease.  
Considering the differences observed within the eyes of the donor mice, cytokine secretion 
and leukocyte cell number was analysed within the cell cultures before the adoptive transfer 
of leukocytes into recipients. Overall, the IL-27Rα-/- cultures expressed increased levels of 
numerous cytokines including IFN-γ and IL-17 reflecting the larger number of CD4+ T cells are 
present within the cultures. To understand further if the increase in cytokine secretion is 
purely per culture or if there are more cytokines produced by individual cells                                
intra-cytoplasmic staining of cell cultures could be obtained. The increase in overall cytokine 
secretion in the IL-27Rα-/- culture suggests a more pathogenic or potent phenotype present. 
The total cell number in the IL-27Rα-/- cultures is nearly doubled in comparison to the 
C57BL/6, but the percentage of CD4+ T cells is comparable in both,  equal cell numbers were 
then transferred into recipients, therefore any difference in disease is due to the difference 
in the pathogenicity of the leukocytes transferred not any difference in cell number. Further 
analysis of growth factors present within the cultures would explain the increase in total 
leukocytes present in the IL-27Rα-/- cultures. 
Whereas early onset of clinical disease was observed in immunised IL-27Rα-/- mice in 
comparison to the C57BL/6 immunised group, in the adoptive transfer model of IL-27Rα-/- or 
C57BL/6 T cells into C57BL/6 Ly5 recipients, no difference is observed in the two groups. This 
could be due to the cells being transferred already having an activated, antigen-specific 
phenotype whereas the immunisation of mice in both groups has had no pre-priming of CD4+ 
T cells and therefore when the two groups were immunised the more rapid expansion of the 
IL-27Rα-/- causes an earlier onset and more severe disease phenotype. 
OCT of early disease shows no differences between clinical disease onset and a similar disease 
severity at peak disease in both groups.  Resolution of active clinical disease in the C57BL/6 
group occurs by day 28, whereas in the IL-27Rα-/- recipient group clinical disease remains 
active. When studying late disease by OCT, clinical disease in the C57BL/6 recipient group 
remains generally inactive throughout the time course. In the IL-27Rα-/- recipient group 
disease is generally more severe and clinical infiltration remains through to day 67. This 
observation further confirms that T cells isolated from an IL-27Rα-/- mouse are more potent 
and drive a more severe persistent disease phenotype consistent with active immunisation 
models of AIA and EAE (269, 275). 
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At day 67 the recipient’s eyes from both groups were isolated and analysed by flow cytometry 
or fluorescence microscopy.  
The data obtained from quantification of leukocytes by flow cytometry supports the 
observations made by OCT in relation to disease severity across the two groups. Firstly, total 
number of leukocytes within the eyes of the IL-27Rα-/- recipients is increased in comparison 
to the C57BL/6 recipient group.  
When studying the ratio of endogenous and transferred leukocytes present within the eyes 
of both groups of recipients in these long-term experiments most transferred leukocyte 
populations, except CD4+ cells, did not survive from the donor groups. In the CD4+ T cell 
compartment, transferred C57BL/6 CD4+ T cells are found in low numbers in the eyes of 
recipients at all time points studied. The decrease in transfer cell number is consistent with 
the resolution of active clinical disease in these recipients. In the eyes of the IL-27Rα-/- 
recipients a large transferred CD4+ T cell population persists within the eyes of recipients 
through to day 67. This is the only transferred leukocyte population to persist long-term 
within the eyes of recipients suggesting that it is the absence of IL-27Rα specifically on CD4+ 
T cells that is required to drive a more severe persistent disease. Even with intact Treg 
function within recipients, the transferred cells are still highly pathogenic, driving active 
clinical disease and causing recruitment of endogenous CD4+ T cells.  
To study if during clinical disease any ectopic lymphoid tissue aggregates form, fluorescence 
microscopy was performed on whole retinas by flat mount or lightsheet microscopy. Both 
forms of analysis showed no signs of ectopic lymphoid structures being present using a CD3 
stain to mark formation. Further analysis was performed using whole eye sections stained 
with fluorescence, but this further analysis also showed no ectopic lymphoid structure 
formations. However, the differences in CD4+ T cell number between the two groups is 
further supportive of the OCT and flow cytometry analysis at the same time point, illustrating 
more active disease in the IL-27Rα-/- recipient mice. The CD8+ population present within the 
retinas are larger and therefore suggests an active environment, specifically in the IL-27Rα-/- 
recipients where an increased number of larger more activated CD8+ T cells are present in 
comparison to the C57BL/6 transfer. 
To extend the analysis of the effect of IL-27Rα-/- on transferred CD4+ T cells, in a small number 
of animals, disease was monitored through to day 144. As previously observed in earlier OCT 
images the recipients of the C57BL/6 transfer show no signs of active clinical disease from day 
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28 and disease appears to be quiescent through to day143 (figure 7.17) when eyes are 
analysed by flow cytometry to quantify total CD4+ T cell number (figure 7.18) the total 
number is not increased when compared to a naïve control, although damage to the retina is 
present in the OCT the disease does not remain active. In contrast in the OCT images of the 
IL-27Rα-/- recipients active disease is present but has reduced in severity when compared to 
previous OCT acquired at day 67. However, the disease, remains active in some animals 
through to day 144. Flow cytometric quantification shows an increase in the total CD4+ T cell 
number present within the eyes at day 144 and persistence of transferred IL-27Rα-/- CD4+ T 
cells.  Overall, using the adoptive transfer technique has highlighted the IL-27Rα knockout 
CD4+ T cells persist throughout clinical disease and continue to recruit endogenous cells 
including CD4+ T cells and neutrophils specifically to drive active disease to persist. Suggesting 
that in the active immunisation model the effect observed is based on the presence of a more 
pathogenic and potent CD4+ T cell. 
In conclusion, IL-27Rα knockout on leukocytes causes a more potent pathogenic phenotype 
that induces a more severe and persistent autoimmune disease in models of active 
immunisation. Using the adoptive transfer technique highlights that IL-27Rα-/- specifically 
within the CD4+ T cell population is sufficient to induce a more severe and persistent disease 
phenotype even in the presence of functional Tregs. This data also supports IL-27 as an 
immunoregulatory cytokine as active clinical disease persists within the IL-27Rα-/- recipients 
but within the C57BL/6 recipients with functional IL-27 present active clinical disease has 
resolved by day 28. The IL-27Rα-/-  CD4+ T cells are also more long lived and continue to drive 
clinical disease in comparison to the small numbers found in the C57BL/6 transfer group 






































8.1 General Discussion 
CD4+ T cells are important mediators and drivers of autoimmune disease. To induce EAU it is 
well established that immunisation of susceptible animals with a uveitogenic peptide triggers 
an immune response within the periphery of the animal, characterised by the activation and 
clonal expansion of pathogenic autoreactive T cells. T cells then cross the blood-retinal barrier 
this induces leukocyte recruitment and retinal disruption (1). 
Research presented in this thesis investigated the role of antigen-specific pathogenic T cells 
in the EAU model of uveitis. The effects of upregulation of specific chemokines and knock-out 
of cytokine receptors on transferred antigen-specific T cells was also investigated using the 
model. In coordination with these studies non-antigen specific recruitment to the ocular 
tissue was analysed with or without an antigen-specific stimulus and the work demonstrated 
the effects of antigen-specific T cell recruitment on the endothelium of the ocular tissue. Key 
findings were: 
• Transfer of pathogenic leukocytes causes increased retention of endogenous CD4+ 
cells to the eye in addition to sticking of transferred CD4+ T cells. (chapter 5) 
• Active uveitis enhances the recruitment of non-antigen specific activated T cells. 
(chapter 5) 
• CX3CR1 is upregulated on CD4+ T cells in the eye during EAU. The upregulation of 
CX3CR1 is due to antigen-specific response by CD4+ T cells. (chapter 6) 
• IL-27Rα-/- CD4+ T cells cause a more severe persistent clinical disease when adoptively 
transferred into wildtype C57BL/6 recipients. CD4+ T cells that are IL-27Rα-/- are more 
pathogenic and persist long term within the eye driving clinical disease. (chapter 7) 
Thus, this work provides new insights into the role of antigen-specific uveitogenic CD4+ T 
cells, disease-associated non-antigen-specific CD4+ T cells and the important role of IL-27 








8.2 Induction of EAU by adoptive transfer 
The work presented in this thesis uses the adoptive transfer of antigen-specific or non-
antigen-specific leukocytes. The adoptive transfer of antigen-specific uveitogenic 
leukocytes efficiently induces EAU in naive C57BL/6 recipients. As demonstrated in RAG2-/- 
mice in Chapter 3, disease induction and progression are CD4+ T cell mediated. Using the 
adoptive transfer of whole leukocyte populations allows the transferred and endogenous 
T cell populations to be distinguished and therefore gives us the ability to determine the 
long-term fate of the initial transferred cells, including the CD4+ transferred population. 
 
8.2.1 The fate of transferred antigen specific CD4+ T cells throughout clinical disease 
Transferred pathogenic antigen-specific cells are capable of inducing clinical disease in 
wildtype C57BL/6 (Ly5) recipients. The transferred CD4+ T cells give rise to a population 
that persists within the eye throughout clinical disease course this is highlighted in 
Chapter 4. This leads to a recruitment of endogenous CD4+ T cells that is observed from 
day 2 and increases as peak disease is reached at day 7-10 thus suggesting the host’s own 
immune response responds to the pathogenic stimulus of the transferred antigen-specific 
T cells.  
At day 2, the number of endogenous CD4+ T cells present within the eyes of recipient mice 
increases concurrently with the presence of transferred CD4+ T cells at this time point, 
suggesting an activation of the endothelium has occurred due to the transfer of antigen 
specific activated CD4+ T cells. We hypothesised that activation of the endothelium could 
be due to an antigen-specific stimulus due to the pathogenic nature of the transferred 
CD4+ T cells or alternatively due to the activation status of the transferred CD4+ T cells. 
This question will be discussed later on in this section. 
Analysis of clinical disease course after adoptive transfer was achieved by OCT imaging 
and by quantification of leukocyte number by flow cytometry. These methods of analysis 
allowed active clinical disease to be monitored and the proportion of endogenous and 
transferred cells. It has previously been reported that initial disease causing CD4+ T cells 
or the progeny of these cells do not persist within the inflamed tissue throughout active 
disease and go through apoptosis as active clinical disease is resolving (282), however the 
data presented in chapter 4, suggests that in EAU the original antigen specific transferred 
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CD4+ T cells or their progeny have persisted within the eyes of the recipient mice and 
have driven the disease process or have been recruited to the eye during the disease 
process and have persisted within the tissue past active clinical disease. This finding is in 
contrast to a study by Oh et al where they describe the fate of autoreactive T cells that 
mediate uveitis to reside in the bone marrow after acute uveitic disease and not the ocular 
tissue (283).  However, fate mapping would be required to understand the population of 
transferred cells that have survived within the tissue. 
 
8.2.2 Transferred cells activate the endothelium after adoptive transfer causing a 
recruitment of both endogenous and transferred CD4+ T cells 
After adoptive transfer of leukocytes, recipients were monitored using OCT imaging to 
assess early signs of clinical disease. Active disease was not detected on OCT before day 
5, at this point swelling of the optic disc was a sign of early active clinical disease. 
Although changes are not detectable by OCT at day 2 in many recipients, quantification of 
leukocytes at day 2 after adoptive transfer is a more sensitive measure of active clinical 
disease. As highlighted in Chapter 4 at day 2 after adoptive transfer an increase in 
endogenous CD4+ T cell number is observed. Concurrently with this observation a 
population of transferred CD4+ T cells is detected within the ocular tissue which is not 
seen after transfer of non-antigen specific cells.  
The presence of transferred CD4+ T cells and the increased number of endogenous CD4+ 
T cells suggests a mechanism involved in disease induction has already begun to impact 
the ocular tissue. We hypothesised that the recruitment of transferred CD4 cells to the 
ocular tissue by day 2 after adoptive transfer is due to an activation of the endothelium 
due to the activation status or antigen-specific nature of the transferred cells.  
The role of endothelial cells in the recruitment of lymphocytes, monocytes, neutrophils 
and dendritic cells into lymph nodes and tissues depends on an intimate relationship 
between endothelial cells and immune cells (284). The recruitment of immune cells is 
selective and can be influenced by an immune stimulus to trigger the trafficking process 
along with mediators produced by endothelial cells (284). Therefore, the endothelium can 
play a vital role in the immune response and in the adoptive transfer model of EAU a role 
in disease initiation.  
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Further investigation into the immune stimulus linked to the recruitment of transferred 
CD4+ T cells that induces the increased recruitment and sticking of endogenous CD4+ T 
cells will be discussed with the relevant data presented from chapter 5. 
 
8.3 Antigen specific and non-antigen specific CD4+ T cell recruitment in EAU 
8.3.1 Increased recruitment and retention of endogenous CD4+ T cells at day 2 after 
adoptive transfer of CD4+ T cells is due to an antigen-specific stimulus  
At day 2 after adoptive transfer of uveitogenic, antigen specific CD4+ T cells there is an 
increase in recruitment and retention of endogenous CD4+ T cells.  
Further experimentation investigated whether the endothelium becomes activated in 
response to the transferred CD4+ T cells being in an activated state or due to their antigen 
specificity. Therefore, using OVA TCR transgenic leukocytes allowed us to address the 
question of activation versus antigen-specificity facilitating increased endogenous CD4+ T 
cell recruitment and transferred cells sticking within the ocular tissue to cause clinical 
disease.  
Adoptive transfer of activated non retinal antigen specific leukocytes from an OVA TCR 
transgenic mouse does not initiate activation of the endothelium to the level seen with 
an antigen specific response, this is suggested by no increase in endogenous CD4+ T cell 
recruitment and almost no retention of the transferred OVA- specific activated. However, 
previous studies have highlighted the ability of activated T cells to migrate across normal, 
non-inflamed endothelium at day 1 ~44 cells had infiltrated the eyes of recipient mice 
when 10x106 activated T cells are transferred (285). 
An i.p injection of PBS, without activated or unactivated cells will still initiate a measurable 
and statistically significant increase in recruitment and retention of endogenous CD4+ T 
cells at day 2 after injection, this effect could be caused by endotoxin release at the site 
of injection that stimulates the endothelium to upregulate molecules that retain CD4+ T 
cells at this early time point. Increased trafficking does not lead to initiation of uveitic 
disease and by day 7 has resolved, thus suggesting that without a pathogenic stimulus the 
endothelium does not become activated to recruit and retain endogenous and transferred 
cells that cause disease.  
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Therefore, this data suggests a local antigen-specific response is required to induce 
disease progression through endothelial activation that leads to endogenous and 
transferred CD4+ T cell recruitment. This conclusion was further confirmed using the OVA 
TCR specific cell transfer of activated OVA antigen-specific OTII cells with a concurrent 
intravitreal injection of OVA given just prior to cell transfer presented in chapter 5. This 
data confirmed that the recruitment of transferred and endogenous cells observed at day 
2 after adoptive transfer is not retinal antigen specific but an antigen-specific response to 
any antigen in the local environment and has the ability to induce recruitment of 
endogenous and transferred CD4+ T cells.  
 
8.3.2 Antigen-specific transferred CD4+ T cells initiate recruitment of antigen and non-
antigen specific CD4+ T cells throughout ocular inflammation 
As previously discussed, activated non-antigen specific CD4+ T cells are not capable of 
inducing endothelial activation defined by significant endogenous cell recruitment and do 
not remain within the ocular tissue past day 2 after adoptive transfer. Although the 
endogenous CD4+ T cell number does increase due to the release of endotoxin at the site 
of injection.  
Data has demonstrated an antigen-specific stimulus induces the activation of the 
endothelium. However, further experiments including the co-transfer of retinal antigen 
specific activated CD4+ T cells with OVA specific activated CD4+ T cells at a 1:1 ratio. These 
experiments allowed for tracking of transferred ‘pathogenic’ retinal antigen specific CD4+ 
T cells, ‘activated’ OVA specific CD4+ T cells and endogenous CD4+ T cells.  
The concurrent transfer of ‘pathogenic’ and ‘activated’ CD4+ T cells illustrated a 
recruitment and retention of ‘activated’ OVA specific CD4+ T cells that are not specific for 
retinal antigen, which is compatible with a non-antigen specific CD4+ T cell role in active 
clinical disease. However, what this data also suggests is that activation alone on T cells is 
not sufficient enough to induce clinical disease. 
However, an antigen specific stimulus is capable of inducing disease and when the 
stimulus is present in the form of ‘pathogenic’ cells to facilitate, recruitment of the OVA 
specific ‘activated’ CD4+ T cells occurs. Therefore, suggesting a non-specific recruitment 
of CD4+ T cells throughout clinical disease that is contributing to clinical disease course. 
Looking at the total cell number of the endogenous, ‘pathogenic’ and ‘activated’ 
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populations, it illustrates that the number of activated cells is proportionate to the other 
CD4+ T cell population present within the eye during active clinical disease.  
Further to this the endogenous cells accumulating within the eye at this time point may 
also be of an activated phenotype. Due to the size of this ‘activated’ non-retinal specific 
CD4+ T cell population it suggests these cells play a role in clinical disease progression and 
that the recruitment of these cells suggest a non-retinal antigen specific drive takes place 
during disease course, the minimal CX3CR1 expression present on this population 
supports the hypothesis that these cells are recruited non-specifically. This data also 
suggests that without the pathogenic stimulus activated non-retinal specific CD4+ T cells 
don’t remain within the ocular tissue, whereas with a pathogenic retinal antigen specific 
stimulus present activated non-retinal antigen specific cells are recruited to the eye and 
they or their progeny remain within the eye throughout clinical disease and contribute to 
active disease progression. 
 
8.4 CX3CR1 in EAU 
8.4.1 CX3CR1 deficiency does not affect disease severity in donor cells or recipient tissue 
After determining disease course using the adoptive transfer technique in chapter 3, 
experiments investigated how knocking out both or one of the alleles of the CX3CR1 
receptor effected disease course. The literature surrounding the effect of CX3CR1 on 
disease course in EAU is conflicted. 
Firstly, comparing CX3CR1 heterozygous or total CX3CR1 allelic knockout transferred cells 
in RAG2-/- recipient mice. In comparison to the wildtype transferred cell control group, the 
data presented in chapter 6 suggests no effect on severity of disease caused in recipients 
between the three groups, although differences in timing of disease induction is observed 
within the three groups. Active clinical disease is observed in the wildtype group at day 7 
whereas in both the CX3CR1 heterozygous and knockout groups, active disease was not 
observed until day 14 after adoptive transfer. The delay in disease onset suggests that 
CX3CR1 heterozygous or knockout cells have reduced or slower trafficking in comparison 
to the wildtype control group. 
On the other hand, when wildtype cells were transferred into CX3CR1 heterozygous 
knockout or CX3CR1 knockout recipient mice no difference in disease induction, severity 
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or incidence was observed. Therefore, suggesting CX3CR1 has a modest effect on disease 
when one or both alleles are knocked out on the transferred population in contrast to 
being knocked out on the endogenous population. CX3CR1 is known to be involved in 
leukocyte trafficking and therefore by knocking out the chemokine trafficking is slowed to 
the ocular tissue in the transferred population, whereas due to CX3CR1 receptor being 
intact on the transferred wild type cells trafficking of the cells to the ocular tissue is not 
effected and the host responds to the trafficking of the transferred population.  However 
more experimentation is needed to further investigate this effect. 
 
8.4.2 CX3CR1 is upregulated on CD4+ T cells throughout active EAU 
CX3CR1 is known to be expressed on cells of myeloid lineage, but recent studies have 
started to investigate a role for CX3CR1 expression on CD4+ and CD8+ T cells in models of 
inflammation. 
CX3CR1 heterozygous knockout leukocytes were transferred into wildtype Ly5 recipients 
to assess using the GFP present in place of one CX3CR1 allele to track CX3CR1 expression. 
Data presented in chapter 6 suggests that in EAU disease progression CX3CR1 is expressed 
on CD4+ T cells present within the eye during disease. The proportion of transferred cells 
expressing CX3CR1 increases as disease progresses and reaches its peak in the eye at day 
14 after adoptive transfer of leukocytes in comparison to non-lymphoid tissue. Thus, 
suggesting that these cells have switched on CX3CR1 expression when recruited to the 
eye and then have been retained throughout disease making up by day 14 a larger 
population of the transferred CD4+ T cells.  
Previous studies have suggested that CX3CR1 upregulation on CD4+ T cells has led to 
increased survival and retention in the inflamed tissue. The data presented in this thesis 
suggests a similar potentially selective retention in the diseased tissue during active EAU 
of the CX3CR1 expressing CD4+ T cells. However, the mechanism for the switching on of 







8.4.3 CX3CR1 is not expressed on CD4+ T cells unless the cognate antigen is present 
within the tissue 
The previous observation that CX3CR1 is expressed on CD4+ T cells during active clinical 
disease specifically in the ocular tissue in contrast to non-lymphoid tissues suggested the 
involvement of TCR activation directly or indirectly in CX3CR1 expression. 
In chapter 5 a double transfer technique was described utilising pathogenic retinal antigen 
specific CD4+ T cells transferred concurrently with a population of CD4+ T cells that are 
activated, OVA antigen specific. Both cell populations had one allele of the CX3CR1 locus 
replaced by a green fluorescent protein so in both populations CX3CR1 expression on 
CD4+ T cells can be monitored throughout disease course.  
Data presented in chapter 6 using this method of disease induction illustrates a specific 
expression of CX3CR1 on CD4+ T cells that are retinal antigen specific within the eyes in 
comparison to minimal CX3CR1 expression on activated OVA specific CD4+ T cells that 
remain in the eye sticking non-specifically during active disease. This observation suggests 
that activation alone is not sufficient to induce CX3CR1 expression on CD4+ T cells. Further 
to this, activation using an antigen in vitro (RBP or OVA) does not induce CX3CR1 
expression on CD4+ T cells in both populations. However in vivo CX3CR1 expression is 
upregulated on retinal antigen specific CD4+ T cells that have been re-exposed to retinal 
antigen present in the eye, in contrast the OVA specific activated CD4+ T cell population 
present within the eye express minimal levels of CX3CR1. This data supports a model that 
when antigen specific cells are re-exposed to the antigen in vivo the response engages the 
TCR and therefore induces CX3CR1 on CD4+ retinal antigen specific cells that enter the 
eye. At time of transfer CX3CR1 expression on CD4+ T cells is <2% of the population. 
Whereas in the OVA specific activated CD4+ T cells, the OVA antigen is not present within 
the recipient mice so therefore the cells do not come into contact with the antigen in vivo. 
Minimal CX3CR1 expression is observed on these cells suggesting that because the cells 
are not re-exposed to the antigen CX3CR1 expression is not induced in these cells. 
This data suggests that activation alone with the antigen is not sufficient to induce CX3CR1 
expression, however when re-exposed to the antigen in vivo, CX3CR1 expression on CD4+ 





8.4.4 CX3CR1 expression on CD4+ T cells is due to re-exposure to antigen in vivo 
To determine if the expression of CX3CR1 on CD4+ T cells is retinal antigen specific in vivo, 
the experimental design described in chapter 5 was used, OVA specific CD4+ CX3CR1 
heterozygous cells were activated in culture similarly to the uveitogenic cell transfer 
technique but are stimulated using OVA peptide instead of the RBP3. After the cell culture 
stage recipient CX3CR1 heterozygous mice receive an intravitreal injection of OVA peptide 
when cells are transferred. Data presented in chapter 5 illustrates a peak in disease at day 
7/8 using clinical imaging and flow cytometry and the presence of both endogenous and 
transferred CD4+ T cells within the eye.  
Analysis of CX3CR1 expression on CD4+ T cells using the OVA intravitreal transfer is 
presented in chapter 6. The eye injected with OVA peptide gets clinical disease that 
recruits both endogenous and transferred CD4+ T cells whereas the eye that receives PBS 
or control peptide has elevated endogenous CD4+ T cell numbers in comparison to naïve 
eyes but minimal transferred CD4+ are detected throughout active disease in the ocular 
tissue.  
CX3CR1 expression is observed on both the transferred and endogenous CD4+ T cell 
population especially within the eye that received the intravitreal OVA. The expression of 
CX3CR1 on transferred CD4+ OVA specific cells support the hypothesis that CX3CR1 is 
expressed on CD4+ T cells in the presence of the antigen the cells are familiar with and 
therefore the TCR is involved in the expression of CX3CR1. However, upregulation of 
CX3CR1 on the endogenous CD4+ T cell population suggests expression of CX3CR1 on the 
endogenous CD4+ population indicates at least some of this population are interacting in 
the eye with cognate antigen. Therefore, suggesting CX3CR1 expression on endogenous 
CD4+ T cells is switched on when cells are recruited to the eye during active disease where 
they encounter the ocular antigen and are activated which switches CX3CR1 expression 
on in CD4+ T cells. In the transferred compartment it can be concluded that CX3CR1 
expression is not just retinal antigen specific but specific to any antigen the CD4+ T cells 






8.5 The role of IL-27 in EAU 
8.5.1 Disease onset is earlier in the IL-27Rα-/- after active immunisation 
Using the adoptive transfer technique described in chapter 3 combined with the data 
presented in chapter 4 that describes a conventional disease course gives a robust 
technique and comparable data set to manipulate donor or recipient leukocytes (as 
previously demonstrated using the CX3CR1 heterozygous or CX3CR1 knockout). Due to 
recent studies in models of arthritis and multiple sclerosis illustrating an effect on clinical 
disease when inducing disease in the IL-27Rα-/- mouse, experiments were designed to 
utilise these mice as donors for adoptive transfer. 
Firstly, eyes and organs from naïve IL-27Rα-/- mice were analysed to give a baseline for the 
study to detect changes in leukocyte number within the eyes of immunised mice. At day 
7 after immunisation, increased leukocyte recruitment is observed in immunised mice in 
comparison to the naïve baseline obtained from naïve IL-27Rα-/- mice. Further to this, eyes 
from donor mice immunised for adoptive transfer from IL-27Rα-/- and C57BL/6 mice were 
analysed, and leukocytes quantified using flow cytometry. By day 11 after immunisation 
the IL-27Rα-/- mice have leukocyte numbers similar to that of peak disease in a C57BL/6 
whereas in the eyes of C57BL/6 mice at day 11 after immunisation elevated leukocyte 
numbers are present within the eye but not comparable to peak clinical disease. In 
contrast to studies of EAE this data demonstrates that uveitis onset is accelerated in           
IL-27Rα-/- animals when using the active immunisation method. This could be down to the 
pathogenicity of the CD4+ T cells that lack the IL-27Rα-/- initiating a more severe response 
when immunised with the RBP3 antigen. Studies (280) have also suggested dysfunction of 
the Treg population due to the lack of the IL-27Rα  could contribute to disease induction 
and severity due to lack of regulation.   
 
8.5.2 IL-27Rα-/- leukocytes are more pathogenic and cause a more severe and persistent 
disease phenotype when disease is induced using the adoptive transfer technique 
The evidence presented in this thesis leads to the conclusion that CD4+ T cells are more 
pathogenic from an IL-27Rα-/- mouse in comparison to CD4+ T cells from a wildtype 
C57BL/6. Firstly, after immunisation leukocytes were isolated and stimulated in cell 
culture, after this step supernatant from the cell cultures was obtained and analysed using 
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the LegendPLex platform. Concentration of cytokines within the supernatant of both the 
IL-27Rα-/- and wildtype C57BL/6 cell cultures were calculated. There is a significant 
increase in the concentration of cytokines present within the IL-27Rα-/- leukocyte cultures 
in comparison to the wildtype C57BL/6 cultures. The increase in cytokine production in 
the IL-27Rα-/- culture supernatant suggests a more pathogenic phenotype is present.  
This is further supported by observations made about disease phenotype after the 
adoptive transfer of IL-27Rα-/- leukocytes into wildtype C57BL/6 recipients. At early time 
points a more severe disease is present within the eyes of recipients in comparison to the 
wildtype transfer with the same number of CD4+ T cells. The differences in disease 
severity between the two groups cannot be attributed to Tregs as the recipient wildtype 
mice have intact Treg populations. But no difference was observed in disease initiation 
between the two groups which was observed within the active immunisation group of     
IL-27Rα-/- mice, which further supports the hypothesis that dysfunctional Tregs due to      
IL-27Rα-/- initiates early onset disease.  
Using OCT imaging to follow clinical disease course allows analysis of disease throughout 
active disease and during disease resolution. The imaging data illustrates a persistent and 
more severe disease phenotype in the IL-27Rα-/- transfer recipients in comparison to the 
C57BL/6 transfer. IL-27Rα-/- has been implicated in causing a more severe and persistent 
disease phenotype in other models of autoimmune disease including adjuvant induced 
arthritis and experimental autoimmune encephalitis. AIA was induced in IL-27Rα-/-mice 
and disease monitored in comparison to a wildtype group, exacerbated joint pathology 
denoted by increased leukocyte infiltration, synovial exudate, hypertrophy and hallmarks 
of cartilage and bone erosion (269). This data suggests IL-27 is a key mediator of immune 
response homeostasis in autoimmune conditions such as arthritis. The same pattern of 
more severe disease pathology is observed within the adoptive transfer model of EAU. 
Further to this using the clinical imaging to monitor clinical disease, the IL-27Rα-/- 
recipients illustrate no disease resolution and persistence of active clinical disease 
through to day 67. Analysis of clinical disease from day 67 to day 144 using clinical imaging 
illustrates active disease resolution in some recipients however in others active disease 





8.5.3 IL-27Rα-/- CD4+ T cells persist within the eyes of recipients through to day 144 after 
adoptive transfer 
Clinical imaging allows disease monitoring throughout active disease and to compare 
disease phenotype across recipient groups. Combined with quantification of leukocytes 
present within the eyes of recipient’s differences in leukocyte infiltration can be 
attributed to differences in disease severity or phenotype. 
At day 67 after adoptive transfer the only population to persist within the eyes of the        
IL-27Rα-/- recipients are transferred CD4+ T cells, and in large enough numbers to drive 
clinical disease whereas in the wildtype transfer group minimal numbers of transferred 
and endogenous leukocytes are present within the recipient tissue. This data suggests 
that the persistence of the IL-27Rα-/- CD4+ T cells is driving active disease and initiating 
recruitment of endogenous CD4+ T cells along with other endogenous leukocytes such as 
neutrophils and myeloid cells. 
Continuing disease course through to day 144 illustrates a further persistence of the          
IL-27Rα-/- CD4+ T cells. With many recipients still with active clinical disease at this time 
point due to the persistence of this CD4+ T cell population driving disease. 
This collated data suggests a more potent and persistent phenotype of CD4+ T cell that 
can survive within the tissue and drive disease through to day 144 after adoptive transfer. 
 
8.6 Final Discussion 
This study investigates the basic mechanisms underlying the induction and progression of 
EAU. The basic mechanism underpinning clinical symptoms is poorly understood within 
human uveitis, in order to develop new treatments for the disease it is important to 
understand how and why disease develops. The work in this thesis can help with further 
understanding on the disease process. 
The work in this thesis illustrates manipulation of disease using IL-27Rα-/- and CX3CR1+/GFP 
and CX3CR1GFP/GFP knockout mice, therefore using the adoptive transfer model optimised 
in previous chapters more detailed investigation of how these targets affect disease 
course and determine further targets for treatment of uveitis can be determined. Further 
studies of the effects of different cytokines and chemokines on disease course could be 
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achieved by combining different knockout mouse strains or by CRISPR/Cas9 knockout of 
genes of interest. 
Overall, the data in this thesis gives an optimised method of tracking antigen specific cells 
that drive disease and non-retinal antigen specific cells which are non-specifically 
recruited throughout disease course. The adoptive transfer technique further allows 
expression of chemokines to be monitored throughout disease and how receptor 
knockouts influence disease course.  
Further to this from the original hypothesis set out for this thesis we have developed and 
optimised sensitive method of analysis of naïve and diseased ocular tissue and used this 
method to track allelically marked CD4+ T cells that drive disease and persist within the 
tissue after active clinical disease has resolved along with the recruitment of endogenous 
CD4+ T cells and studied their role in disease. The mechanism of recruitment of 
endogenous and transferred cells to the ocular tissue has been observed to be of antigen-
specific nature but recruitment of transferred non-antigen specific cells is observed when 
a pathogenic cell stimulus is present. Upregulation of CX3CR1 in increased frequencies 
was observed during active clinical disease due to an antigen-specific response and finally 
IL-27Rα-/- T cells cause a more long-lived and severe disease phenotype and persist within 










































9. Future Directions 
9.1 Nonspecific recruitment of CD4+ T cells throughout clinical disease 
As illustrated in chapter 5 recruitment of non-antigen specific CD4+ T cells when a uveitogenic 
stimulus is present was observed throughout active clinical disease. Further experimentation 
into what is causing the retention of non-specific CD4+ T cells within the eye could be 
achieved by the use of endothelial cell markers that are upregulated during active disease 
course that would influence retention of non-antigen specific CD4+ T cells. Distribution within 
the tissue of the antigen-specific and non-specific cells are retained specifically if they are 
resting on the endothelium or dispersed throughout the retina and vitreous. 
Further to this, the CRISPR/Cas9 system of gene editing could be utilised to knock out genes 
that effect disease progression and could be involved in the non-specific retention of CD4+ T 
cells. Firstly, to test if virally transduced cells survive in vivo and are capable of causing 
disease. Using a retroviral construct of F-tractin tagged GFP. CRISPR/Cas9 can then be utilised 
to knockout genes that can be assumed to cause a more severe disease phenotype including 
CTLA-4 or from the work presented in this thesis IL-27Rα or knockout genes that can be 
assumed to cause a less severe disease phenotype including CD28. After optimisation of this 
platform specific genes can be selected to target on OVA antigen specific CD4+ T cells before 
concurrent adoptive transfer with retinal antigen specific CD4+ T cells to monitor if the OVA 
specific cells are retained throughout active disease after specific genes are knocked out to 
manipulate disease course and reduce disease severity. 
 
9.2 The role of initial disease-causing antigen specific cells in EAU disease 
course 
The persistence of the disease initiating antigen specific CD4+ T cells throughout clinical 
disease is highlighted within this thesis (chapter 4). Using RNA sequencing at a number of late 
disease time points could identify genes present in the total CD4+ and CD8+ T cell population 
to identify differences in gene expression in cells retained in the eye past active clinical 
disease. This technique allows comparisons between clinical disease points past active 
disease but also could be used to analyse differential gene expression in endogenous and 
transferred CD4+ T cell populations during active disease. 
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 The role of the transferred antigen specific cells in disease initiation by activation of the 
endothelium was highlighted in (chapter 4) but further analysis into how transferred cells are 
involved in the initiation and progression of clinical disease can be investigated using antibody 
depletion of the transferred population before active peak disease occurs. This experiment 
will determine the role of transferred antigen specific cells in continuing active disease course 
and whether the endogenous compartment of CD4+ T cells is capable of continuing disease 
course without the presence of the antigen specific pathogenic transferred CD4+ T cells. 
Further to this the proliferation status of the transferred CD4+ population during active 
disease. Using a Ki67 antibody stain we can determine if the cells are in the active phase of 
the cell cycle and are therefore proliferating or the increase in transferred number present in 
the eye during active clinical disease is due purely to recruitment of transferred cells from the 
blood, spleen and lymph nodes. 
 
9.3 CX3CR1 expression on CD4+ T cells throughout clinical disease  
The expression of CX3CR1 on CD4+ T cells due to an antigen specific response is presented in 
chapter 6. To investigate if CX3CR1 is also expressed on CD4+ T cells in vitro cultures, OVA 
specific CD4+ T cells cocultured with antigen and CD3 CD28 stimulation to quantify CX3CR1 
expression on CD4+ T cells.  
Further experiments include utilising the RAG2-/- mice to transfer cells from transfer recipients 
at peak disease in Ly5 recipients. CD4+ transferred T cells from recipient eyes at peak disease 
can be sorted into CX3CR1+ CD4+ T cells and transferred into one group of recipients and sort 
CX3CR1- CD4+ T cells to transfer into another group of recipients. This experiment will allow 
differences in disease course based on CX3CR1 expression of CD4+ T cells with the hypothesis 
that CX3CR1+ CD4+ T cells are more capable of causing disease and persisting during active 
disease in comparison to the CX3CR1- CD4+ T cell population. 
Analysis of differential gene expression in these recipients could be investigated by focussed 
analysis of the expression of functional gene sets that are associated with changes in T cell 
effector potential specifically analysing intracellular cytokine expression including IFN-γ, IL-17 
and TNF. Regulatory and activation threshold markers including; FoxP3, CD5, CD39 and CD73, 
coinhibitory markers BTLA, TIM3, CTLA4, LAG3, PD1 and TIGIT and costimulatory markers 
(41BB, CD25, CD28, GITR, ICOS and OX40 using flow cytometry antibody panels. 
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Further to this RNA seq analysis of levels of mRNA followed by unsupervised analysis of 
differential gene expression will complement the previous study. Using total cell count of 
CD4+ T cells at different time points throughout disease course and with differing CX3CR1 
expression levels to compare cross different disease-causing cells. 
Due to the antigen specific nature of CX3CR1 expression on CD4+ T cells analysis of the TCR 
of CX3CR1+ CD4+ T cells using single cell sequencing. This platform allows single cell analysis 
at the transcript level with concurrent analysis of the TCR repertoire of each individual cell. 
Firstly, using the OTII transfer model with intravitreal OVA followed by analysis of the 
uveitogenic transfer model. 
 
9.4 IL-27Rα-/- causes a more potent CD4+ T cell phenotype 
 As described in chapter 7 knocking out the IL-27Rα in transferred CD4+ T cells causes a more 
severe cell phenotype that persists throughout active disease and continues to drive disease 
to cause a longer more severe disease within the recipients. Further experimentation could 
include phenotyping the CD4+ T cell populations within both groups of recipients to identify 
the role of CD4+ T cell phenotype in disease progression including early disease time points 
and late disease time points such as staining for IFN-γ, IL-17 and FoxP3 using flow cytometry 
antibodies before including analysis of differential gene expression in recipients by 
quantifying expression of functional gene sets that are associated with changes in T cell 
effector potential specifically analysing intracellular cytokine expression including IFN-γ, IL-17 
and TNF. Regulatory and activation threshold markers including FoxP3, CD5, CD39 and CD73, 
coinhibitory markers BTLA, TIM3, CTLA4, LAG3, PD1 and TGIT and costimulatory markers 
(41BB, CD25, CD28, GITR, ICOS and OX40. 
The effect of IL-27Rα knockout on CD4+ T cells has contributed to differences in disease 
phenotype but how this difference in clinical disease affects the structure and function of the 
tissue. Using histological sections to analyse the structures present within the eye to 
determine any abnormalities across disease groups, alternatively further analysis using whole 
retina flat mounts allows study of dispersion within the retina of immune infiltrate. 
• T cells to the eye in addition to sticking of transferred CD4+ T cells. (chapter 5) 




• CX3CR1 is upregulated on CD4+ T cells in the eye during EAU. The upregulation of 
CX3CR1 is due to antigen-specific response by CD4+ T cells. (chapter 6) 
• IL-27Rα-/- CD4+ T cells cause a more severe persistent clinical disease when adoptively 
transferred into wildtype C57BL/6 recipients. CD4+ T cells that are IL-27Rα-/- are more 
pathogenic and persist long term within the eye driving clinical disease. (chapter 7) 
Thus, this work provides new insights into the role of antigen-specific uveitogenic CD4+ T 
cells, disease-associated non-antigen-specific CD4+ T cells and the important role of IL-27 






8.2 Induction of EAU by adoptive transfer 
The work presented in this thesis uses the adoptive transfer of antigen-specific or non-
antigen-specific leukocytes. The adoptive transfer of antigen-specific uveitogenic 
leukocytes efficiently induces EAU in naive C57BL/6 recipients. As demonstrated in RAG2-/- 
mice in Chapter 3, disease induction and progression are CD4+ T cell mediated. Using the 
adoptive transfer of whole leukocyte populations allows the transferred and endogenous 
T cell populations to be distinguished and therefore gives us the ability to determine the 
long-term fate of the initial transferred cells, including the CD4+ transferred population. 
 
8.2.1 The fate of transferred antigen specific CD4+ T cells throughout clinical disease 
Transferred pathogenic antigen-specific cells are capable of inducing clinical disease in 
wildtype C57BL/6 (Ly5) recipients. The transferred CD4+ T cells give rise to a population 
that persists within the eye throughout clinical disease course this is highlighted in 
Chapter 4. This leads to a recruitment of endogenous CD4+ T cells that is observed from 
day 2 and increases as peak disease is reached at day 7-10 thus suggesting the host’s own 
immune response responds to the pathogenic stimulus of the transferred antigen-specific 
T cells.  
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At day 2, the number of endogenous CD4+ T cells present within the eyes of recipient mice 
increases concurrently with the presence of transferred CD4+ T cells at this time point, 
suggesting an activation of the endothelium has occurred due to the transfer of antigen 
specific activated CD4+ T cells. We hypothesised that activation of the endothelium could 
be due to an antigen-specific stimulus due to the pathogenic nature of the transferred 
CD4+ T cells or alternatively due to the activation status of the transferred CD4+ T cells. 
This question will be discussed later on in this section. 
Analysis of clinical disease course after adoptive transfer was achieved by OCT imaging 
and by quantification of leukocyte number by flow cytometry. These methods of analysis 
allowed active clinical disease to be monitored and the proportion of endogenous and 
transferred cells. It has previously been reported that initial disease causing CD4+ T cells 
or the progeny of these cells do not persist within the inflamed tissue throughout active 
disease and go through apoptosis as active clinical disease is resolving (282), however the 
data presented in chapter 4, suggests that in EAU the original antigen specific transferred 
CD4+ T cells or their progeny have persisted within the eyes of the recipient mice and 
have driven the disease process or have been recruited to the eye during the disease 
process and have persisted within the tissue past active clinical disease. This finding is in 
contrast to a study by Oh et al where they describe the fate of autoreactive T cells that 
mediate uveitis to reside in the bone marrow after acute uveitic disease and not the ocular 
tissue (283).  However, fate mapping would be required to understand the population of 
transferred cells that have survived within the tissue. 
 
8.2.2 Transferred cells activate the endothelium after adoptive transfer causing a 
recruitment of both endogenous and transferred CD4+ T cells 
After adoptive transfer of leukocytes, recipients were monitored using OCT imaging to 
assess early signs of clinical disease. Active disease was not detected on OCT before day 
5, at this point swelling of the optic disc was a sign of early active clinical disease. 
Although changes are not detectable by OCT at day 2 in many recipients, quantification of 
leukocytes at day 2 after adoptive transfer is a more sensitive measure of active clinical 
disease. As highlighted in Chapter 4 at day 2 after adoptive transfer an increase in 
endogenous CD4+ T cell number is observed. Concurrently with this observation a 
312 
 
population of transferred CD4+ T cells is detected within the ocular tissue which is not 
seen after transfer of non-antigen specific cells.  
The presence of transferred CD4+ T cells and the increased number of endogenous CD4+ 
T cells suggests a mechanism involved in disease induction has already begun to impact 
the ocular tissue. We hypothesised that the recruitment of transferred CD4 cells to the 
ocular tissue by day 2 after adoptive transfer is due to an activation of the endothelium 
due to the activation status or antigen-specific nature of the transferred cells.  
The role of endothelial cells in the recruitment of lymphocytes, monocytes, neutrophils 
and dendritic cells into lymph nodes and tissues depends on an intimate relationship 
between endothelial cells and immune cells (284). The recruitment of immune cells is 
selective and can be influenced by an immune stimulus to trigger the trafficking process 
along with mediators produced by endothelial cells (284). Therefore, the endothelium can 
play a vital role in the immune response and in the adoptive transfer model of EAU a role 
in disease initiation.  
Further investigation into the immune stimulus linked to the recruitment of transferred 
CD4+ T cells that induces the increased recruitment and sticking of endogenous CD4+ T 
cells will be discussed with the relevant data presented from chapter 5. 
 
8.3 Antigen specific and non-antigen specific CD4+ T cell recruitment in EAU 
8.3.1 Increased recruitment and retention of endogenous CD4+ T cells at day 2 after 
adoptive transfer of CD4+ T cells is due to an antigen-specific stimulus  
At day 2 after adoptive transfer of uveitogenic, antigen specific CD4+ T cells there is an 
increase in recruitment and retention of endogenous CD4+ T cells.  
Further experimentation investigated whether the endothelium becomes activated in 
response to the transferred CD4+ T cells being in an activated state or due to their antigen 
specificity. Therefore, using OVA TCR transgenic leukocytes allowed us to address the 
question of activation versus antigen-specificity facilitating increased endogenous CD4+ T 
cell recruitment and transferred cells sticking within the ocular tissue to cause clinical 
disease.  
Adoptive transfer of activated non retinal antigen specific leukocytes from an OVA TCR 
transgenic mouse does not initiate activation of the endothelium to the level seen with 
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an antigen specific response, this is suggested by no increase in endogenous CD4+ T cell 
recruitment and almost no retention of the transferred OVA- specific activated. However, 
previous studies have highlighted the ability of activated T cells to migrate across normal, 
non-inflamed endothelium at day 1 ~44 cells had infiltrated the eyes of recipient mice 
when 10x106 activated T cells are transferred (285). 
An i.p injection of PBS, without activated or unactivated cells will still initiate a measurable 
and statistically significant increase in recruitment and retention of endogenous CD4+ T 
cells at day 2 after injection, this effect could be caused by endotoxin release at the site 
of injection that stimulates the endothelium to upregulate molecules that retain CD4+ T 
cells at this early time point. Increased trafficking does not lead to initiation of uveitic 
disease and by day 7 has resolved, thus suggesting that without a pathogenic stimulus the 
endothelium does not become activated to recruit and retain endogenous and transferred 
cells that cause disease.  
Therefore, this data suggests a local antigen-specific response is required to induce 
disease progression through endothelial activation that leads to endogenous and 
transferred CD4+ T cell recruitment. This conclusion was further confirmed using the OVA 
TCR specific cell transfer of activated OVA antigen-specific OTII cells with a concurrent 
intravitreal injection of OVA given just prior to cell transfer presented in chapter 5. This 
data confirmed that the recruitment of transferred and endogenous cells observed at day 
2 after adoptive transfer is not retinal antigen specific but an antigen-specific response to 
any antigen in the local environment and has the ability to induce recruitment of 
endogenous and transferred CD4+ T cells.  
 
8.3.2 Antigen-specific transferred CD4+ T cells initiate recruitment of antigen and non-
antigen specific CD4+ T cells throughout ocular inflammation 
As previously discussed, activated non-antigen specific CD4+ T cells are not capable of 
inducing endothelial activation defined by significant endogenous cell recruitment and do 
not remain within the ocular tissue past day 2 after adoptive transfer. Although the 
endogenous CD4+ T cell number does increase due to the release of endotoxin at the site 
of injection.  
Data has demonstrated an antigen-specific stimulus induces the activation of the 
endothelium. However, further experiments including the co-transfer of retinal antigen 
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specific activated CD4+ T cells with OVA specific activated CD4+ T cells at a 1:1 ratio. These 
experiments allowed for tracking of transferred ‘pathogenic’ retinal antigen specific CD4+ 
T cells, ‘activated’ OVA specific CD4+ T cells and endogenous CD4+ T cells.  
The concurrent transfer of ‘pathogenic’ and ‘activated’ CD4+ T cells illustrated a 
recruitment and retention of ‘activated’ OVA specific CD4+ T cells that are not specific for 
retinal antigen, which is compatible with a non-antigen specific CD4+ T cell role in active 
clinical disease. However, what this data also suggests is that activation alone on T cells is 
not sufficient enough to induce clinical disease. 
However, an antigen specific stimulus is capable of inducing disease and when the 
stimulus is present in the form of ‘pathogenic’ cells to facilitate, recruitment of the OVA 
specific ‘activated’ CD4+ T cells occurs. Therefore, suggesting a non-specific recruitment 
of CD4+ T cells throughout clinical disease that is contributing to clinical disease course. 
Looking at the total cell number of the endogenous, ‘pathogenic’ and ‘activated’ 
populations, it illustrates that the number of activated cells is proportionate to the other 
CD4+ T cell population present within the eye during active clinical disease.  
Further to this the endogenous cells accumulating within the eye at this time point may 
also be of an activated phenotype. Due to the size of this ‘activated’ non-retinal specific 
CD4+ T cell population it suggests these cells play a role in clinical disease progression and 
that the recruitment of these cells suggest a non-retinal antigen specific drive takes place 
during disease course, the minimal CX3CR1 expression present on this population 
supports the hypothesis that these cells are recruited non-specifically. This data also 
suggests that without the pathogenic stimulus activated non-retinal specific CD4+ T cells 
don’t remain within the ocular tissue, whereas with a pathogenic retinal antigen specific 
stimulus present activated non-retinal antigen specific cells are recruited to the eye and 
they or their progeny remain within the eye throughout clinical disease and contribute to 
active disease progression. 
 
8.4 CX3CR1 in EAU 
8.4.1 CX3CR1 deficiency does not affect disease severity in donor cells or recipient tissue 
After determining disease course using the adoptive transfer technique in chapter 3, 
experiments investigated how knocking out both or one of the alleles of the CX3CR1 
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receptor effected disease course. The literature surrounding the effect of CX3CR1 on 
disease course in EAU is conflicted. 
Firstly, comparing CX3CR1 heterozygous or total CX3CR1 allelic knockout transferred cells 
in RAG2-/- recipient mice. In comparison to the wildtype transferred cell control group, the 
data presented in chapter 6 suggests no effect on severity of disease caused in recipients 
between the three groups, although differences in timing of disease induction is observed 
within the three groups. Active clinical disease is observed in the wildtype group at day 7 
whereas in both the CX3CR1 heterozygous and knockout groups, active disease was not 
observed until day 14 after adoptive transfer. The delay in disease onset suggests that 
CX3CR1 heterozygous or knockout cells have reduced or slower trafficking in comparison 
to the wildtype control group. 
On the other hand, when wildtype cells were transferred into CX3CR1 heterozygous 
knockout or CX3CR1 knockout recipient mice no difference in disease induction, severity 
or incidence was observed. Therefore, suggesting CX3CR1 has a modest effect on disease 
when one or both alleles are knocked out on the transferred population in contrast to 
being knocked out on the endogenous population. CX3CR1 is known to be involved in 
leukocyte trafficking and therefore by knocking out the chemokine trafficking is slowed to 
the ocular tissue in the transferred population, whereas due to CX3CR1 receptor being 
intact on the transferred wild type cells trafficking of the cells to the ocular tissue is not 
effected and the host responds to the trafficking of the transferred population.  However 
more experimentation is needed to further investigate this effect. 
 
8.4.2 CX3CR1 is upregulated on CD4+ T cells throughout active EAU 
CX3CR1 is known to be expressed on cells of myeloid lineage, but recent studies have 
started to investigate a role for CX3CR1 expression on CD4+ and CD8+ T cells in models of 
inflammation. 
CX3CR1 heterozygous knockout leukocytes were transferred into wildtype Ly5 recipients 
to assess using the GFP present in place of one CX3CR1 allele to track CX3CR1 expression. 
Data presented in chapter 6 suggests that in EAU disease progression CX3CR1 is expressed 
on CD4+ T cells present within the eye during disease. The proportion of transferred cells 
expressing CX3CR1 increases as disease progresses and reaches its peak in the eye at day 
14 after adoptive transfer of leukocytes in comparison to non-lymphoid tissue. Thus, 
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suggesting that these cells have switched on CX3CR1 expression when recruited to the 
eye and then have been retained throughout disease making up by day 14 a larger 
population of the transferred CD4+ T cells.  
Previous studies have suggested that CX3CR1 upregulation on CD4+ T cells has led to 
increased survival and retention in the inflamed tissue. The data presented in this thesis 
suggests a similar potentially selective retention in the diseased tissue during active EAU 
of the CX3CR1 expressing CD4+ T cells. However, the mechanism for the switching on of 





8.4.3 CX3CR1 is not expressed on CD4+ T cells unless the cognate antigen is present 
within the tissue 
The previous observation that CX3CR1 is expressed on CD4+ T cells during active clinical 
disease specifically in the ocular tissue in contrast to non-lymphoid tissues suggested the 
involvement of TCR activation directly or indirectly in CX3CR1 expression. 
In chapter 5 a double transfer technique was described utilising pathogenic retinal antigen 
specific CD4+ T cells transferred concurrently with a population of CD4+ T cells that are 
activated, OVA antigen specific. Both cell populations had one allele of the CX3CR1 locus 
replaced by a green fluorescent protein so in both populations CX3CR1 expression on 
CD4+ T cells can be monitored throughout disease course.  
Data presented in chapter 6 using this method of disease induction illustrates a specific 
expression of CX3CR1 on CD4+ T cells that are retinal antigen specific within the eyes in 
comparison to minimal CX3CR1 expression on activated OVA specific CD4+ T cells that 
remain in the eye sticking non-specifically during active disease. This observation suggests 
that activation alone is not sufficient to induce CX3CR1 expression on CD4+ T cells. Further 
to this, activation using an antigen in vitro (RBP or OVA) does not induce CX3CR1 
expression on CD4+ T cells in both populations. However in vivo CX3CR1 expression is 
upregulated on retinal antigen specific CD4+ T cells that have been re-exposed to retinal 
antigen present in the eye, in contrast the OVA specific activated CD4+ T cell population 
present within the eye express minimal levels of CX3CR1. This data supports a model that 
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when antigen specific cells are re-exposed to the antigen in vivo the response engages the 
TCR and therefore induces CX3CR1 on CD4+ retinal antigen specific cells that enter the 
eye. At time of transfer CX3CR1 expression on CD4+ T cells is <2% of the population. 
Whereas in the OVA specific activated CD4+ T cells, the OVA antigen is not present within 
the recipient mice so therefore the cells do not come into contact with the antigen in vivo. 
Minimal CX3CR1 expression is observed on these cells suggesting that because the cells 
are not re-exposed to the antigen CX3CR1 expression is not induced in these cells. 
This data suggests that activation alone with the antigen is not sufficient to induce CX3CR1 
expression, however when re-exposed to the antigen in vivo, CX3CR1 expression on CD4+ 
T cells is present. 
 
 
8.4.4 CX3CR1 expression on CD4+ T cells is due to re-exposure to antigen in vivo 
To determine if the expression of CX3CR1 on CD4+ T cells is retinal antigen specific in vivo, 
the experimental design described in chapter 5 was used, OVA specific CD4+ CX3CR1 
heterozygous cells were activated in culture similarly to the uveitogenic cell transfer 
technique but are stimulated using OVA peptide instead of the RBP3. After the cell culture 
stage recipient CX3CR1 heterozygous mice receive an intravitreal injection of OVA peptide 
when cells are transferred. Data presented in chapter 5 illustrates a peak in disease at day 
7/8 using clinical imaging and flow cytometry and the presence of both endogenous and 
transferred CD4+ T cells within the eye.  
Analysis of CX3CR1 expression on CD4+ T cells using the OVA intravitreal transfer is 
presented in chapter 6. The eye injected with OVA peptide gets clinical disease that 
recruits both endogenous and transferred CD4+ T cells whereas the eye that receives PBS 
or control peptide has elevated endogenous CD4+ T cell numbers in comparison to naïve 
eyes but minimal transferred CD4+ are detected throughout active disease in the ocular 
tissue.  
CX3CR1 expression is observed on both the transferred and endogenous CD4+ T cell 
population especially within the eye that received the intravitreal OVA. The expression of 
CX3CR1 on transferred CD4+ OVA specific cells support the hypothesis that CX3CR1 is 
expressed on CD4+ T cells in the presence of the antigen the cells are familiar with and 
therefore the TCR is involved in the expression of CX3CR1. However, upregulation of 
318 
 
CX3CR1 on the endogenous CD4+ T cell population suggests expression of CX3CR1 on the 
endogenous CD4+ population indicates at least some of this population are interacting in 
the eye with cognate antigen. Therefore, suggesting CX3CR1 expression on endogenous 
CD4+ T cells is switched on when cells are recruited to the eye during active disease where 
they encounter the ocular antigen and are activated which switches CX3CR1 expression 
on in CD4+ T cells. In the transferred compartment it can be concluded that CX3CR1 
expression is not just retinal antigen specific but specific to any antigen the CD4+ T cells 




8.5 The role of IL-27 in EAU 
8.5.1 Disease onset is earlier in the IL-27Rα-/- after active immunisation 
Using the adoptive transfer technique described in chapter 3 combined with the data 
presented in chapter 4 that describes a conventional disease course gives a robust 
technique and comparable data set to manipulate donor or recipient leukocytes (as 
previously demonstrated using the CX3CR1 heterozygous or CX3CR1 knockout). Due to 
recent studies in models of arthritis and multiple sclerosis illustrating an effect on clinical 
disease when inducing disease in the IL-27Rα-/- mouse, experiments were designed to 
utilise these mice as donors for adoptive transfer. 
Firstly, eyes and organs from naïve IL-27Rα-/- mice were analysed to give a baseline for the 
study to detect changes in leukocyte number within the eyes of immunised mice. At day 
7 after immunisation, increased leukocyte recruitment is observed in immunised mice in 
comparison to the naïve baseline obtained from naïve IL-27Rα-/- mice. Further to this, eyes 
from donor mice immunised for adoptive transfer from IL-27Rα-/- and C57BL/6 mice were 
analysed, and leukocytes quantified using flow cytometry. By day 11 after immunisation 
the IL-27Rα-/- mice have leukocyte numbers similar to that of peak disease in a C57BL/6 
whereas in the eyes of C57BL/6 mice at day 11 after immunisation elevated leukocyte 
numbers are present within the eye but not comparable to peak clinical disease. In 
contrast to studies of EAE this data demonstrates that uveitis onset is accelerated in           
IL-27Rα-/- animals when using the active immunisation method. This could be down to the 
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pathogenicity of the CD4+ T cells that lack the IL-27Rα-/- initiating a more severe response 
when immunised with the RBP3 antigen. Studies (280) have also suggested dysfunction of 
the Treg population due to the lack of the IL-27Rα  could contribute to disease induction 
and severity due to lack of regulation.   
 
8.5.2 IL-27Rα-/- leukocytes are more pathogenic and cause a more severe and persistent 
disease phenotype when disease is induced using the adoptive transfer technique 
The evidence presented in this thesis leads to the conclusion that CD4+ T cells are more 
pathogenic from an IL-27Rα-/- mouse in comparison to CD4+ T cells from a wildtype 
C57BL/6. Firstly, after immunisation leukocytes were isolated and stimulated in cell 
culture, after this step supernatant from the cell cultures was obtained and analysed using 
the LegendPLex platform. Concentration of cytokines within the supernatant of both the 
IL-27Rα-/- and wildtype C57BL/6 cell cultures were calculated. There is a significant 
increase in the concentration of cytokines present within the IL-27Rα-/- leukocyte cultures 
in comparison to the wildtype C57BL/6 cultures. The increase in cytokine production in 
the IL-27Rα-/- culture supernatant suggests a more pathogenic phenotype is present.  
This is further supported by observations made about disease phenotype after the 
adoptive transfer of IL-27Rα-/- leukocytes into wildtype C57BL/6 recipients. At early time 
points a more severe disease is present within the eyes of recipients in comparison to the 
wildtype transfer with the same number of CD4+ T cells. The differences in disease 
severity between the two groups cannot be attributed to Tregs as the recipient wildtype 
mice have intact Treg populations. But no difference was observed in disease initiation 
between the two groups which was observed within the active immunisation group of     
IL-27Rα-/- mice, which further supports the hypothesis that dysfunctional Tregs due to      
IL-27Rα-/- initiates early onset disease.  
Using OCT imaging to follow clinical disease course allows analysis of disease throughout 
active disease and during disease resolution. The imaging data illustrates a persistent and 
more severe disease phenotype in the IL-27Rα-/- transfer recipients in comparison to the 
C57BL/6 transfer. IL-27Rα-/- has been implicated in causing a more severe and persistent 
disease phenotype in other models of autoimmune disease including adjuvant induced 
arthritis and experimental autoimmune encephalitis. AIA was induced in IL-27Rα-/-mice 
and disease monitored in comparison to a wildtype group, exacerbated joint pathology 
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denoted by increased leukocyte infiltration, synovial exudate, hypertrophy and hallmarks 
of cartilage and bone erosion (269). This data suggests IL-27 is a key mediator of immune 
response homeostasis in autoimmune conditions such as arthritis. The same pattern of 
more severe disease pathology is observed within the adoptive transfer model of EAU. 
Further to this using the clinical imaging to monitor clinical disease, the IL-27Rα-/- 
recipients illustrate no disease resolution and persistence of active clinical disease 
through to day 67. Analysis of clinical disease from day 67 to day 144 using clinical imaging 
illustrates active disease resolution in some recipients however in others active disease 
persisted to day 144 after adoptive transfer when samples were taken for flow cytometric 
analysis. 
 
8.5.3 IL-27Rα-/- CD4+ T cells persist within the eyes of recipients through to day 144 after 
adoptive transfer 
Clinical imaging allows disease monitoring throughout active disease and to compare 
disease phenotype across recipient groups. Combined with quantification of leukocytes 
present within the eyes of recipient’s differences in leukocyte infiltration can be 
attributed to differences in disease severity or phenotype. 
At day 67 after adoptive transfer the only population to persist within the eyes of the        
IL-27Rα-/- recipients are transferred CD4+ T cells, and in large enough numbers to drive 
clinical disease whereas in the wildtype transfer group minimal numbers of transferred 
and endogenous leukocytes are present within the recipient tissue. This data suggests 
that the persistence of the IL-27Rα-/- CD4+ T cells is driving active disease and initiating 
recruitment of endogenous CD4+ T cells along with other endogenous leukocytes such as 
neutrophils and myeloid cells. 
Continuing disease course through to day 144 illustrates a further persistence of the          
IL-27Rα-/- CD4+ T cells. With many recipients still with active clinical disease at this time 
point due to the persistence of this CD4+ T cell population driving disease. 
This collated data suggests a more potent and persistent phenotype of CD4+ T cell that 
can survive within the tissue and drive disease through to day 144 after adoptive transfer. 
 
8.6 Final Discussion 
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This study investigates the basic mechanisms underlying the induction and progression of 
EAU. The basic mechanism underpinning clinical symptoms is poorly understood within 
human uveitis, in order to develop new treatments for the disease it is important to 
understand how and why disease develops. The work in this thesis can help with further 
understanding on the disease process. 
The work in this thesis illustrates manipulation of disease using IL-27Rα-/- and CX3CR1+/GFP 
and CX3CR1GFP/GFP knockout mice, therefore using the adoptive transfer model optimised 
in previous chapters more detailed investigation of how these targets affect disease 
course and determine further targets for treatment of uveitis can be determined. Further 
studies of the effects of different cytokines and chemokines on disease course could be 
achieved by combining different knockout mouse strains or by CRISPR/Cas9 knockout of 
genes of interest. 
Overall, the data in this thesis gives an optimised method of tracking antigen specific cells 
that drive disease and non-retinal antigen specific cells which are non-specifically 
recruited throughout disease course. The adoptive transfer technique further allows 
expression of chemokines to be monitored throughout disease and how receptor 
knockouts influence disease course.  
Further to this from the original hypothesis set out for this thesis we have developed and 
optimised sensitive method of analysis of naïve and diseased ocular tissue and used this 
method to track allelically marked CD4+ T cells that drive disease and persist within the 
tissue after active clinical disease has resolved along with the recruitment of endogenous 
CD4+ T cells and studied their role in disease. The mechanism of recruitment of 
endogenous and transferred cells to the ocular tissue has been observed to be of antigen-
specific nature but recruitment of transferred non-antigen specific cells is observed when 
a pathogenic cell stimulus is present. Upregulation of CX3CR1 in increased frequencies 
was observed during active clinical disease due to an antigen-specific response and finally 
IL-27Rα-/- T cells cause a more long-lived and severe disease phenotype and persist within 










































9. Future Directions 
9.1 Nonspecific recruitment of CD4+ T cells throughout clinical disease 
As illustrated in chapter 5 recruitment of non-antigen specific CD4+ T cells when a uveitogenic 
stimulus is present was observed throughout active clinical disease. Further experimentation 
into what is causing the retention of non-specific CD4+ T cells within the eye could be 
achieved by the use of endothelial cell markers that are upregulated during active disease 
course that would influence retention of non-antigen specific CD4+ T cells. Distribution within 
the tissue of the antigen-specific and non-specific cells are retained specifically if they are 
resting on the endothelium or dispersed throughout the retina and vitreous. 
Further to this, the CRISPR/Cas9 system of gene editing could be utilised to knock out genes 
that effect disease progression and could be involved in the non-specific retention of CD4+ T 
cells. Firstly, to test if virally transduced cells survive in vivo and are capable of causing 
disease. Using a retroviral construct of F-tractin tagged GFP. CRISPR/Cas9 can then be utilised 
to knockout genes that can be assumed to cause a more severe disease phenotype including 
CTLA-4 or from the work presented in this thesis IL-27Rα or knockout genes that can be 
assumed to cause a less severe disease phenotype including CD28. After optimisation of this 
platform specific genes can be selected to target on OVA antigen specific CD4+ T cells before 
concurrent adoptive transfer with retinal antigen specific CD4+ T cells to monitor if the OVA 
specific cells are retained throughout active disease after specific genes are knocked out to 
manipulate disease course and reduce disease severity. 
 
9.2 The role of initial disease-causing antigen specific cells in EAU disease 
course 
The persistence of the disease initiating antigen specific CD4+ T cells throughout clinical 
disease is highlighted within this thesis (chapter 4). Using RNA sequencing at a number of late 
disease time points could identify genes present in the total CD4+ and CD8+ T cell population 
to identify differences in gene expression in cells retained in the eye past active clinical 
disease. This technique allows comparisons between clinical disease points past active 
disease but also could be used to analyse differential gene expression in endogenous and 
transferred CD4+ T cell populations during active disease. 
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 The role of the transferred antigen specific cells in disease initiation by activation of the 
endothelium was highlighted in (chapter 4) but further analysis into how transferred cells are 
involved in the initiation and progression of clinical disease can be investigated using antibody 
depletion of the transferred population before active peak disease occurs. This experiment 
will determine the role of transferred antigen specific cells in continuing active disease course 
and whether the endogenous compartment of CD4+ T cells is capable of continuing disease 
course without the presence of the antigen specific pathogenic transferred CD4+ T cells. 
Further to this the proliferation status of the transferred CD4+ population during active 
disease. Using a Ki67 antibody stain we can determine if the cells are in the active phase of 
the cell cycle and are therefore proliferating or the increase in transferred number present in 
the eye during active clinical disease is due purely to recruitment of transferred cells from the 
blood, spleen and lymph nodes. 
 
9.3 CX3CR1 expression on CD4+ T cells throughout clinical disease  
The expression of CX3CR1 on CD4+ T cells due to an antigen specific response is presented in 
chapter 6. To investigate if CX3CR1 is also expressed on CD4+ T cells in vitro cultures, OVA 
specific CD4+ T cells cocultured with antigen and CD3 CD28 stimulation to quantify CX3CR1 
expression on CD4+ T cells.  
Further experiments include utilising the RAG2-/- mice to transfer cells from transfer recipients 
at peak disease in Ly5 recipients. CD4+ transferred T cells from recipient eyes at peak disease 
can be sorted into CX3CR1+ CD4+ T cells and transferred into one group of recipients and sort 
CX3CR1- CD4+ T cells to transfer into another group of recipients. This experiment will allow 
differences in disease course based on CX3CR1 expression of CD4+ T cells with the hypothesis 
that CX3CR1+ CD4+ T cells are more capable of causing disease and persisting during active 
disease in comparison to the CX3CR1- CD4+ T cell population. 
Analysis of differential gene expression in these recipients could be investigated by focussed 
analysis of the expression of functional gene sets that are associated with changes in T cell 
effector potential specifically analysing intracellular cytokine expression including IFN-γ, IL-17 
and TNF. Regulatory and activation threshold markers including; FoxP3, CD5, CD39 and CD73, 
coinhibitory markers BTLA, TIM3, CTLA4, LAG3, PD1 and TIGIT and costimulatory markers 
(41BB, CD25, CD28, GITR, ICOS and OX40 using flow cytometry antibody panels. 
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Further to this RNA seq analysis of levels of mRNA followed by unsupervised analysis of 
differential gene expression will complement the previous study. Using total cell count of 
CD4+ T cells at different time points throughout disease course and with differing CX3CR1 
expression levels to compare cross different disease-causing cells. 
Due to the antigen specific nature of CX3CR1 expression on CD4+ T cells analysis of the TCR 
of CX3CR1+ CD4+ T cells using single cell sequencing. This platform allows single cell analysis 
at the transcript level with concurrent analysis of the TCR repertoire of each individual cell. 
Firstly, using the OTII transfer model with intravitreal OVA followed by analysis of the 
uveitogenic transfer model. 
 
9.4 IL-27Rα-/- causes a more potent CD4+ T cell phenotype 
 As described in chapter 7 knocking out the IL-27Rα in transferred CD4+ T cells causes a more 
severe cell phenotype that persists throughout active disease and continues to drive disease 
to cause a longer more severe disease within the recipients. Further experimentation could 
include phenotyping the CD4+ T cell populations within both groups of recipients to identify 
the role of CD4+ T cell phenotype in disease progression including early disease time points 
and late disease time points such as staining for IFN-γ, IL-17 and FoxP3 using flow cytometry 
antibodies before including analysis of differential gene expression in recipients by 
quantifying expression of functional gene sets that are associated with changes in T cell 
effector potential specifically analysing intracellular cytokine expression including IFN-γ, IL-17 
and TNF. Regulatory and activation threshold markers including FoxP3, CD5, CD39 and CD73, 
coinhibitory markers BTLA, TIM3, CTLA4, LAG3, PD1 and TGIT and costimulatory markers 
(41BB, CD25, CD28, GITR, ICOS and OX40. 
The effect of IL-27Rα knockout on CD4+ T cells has contributed to differences in disease 
phenotype but how this difference in clinical disease affects the structure and function of the 
tissue. Using histological sections to analyse the structures present within the eye to 
determine any abnormalities across disease groups, alternatively further analysis using whole 










































Appendix 1: Control experiment OVA and L144 control invit with no cell transfer performed to 
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Appendix 2: Pathogenic or OTII activated intravitreal injection of cells into the left eye of RAG2-/- 
mice. Eyes were then analysed by flow cytometry at day 7 and 14 to quantify presence of transferred 



























Appendix 3: Leukocytes quantified in organs from IL-27Rα-/- mice to compare to leukocyte numbers 




























Appendix 4: Leukocytes quantified in organs from C57BL/6 mice to compare to leukocyte numbers 
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